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Abstract
4,4’-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) has recently completed a
phase-I clinical trial, and objective responses were seen in advanced breast cancer, lung cancer,
ovarian cancer, melanoma, skin cancer and non-Hodgkin’s lymphoma. Despite the promising
results in the clinical trials, the major disadvantage to using A-007 as a broad-scale therapeutic is
its poor water solubility. To make use of this promising anticancer drug either orally or
intravenously, the short-term obstacle must be to overcome the limited solubility of A-007 in
water. There are several approaches to overcome this obstacle. The first approach is to make
hydrolysable prodrugs of A-007. The second approach is to make an A-007 complex with a
water soluble host, such as cyclodextrin. We used a combination of these two previously
described methods, i.e. transforming A-007 into a more water soluble prodrugs and then further
increasing the prodrug water solubility by making their cyclodextrin inclusion complexes. Our
syntheses and spectroscopic explorations of A-007 prodrugs are presented in this dissertation.
Tetramic acid (2, 4 pyrrolidine-2,4-dione ring system) containing compounds have been found to
display a remarkable diversity of biological activities and have attracted the interest of medicinal
and synthetic chemists. Magnesidin (1-acetyl-3-octanoyl-5-ethylidene tetramic acid) has strong
antimicrobial activity against bacteria that cause gingivitis and dental plaque. Current efforts
toward the synthesis of Magnesidin are discussed along with the plans for the completion of
synthesis.

Keywords: Cancer; Cyclodextrin; Inclusion complexes; A-007 prodrugs; Molecular aggregation;
NOESY; ES mass spectroscopy; azlactone condensation; azlactone ring opening; oxazolones;
tetramic acids; Magnesidin.
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Chapter I. Introduction
Cancer
From an immunological point of view, cancer cells can be defined as the cells that
escaped the regulatory mechanisms that govern normal cell growth to produce non-functional
cells.1 The proliferation of these non-functional cells give rise to clone cells, which continue the
process of cell division and replication, leading to the development of a mass of non-functional,
continuously replicating cells commonly known as a tumor.1 While the human immune system
has cells that have many functions, including maintaining homeostasis of normal tissue by
regulating cellular proliferation and cell death, it is clearly indicated by the number of annual
cancer deaths worldwide that the level of effectiveness of the immune response to tumor cells is
often inadequate or poorly expressed. Because of this, scientists have been increasing focus on
the exploration of the immune system’s response to the regulation and destruction of cancer
cells, designing vaccines as well as molecular systems that enable the reactivation of human
immune responses to cancer cells.1

Overview of the Immune System
An effective immune response involves two cellular groups. These groups are known as
lymphocytes and antigen-presenting cells. There are many types of lymphocytes, and these cells
are produced as white blood cells from bone marrow. Once the lymphocyte leaves the bone
marrow, it circulates in the blood and the lymphatic systems, and finally resides in lymphoid
organs in the body. Lymphocytes have antigen (foreign body) binding cell surface receptors that
mediate immunological responses, such as specificity, diversity, memory, and self-nonself
recognition.1
1

T-lymphocytes leave the bone marrow and travel to the thymus to mature. In the thymus,
these cells differentiate to express a unique antigen binding molecule, known as the T-cell
receptor, on its cell surface membrane. The T-cell receptor can only recognize antigens bound to
cell membrane proteins, known as major histocompatibility complex (MHC) molecules. MHCs
function in recognition, termed “antigen presentation” in which the recognition occurs between
the molecule and glycoproteins found on cell membranes.1
Dendritic cells (DC) are antigen-presenting cells of the human immune system that are
involved in the initiation of the immune response.2a DCs are responsible for the acquisition of
antigens or cancer cells, and their subsequent transport to T- lymphocyte rich areas. They are
present in lymphatic tissues and lymphoid organs. Once the DCs interact with antigens and
become activated, they are able to derive specific immune responses. Secondary lymphoid
organs, such as the skin, recruit both naive T- lymphocytes and antigen-stimulated DCs into Tcell rich lymphoid areas, and the co - localization of these early immune response constituents is
representative of T-cell activation.2a Effective anti-tumor responses elicited from the immune
system require the presence of both antigen presenting cells and T lymphocytes.2b
In order for a T-cell to become activated, which in turn initiates the immune response of
antigen destruction, a T-cell activation signal is required. This signal is triggered by the
recognition of the peptide - MHC molecular complex by the T-cell receptor as well as by a costimulatory signal. The co-stimulatory signal is usually triggered by an interaction between cell
surface glycoproteins of the antigen presenting cell and the T-cell.1 Because tumor cells express
low levels of MHCs and lack necessary co-stimulatory molecules, both necessary to initiate the
proliferation of T-cells, they are not effective modulators of antigen presenting cells.7 Without

2

sufficient antigen presenting cells in the vicinity of a tumor, T-cells receive only partial
activating signals, and tumors are allowed to proliferate.1
Immunotherapy is an approach in cancer treatment that attempts to supplement the
natural immune defenses of the human body.1 To that end, one compound that has been clinically
shown to demonstrate significant anticancer activities is 4,4’- dihydroxybenzophenone - 2,4 dinitrophenylhydrazone (A-007 Figure I.1).3 X-ray crystallography data revealed that A-007
(monoclinic crystals) exists as two unique rotamers.1 These rotamers differ only in the
orientation of the bis-diphenylmethane group, where the rings are approximately perpendicular
to each other and rotated approximately 90° from the orientation of the rings in each rotamer
(Figure I.1). 4a Both rotamers show strong intramolecular hydrogen bonds between the – NH of
the – HN– N=C– moiety and an oxygen of the -nitro group. Examining the structure of A-007,
one can see that there are three unique functional moieties present in A-007 that may contribute
to its overall biological activity. These three moieties are the dihydroxy-bis-diphenylmethane
rings, the hydrazone moiety and the dinitrophenyl moiety. However, despite A-007's high
electrophilicity, it has no chemical reactivity with cell surface glycoproteins, making this
compound and analogs of this compound promising new anti-cancer treatments.4b
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Figure I.1: Structural crystallography characteristics of A-007.4

A-007 and its structural analogs appear to act as T-cell activators via CD45+ surface
receptors on lymphoendothelial cells, and in particular with dendritic cells. Thus far, thirty-three
people have been treated with topical A-007 (as a 0.25% gel) in the Phase I study, and of these
subjects, 31% objective remissions have been observed with two complete responses.3 During
the Phase I study, it was discovered that A-007 was not acting through a cytotoxic mechanism.
There was no local or systemic toxicity noted, and histochemical reviews of biopsies of human
skin topically treated with A-007 revealed that increased infiltrates of T-lymphocytes containing
the membrane glycoproteins CD4+ (T-helper cells), CD3+(T-cytotoxic cells), CD8+(T-cytotoxic
cells), and CD45+ had occurred after treatment.3 Increased skin infiltrates of CD11c+ dendritic
cells (function as antigen presenters to T-helper cells) were also observed in treated areas.4
Further immunohistochemical studies suggested that immune modulation had occurred in vitro
and in vivo following exposure to A-007.3,5
A-007 is a simple organic molecule that appears to act as an antigen, possibly due to the
unique electronic properties associated with this molecule. It has been hypothesized by Morgan,
et al.1 that up-regulation of the CD45+ receptor is an initiation site for the A-007-induced
4

immune modulations that are being observed in patients with cancer.5 Our hypothesis is that if
this is in fact the initiation site for up-regulation of receptor glycoproteins involved in immune
modulation, then other water soluble analogs of A-007 should be able to elicit the same, or
greater responses.
CD45+ is expressed on dendritic cells, lymphocytes, monocytes, and leukocytes, as well
as some neoplastic cells, as a protein tyrosine phosphatase (PTP), which together with other
members of the PTPs, are responsible for phosphorylating tyrosine residues.2d Blocking the
CD45+ sites with anti-CD45 antibodies has been shown to inhibit T-cell activation and prevent
mitogen (lectin) activation of naïve T-cells6a CD45+ receptor surfaces contain the amino acid
residues of arginine, serine/threonine, and cysteine, and these residues can bind to or transfer
natural ligands to the surface of antigen presenting cells and hydrolyze tyrosyl phosphates.6b
Morgan et al. hypothesized that A-007 does not inhibit or block CD45+, but up-regulates
lymphocytes and dendritic cells (to antigen presenting cells) via electrostatic and/or non-covalent
binding with the Arg, Cys, Ser/Threo residues, as depicted in Figure I.2.5 Furthermore, A-007activated DCs are capable of initiating mitotic events with naïve human blood peripheral
mononuclear cells (PBMC) and up-regulating both CD45+ and CD11c+ receptors in human
peripheral dendritic cells,6c all exemplifying the fact that A-007 is not an inhibitor of CD45+, but
rather an up-regulator or modulator of the molecular sites (Figure I.2). The influence that
functional group substitutions may have on A-007's intra-/inter-molecular hydrogen bonding and
electrostatic interactions is presented below (This figure illustrates several possible interactions,
and is not meant to illustrate the fact that all interactions occur).
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Figure I.2: Postulated interactions of A-007 with the CD45 receptor (modified from Ref. 2d).

To improve the activity of A-007, functional group modifications to three functional
moieties present in A-007 that could influence biological activity have been performed.7
Analogues of A-007 were prepared to introduce rigidity in the diphenylmethane ring system, as
well as to influence electrostatic properties. Compounds that have evolved by fusing the
diphenyl ring system into polyaryl coplanar rings not only improved anticancer activity but also
introduced potential problems from cardiac and bone marrow toxicities7. Substitutions of
electron withdrawing groups into the dinitrophenyl ring system influenced activity. A-007 and
some of the simple analogues have intramolecular hydrogen bonding between the dinitrophenyl
ring system and the N-NH of the hydrazone group, as well as between the hydrazone moiety and
the hydroxyls of the diphenylmethane ring, all of which had an impact on biological activity.7
Fresh human cancer tissue were studied as a test system because of the natural heterogeneity that
exists in a tumor nodule or mass, i.e., cancer cells, lymphocytes, fibroblasts, endothelial cells,
and natural extracellular connective tissue matrices.

6

Considering the fact that to date, no analog of A-007 with improved immune modulating
activity (apoptosis without direct cytotoxicity) has been identified, it was important that A-007
itself should be brought into a form that could be used as broad scale therapeutic. Despite
promising results in the clinical trials with A-007, the major disadvantage to using A-007 as a
broad scale therapeutic was its low water solubility. In the current formulation, A-007 is used
only as a topically applied 0.25% gel, making the uses of this very potent immune modulating
compound limited.7 To further advance the use of A-007as an anticancer therapeutic that can be
used orally or intravenously, the short-term obstacle to overcome is the limited solubility of A007 in water.8 Prodrug design is an approach that can be effectively used to overcome obstacles
such as solubility in promising drug candidates.

The Prodrug Concept
Albert and coworkers were the first to suggest the concept of the prodrug approach in
increasing the efficiency of drugs in 1950.9 They described prodrugs as pharmacologically
inactive chemical derivatives that could be used to alter the physicochemical properties of drugs,
in a temporary manner, to increase their usefulness and/or to decrease associated toxicity9.
Subsequently, such drug-derivatives have also been called ‘latentiated drugs’, ‘bioreversible
derivatives’, and ‘congeners’, but ‘prodrug’ is now the most commonly accepted term.9 Thus,
prodrugs can be defined as a drug derivative that undergoes biotransformations, either
enzymatically or non-enzymatically, inside the body before exhibiting its therapeutic effect.
Ideally, a prodrug is converted to the original drug as soon as the derivative reaches the site of
action, followed by rapid elimination of the released derivatizing group without causing side
effects in the process. The definition of the prodrug indicates that the derivatizing group is

7

covalently linked to the drug molecule. However, the term prodrug has also been used to
describe salts formed by the drug molecules9. A derivative of a known, active drug can be
capped to furnish a prodrug. The prodrug enhances delivery characteristics and/or therapeutic
value of the drug by transforming into the active drug via an enzymatic or a chemical process to
remove the cap at the site of action to regenerate.

Scheme I.1: Capping an active drug to enhance delivery characteristics and/or therapeutic value.9
Characteristics of a Prodrug
In recent years numerous prodrugs have been designed and developed to overcome
barriers to drug utilization, such as low oral absorption properties, lack of site specificity,
chemical instability, toxicity, bad taste, odor, pain at application site, etc. 9 It has been suggested
that an ideal drug carrier must: 9
1) Protect the drug until it is at the site of action.
2) Localize the drug at the site of action.
3) Allow for release of the drug chemically or enzymatically.
4) Minimize host toxicity.
5) Be biodegradable, biochemically inert, and non-immunogenic.
6) Be easily prepared inexpensively.
7) Be chemically and biochemically stable in its dosage form.
8

Development of Prodrugs
Specific prodrugs, which were developed by taking explicit administration properties into
consideration, are utilized for the following:
1. To improve membrane transport:10a Barbiturates (Figure I.3) are a group of compounds
responsible for profound sedative-hypnotic effect10b. They are weakly acidic in nature and are
converted to the corresponding sodium salt in aqueous sodium hydroxide. The sodium salt is
extensively employed for intravenous anesthetic properties. Barbituric acid is the parent member
of this group of compounds. Various barbiturates differ in the time required for the onset of sleep
and in the duration of their effect. Hexobarbitone was found to be an effective drug but its
membrane permeability was found to be low. However, N-methylhexobarbitone a simple
barbituric acid derivative of the parent drug, was found to have better permeability
characteristics. After intake, the N-methyl group is cleaved in the liver to release the
physiologically active drug.

O

H
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O

O

H
N

O

O

N

NH

NH

O
NH

O

O

O

Barbituric acid

Hexobarbitone

N-Methylhexobarbitone

Figure I.3: Hypnotic and sedative agents.

Similarly, membrane transportation characteristics of the neurotransmitter dopamine
(Figure I.4) used for the treatment of Parkinson’s disease can be improved by administering its
prodrug L-3,4 dihydroxyphenylalanine (Levo-DOPA, Figure I.4). This derivative has better
9

blood-brain permeation characteristics since it uses amino acid channels for transportation. Once
inside the cell, decarboxylase enzyme removes the acid group to generate dopamine.

NH2

NH2

HO

COOH

HO
OH

OH

Dopamine

Levo-DOPA

Figure I.4: Dopamine and Levo-Dopa.

2. To prolong the activity:10a Nordazapam (Figure I.5) is a drug used for sedation, particularly as
an anxiolytic. It is also used as a muscle relaxant. However, it loses activity too quickly due to
metabolism and excretion. A prodrug introduced to improve the retention characteristics is
valium (Figure I.5). Due to presence of N-methyl group the prodrug resists quick degradation.
Slow release of the nordazapam in the liver by demethylation prolongs body retention
characteristics.10b
H
N
Cl

O

O

N

N

Cl

N

Valium

Nordazapam

Figure I.5: Nordazapam and Valium.

Decreased or lack of secretion of the enzyme insulin in pancreas leads to diabetes.9
Insulin is responsible for degradation of carbohydrate molecules to smaller units and is important
in the catabolic process. Chronic diabetic patients take bovine insulin supplement through
10

intravenous injections. Retention time of insulin in the blood is about six hours. So, patients need
to administer required dose of insulin frequently. It is desirable to increase the retention
characteristics of the enzyme so as to make it effective for prolonged periods. It was found that
9- fluorenylmethoxycarbonyl (Fmoc) protection (Figure I.6) of the hydroxy/amino groups of the
enzyme makes it inactive and also increase its retention in blood for prolonged periods.10c The
Fmoc group binds to the enzyme covalently and in the process makes it inactive as well as
reduces its rapid degradation by natural body process. However, at the pH of about 7.4 prevalent
in the blood serum the protected enzyme gets hydrolyzed slowly and irreversibly back to the
enzyme and Fmoc protecting group. The hydrolysis process was found to be slow and constant,
which means that the release of enzyme is also slow and regulated. The hydrolysis rate can be
fine tuned by selecting derivatives of Fmoc protecting group or number of Fmoc groups. It was
shown that insulin having two Fmoc protecting groups was ten times more stable and more
effective than the parent enzyme. It should be noted that the hydrolysis of the protecting group
takes place in the blood without mediation from other enzymes.

+ insulin
O
O

O
insulin

O
H
Released F moc

Prodrug of insulin

Figure I.6: Fmoc protected prodrug of insulin.

3. Masking from other Enzymes:11a Sometimes drugs are highly toxic when administered
directly. Suitable modification of the drug molecule to an inactive agent reduces toxicity. For
example propiolaldehyde (Figure I.7) is used in the aversion therapy on patients addicted to
11

alcohol. However, it is a highly irritating chemical and causes allergic reactions. As an
alternative, closely related compound, pargylene (Figure I.7), which is converted to
propiolaldehyde by oxidative enzymes only in liver, is used for alcohol addiction.11b

CHO

N

Propiolaldehyde

Pargyline

Figure I.7: Prodrug for anti-alcoholic addiction.

4. Prodrugs to Encourage Patience Acceptance: A fundamental tenet in medicine is that in
order for a drug to be effective, the patient has to take it. Painful injections and unpleasant taste
or odor are the most common reasons for the lack of patient acceptance of a drug. An excellent
example of how a prodrug can increase the potential for patient acceptance is related to the
antibacterial drug clindamycin. Whereas clindamycin causes pain on injection, the prodrug
clindamycin phosphate (trade name Dalacin) is well tolerated; hydrolysis of the prodrug in vivo
occurs with a t1/2 of approximately 10 min.12c Also clindamycin has a bitter taste, so it is not well
accepted orally by children. However, it was found that by increasing the chain length of 2-acyl
esters of clindamycin the taste improved from bitter (acetate ester) to no bitter taste palmitate
ester .12d Bitter taste results from a compound dissolving in the saliva and interacting with taste
receptor in the mouth. Esterification with long-chain fatty acids makes the drug less water
soluble and unable to dissolve in the saliva. It also may alter the interactions of the compound
with the taste receptor.
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Figure I.8: Clindamycin and its prodrugs.

5. Prodrug Design Based on Site-specific Conditions:13 A variety of conditions such as pH and
oxygen content, which are site specific and are different from other parts of the body, can be
effectively utilized for prodrug design.13a This aspect is an important feature in the research on
prodrugs targeted at cancer cells. The cancer cell grows at a much faster rate than normal cells.
Tumor cells associated with cancer can be differentiated from normal cells. The blood vessels in
the tumor tissue often lack regularity and systematic connectivity leaving unvascularized zones,
especially in the interior areas, which leads to unstable blood flow. Cells that do not have
adequate blood supply die as a result of lack of oxygen. The intermediate regions also get a
deficient supply of oxygen. This area is called the hypoxia region. Lack of oxygen in hypoxia
cells or the bio-reductive conditions prevalent in them can be utilized for specific prodrug
development where the active drug can be selectively released under bio-reductive conditions.
The bio reductive enzymes present in the cell perform one electron reduction. In normal cells,
oxygen reverses this reduction process. However, in hypoxia cells, due to near absence of
oxygen, further reduction takes place to generate the active drug from the prodrug moiety.13a, b
For example, Tyrapazamine (Figure I.9) has been developed as a cytotoxic agent. It has two Noxide moieties, which upon one electron reduction twice gets converted to highly reactive
diradical. The diradicals are responsible for cleavage of DNA. Even though such diradicles are
13

generated in normal cells, they get reconverted to N-oxides due to the presence of oxygen. In
hypoxia cells the diradicles have a longer lifetime to interact with DNA molecules and further
cleave them. Such a cleavage of single or double stranded DNA leads to the destruction of cells.
Thus, the N-oxide prodrug was found to be highly effective in hypoxia cells.
O
N
NH
N
O

Tyrapazamine

Figure I.9: Prodrug directed to hypoxia cells.

6. Enzyme Specific Prodrug Design: Certain enzymes express predominantly in the cancer cells.
Prodrug development can take advantage of this aspect so that over expressed enzymes can be
exploited to facilitate the release the drug at the site of action. This condition is of particular
importance in targeting cancer cells. Due to differing physiological conditions, enzyme groups
such as glucuronidases12, proteases-2 show abnormal activity in cancer cells compared to normal
cells. Several prodrugs have been developed by taking advantage of the excessive activity of the
above enzymes in tumor tissues.
Scheeren and colleagues13, 14a demonstrated that the cytotoxic activity of important
antitumor drugs could be enhanced and restricted to tumor-affected tissues by making peptide
derivatives. They prepared derivatives of paclitaxel (Figure I.10) and doxorubicin (Figure I.11)
wherein active sites are blocked by strategically attaching suitable polypeptide to the drug but
separated by a spacer. The spacer was used to expose the polypeptide chain open for plasmin
activity. Both the prodrugs were found to be inactive and stable under biological pH conditions
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but they were readily cleaved with the release of parent drugs in the presence of plasmin
enzymes present in tumor cells. These prodrugs were synthesized by blocking important
functional groups in the molecule with a polypeptide-capping agent to make them inactive. The
spacer group was designed to self eliminate after hydrolysis of the polypeptide chain by the
enzyme.
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Figure I.10: Plasmin targeted anticancer prodrug and its parent drug.

Protease enzymes are responsible for the breakdown of proteins. They scissor the protein
chain at amide bonds linking specific amino acids. It was found that even though protease
enzymes are ubiquitous in all cells and blood serum, their activity is excessively associated with
tumor metastases. 13,14a,b Primary malignant cells are encapsulated in extra cellular matrix made
of proteins. In order to proliferate and to reach metastases the primary tumor has to break
through the matrix through protease activity. It was shown that serine protease plasmin plays an
important role in tumor invasion to other areas. In blood circulation plasmin activity is restricted
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by the presence of anti-plasmin enzymes. 14a,c Plasmin targeted doxorubicin based prodrug
having a spacer Doxorubicin group was designed to self eliminate after hydrolysis of the
polypeptide chain by the enzyme.
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7. Prodrug Design for Increased Water Solubility: Many drugs are poorly water-soluble.9, 15a
To permit aqueous injections or ophthalmic delivery of these drugs, they must be converted into
water-soluble forms. However, there are two considerations one must take into account in the
choice of a solublilizing group: The bond made should be stable enough in aqueous solution so
that a ready-to-inject solution has a reasonably long shelf life, but it must be hydrolyzed in vivo
with a reasonably short half-life after administration (less than 10 minutes). One example of this
is dilemma is the water-soluble prodrug form of methylprednisolone, which is in medical use as
methyl-prednisolone sodium succinate Solu-Medrol.15b
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However, the in vitro stability is low, probably due to intramolecular catalysis;
consequently, it is distributed as a lyophilized (freeze-dried) powder that must be reconstituted
with water and then used within 48 hours. The lyophilization process adds to the cost of the drug
and makes its use less convenient. To overcome the shortfalls associated with using this
compound, a series of more stable water-soluble methylprednisolone esters were synthesized,
and several of the analogs were shown to have shelf lives in solution of greater than 2 years at
room temperature.15b
Another example of poor water solubility affecting the use of anticancer compounds is
associated with the antitumor drug etoposide ( R=H; Vepesid), which has to be formulated with
the detergent Tween 80, polyethylene glycol, and ethanol, all of which have been shown to be
toxic.15c Conversion to the corresponding phosphate ester, etoposide phosphate (Figure I.12b),
allows the drug to be delivered in a more concentrated form over a much shorter period of time
without the detrimental vehicle.15d
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Cyclodextrins as Drug Carrier
Cyclodextrins are a family of cyclic oligosaccharides16a with a hydrophilic outer surface
and a lipophilic central cavity. Cyclodextrin molecules are relatively large with a number of
hydrogen donors and acceptors and thus, in general, they do not permeate lipophilic membranes.
Cyclodextrins have been used in the pharmaceutical industry as complexing agents to increase
aqueous solubility of poorly soluble drugs, and to increase their bioavailability and stability.
Studies in both humans and animals have shown that cyclodextrins can be used to improve drug
delivery from almost any type of drug formulation. Currently there are ~ 30 different
pharmaceutical products worldwide containing drug/cyclodextrin complexes on the market. 16b
Reduction of drug crystalinity on complexation or solid dispersion with CDs also
contributes to the CD increased apparent drug solubility and dissolution rate.17a CDs as a result
of their ability to form in situ inclusion complexes in dissolution medium, can enhance drug
dissolution even when there is no complexation in the solid state. CDs can also act as release
enhancers, for example -CD enhanced the release rate of poorly soluble naproxen and injection
of the drug in a BALB/c mouse model.17b Further CD entrapment of drugs at the molecular level
prevents their direct contact with biological membranes and thus reduces their side effects (by
decreasing drug entry into the cells of nontargeted tissues) and local irritation with no drastic loss
of therapeutic benefits. Inclusion complexation with HP--CD reduced the side effects of 2ethyl hexyl-p-dimethyl aminobenzoate (a UV filter) by limiting the interaction of the UV filter
with skin.17b
Applications of CDs in oral drug delivery include improvement of drug bioavailability
due to increased drug solubility, improvement of rate and extent of dissolution, and/or stability of
the drug at the absorption site, e.g., the gastrointestinal tract or in formulation, reduction of drug
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induced irritation, and taste masking.17b CD complexation was found to decrease local drug
irritation and also modify the time of drug release during GI transit. An itraconazole oral
preparation containing 40% (wt/vol) of HP--CD (with reduced drug irritation) has been
commercialized.17c
The principal advantages of using natural cyclodextrins as drug carriers are the
following18: (1) well-defined chemical structure, yielding many potential sites for chemical
modification or conjugation; (2) availability of cyclodextrins of different cavity size; (3) low
toxicity and low pharmacological activity; (4) certain water solubility; (5) protection of
included/conjugated drugs from biodegradation.

Tetramic Acids
The term tetramic acid was coined in 1901 to refer to the heterocyclic system 1,5dihydro-4-hydroxy-2H-pyrrol-2-one , a tautomer of 2,4-pyrrolidinedione which is the
predominant species in solution.19 Although tetramic acid (Figure I.13) was apparently
synthesized only in 1972, a number of natural substances had been identified as
derivatives of tetramic acids well before that time.20 Secondary metabolites containing
the tetramic acid (2,4-pyrrolidine-2,4-dione) ring system have been known for almost
half a century, and well before the parent system was synthesized. Although the first
naturally occurring tetramic acids were identified because of their activity as antibiotics
and/or mycotoxins, more recently tetramic acid containing compounds have been found
to display a remarkable diversity of biological activities. The often unusual and intricate
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substituents modifying the tetramic acid structural unit make the synthesis of these
metabolites a challenging target.21, 22
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Figure I.13: General structure and some commercially important tetramic acids.

Recent studies have confirmed that tetramic acid metabolites have a wide distribution and
play a significant role in ecological interactions. They have been isolated from marine mollusks,
sponges and cyanobacteria, terrestrial and marine microorganisms, particularly endophytic fungi.
Tetramic acid is a much weaker acid than its oxygen counterpart and exists mainly in 2,4diketone form. The presence of an acyl group at C3 results in an increase in acidity (pKa 3.03.5) and proton NMR spectra indicate complete enolisation and the presence of tautomeric
forms. As shown in Figure I.14 these can be separated into two sets of internal tautomers, which
are rapidly interconverting, and two pairs of external isomers that interconvert slowly on the
NMR time scale and often give rise to separate NMR signals.

13

C-NMR spectroscopy is more

useful in determining the predominant tautomeric form and it indicates that the one represented
by D (Figure I.14) is more important.
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From biosynthetic perspective naturally occurring tetramic acids can be regarded to arise
from the assembly of an aminoacid and an activated acyl entity11, 23 derived from an acetyl group
or a more complex activated ester.
Compounds containing this structural unit (Figure I.14), sometimes intriguingly 23-28
camouflaged, exhibit a diverse range of biological activities and have attracted the interest not
only of natural products chemists, but also of chemical ecologists, medicinal and synthetic
chemists.
Magnesidin is an inseparable mixture of the magnesium chelates of the 3-hexanoyl and 3octanoyl tetramic acid derivatives.23 It was the first recorded example of a naturally occurring
tetramic acid magnesium salt. It was isolated from a new Pseudomonas species, P.
magnesiorubra, obtained from the surface washings of the marine green alga Caulerpa peltata.24
Magnesidin inhibits gram-positive bacteria (MIC 2-7 g/mL), 25 particularly spore bearers, and
prevents the decay of foodstuff caused by spore germinating organisms. An important
application of Magnesidin is it is effective against gingivitis and reducing dental plaque.
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To date, it appears that only chemicals that demonstrate potent anti-plaque and anticariogenic activity are fluoride and chlorhexidine, both of which are halogenated.26a Gingivitis is
a concern for a large number of people. Epidemiological surveys indicate that an average of 50%
of the adult population of the United States (US) have gingivitis. Gingivitis is characterized by
gingival inflammation and/or bleeding and is caused by plaque at and under the gingival
margins. Most people brush their teeth; however, toothbrushes cannot effectively remove plaque
at or under the gum line. Floss is effective at removing plaque in difficult to reach locations;
however only about 20% of the US population use floss. Inconvenience is a commonly cited
reason for not flossing.26b Since gingivitis is caused by plaque and plaque is composed of
various kinds of bacteria, in theory anti-microbial agents should be effective against gingivitis.
There are a number of anti-microbial agents formulated in toothpaste or rinses on the
market. The most effective of these agents is chlorhexidine digluconate (CHG).27 CHG reduced
gingivitis by 50-80% in clinical trials. However, CHG is available in the US by prescription only
and is generally used on a short-term basis (2-4 weeks only). Patient compliance is generally
poor due to the unpleasant side effects associated with the use of CHG, which include staining of
the teeth, interference with taste function, and enhanced calculus formation. Two products
available on the over-the-counter (OTC) market have shown marginal effectiveness in clinical
trials, Total® and Listerine®. Total, a toothpaste containing triclosan, reduced gingivitis by 2025% in clinical trials. Listerine reduced gingivitis by 20-35% in clinical trials. Neither triclosan
nor Listerine are substantive agents, thus the anti-microbial effect is lost quickly.28 The
remaining anti-microbial agents available in OTC products have failed to show effectiveness in
clinical trials. Thus, there is currently no truly efficacious anti-gingivitis product that is both
convenient to use and appealing to the consumer. It appears that the only chemicals that have
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been shown to have potent anti-plaque and anti-cariogenic activity are fluoride and
chlorhexidine, both of which are halogenated. Other commonly used compounds including the
phenolics are not as effective as plaque- and caries-control agents.29-31
Considering the importance of healthy teeth and gums in general human health, and the
lack of availability of a proper remedy, it is very important to develop an industrially viable
synthetic approach for Magnesidin. In addition the synthetic method should be a general method
such that it can be extrapolated to develop other tetramic acids of medicinal significance.
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Chapter II. Synthesis and NMR spectroscopic study of cyclodextrin inclusion
complexes with A-007 prodrugs

Abstract
One- and two-dimensional NMR spectroscopy was used to demonstrate the formation of
inclusion cyclodextrin complexes with several A-007 prodrugs. These complexes are comprised
from the encapsulation of the two phenol moieties of the A-007 prodrugs within the cyclodextrin
cavity. Considering the size of the two phenol moieties of the A-007 prodrugs compared to the
sizes of -, -, and -cyclodextrin cavities, we observed complementary binding of the A-007
prodrug with only -cyclodextrin, which was also demonstrated spectroscopically. The cyclodextrin inclusion complexes increased the prodrug solubility and modified the prodrug halflife in water. Therefore, -cyclodextrin inclusion complexes can be used as an essential form of
A-007 prodrug delivery.

Introduction
4,4’-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007, Figure 2.1) has recently
completed a phase I clinical trial, where it was used as a therapeutic with the targeted treatment
of advanced cancer, with minimal toxicity.1 It was speculated that A-007’s activity is a result of
complementary binding to lymphocyte receptors. This speculation was supported by
experimental findings that indicate that A-007 interacts, presumably through the electron-rich
(phenol) and the electron-poor (dinitrophenyl) moieties, with the CD45 receptor through
complementary interactions.2
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Figure 2.1. Chemical structure of the anticancer compound A-007

Despite promising results in the clinical trials, there is a major disadvantage to using A007 as a broad scale therapeutic. A-007 has low water solubility and in its current formulation, is
used only as a topically applied 0.25% gel.3 To make use of this promising anticancer drug orally
or intravenously, the short-term obstacle must be to overcome the limited solubility of A-007 in
water. Two possibilities exist to overcome the water solubility problem: the first is to make a
hydrolyzable prodrug; and the second is to make an A-007 complex with a water soluble host,
such as cyclodextrin.4,5 Considering the complex structure of A-007, we hypothesized using a
combination of these two previously described methods, which would utilize the chemical
transformation of A-007 into a more water soluble prodrug and then further increase the water
solubility of this newly formed prodrug through the formation of cyclodextrin inclusion
complexes.
The application of cyclodextrins in drug delivery is well documented in the literature.5,6
For example, the toxicity and compatibility of using cyclodextrins in drug delivery has been
previously explored and utilized for several commercialized drugs on the market today.6,7 Our
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intention was to synthesize water soluble prodrugs of A-007 by covalently attaching small
hydrophilic moieties and then spectroscopically explore both the stability of these prodrugs in
aqueous solution, as well as the ability of the prodrugs to form cyclodextrin inclusion complexes.

Results and Discussion
Synthesis of A-007 prodrugs
To explore cyclodextrin inclusion complexes with A-007 prodrugs, we prepared neutral,
anionic, and cationic prodrugs. Scheme 2.1shows the prodrugs synthesized.
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Scheme 2.1. A-007 prodrugs synthesized.

Synthesis of Negative A-007 prodrugs
The synthesis of starts with preparation of A-007. It is made from commercially available
starting materials by the reaction of equivalent amounts of the 2, 4, dinitro phenyl hydrazine and
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4, 4’ dihydroxy benzophenone in methanol or ethanol with sulfuric acid as a catalyst.
Purification is done by recrystallization from ethanol or glacial acetic acid.1,3
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Scheme 2.2. Synthesis of negative A-007 prodrugs

Acetic acid derivative 2Na was prepared by treatment of ethyl 2-bromoacetate with A007 sodium salt. The resulting ester is hydrolyzed, followed by acidification to yield prodrug
2Na according to previously reported methods of preparation for similar phenol derivatives.8
Prodrug 6 is a succenic acid derivative. It is made by coupling A-007 with mono-Boc protected
succenic acid 8 under DCC coupling conditions, followed by trifluoroacetic acid deprotection of
Boc group in dichloromethane. The succenic acid prodrug is used in the form of its ammonium
salt. The salt is made by passing ammonia gas generated from a mixture of ammonium
hydroxide and sodium hydroxide into a dichloromethane solution of 6H. The synthesis is shown
in scheme 2.3.
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Synthesis of Neutral A-007 prodrugs
The neutral A-007 prodrug we synthesized was the glycoside 5(Scheme 2.4). This compound
was synthesized with the intention to use it for Enzyme Specific Prodrug Therapy(ESPT). Under
this approach, excessive expression of glycosidase enzymes in the cancer cells is exploited to
break the glycosidic linkage in the prodrug. This would set the active drug (A-007) free at the
site of action. For this purpose the sugar needs to be linked to A-007 at the anomeric position
regioselectively. We chose to use trichloroacetimidate method of sugar action to carry out this
glycosidation. This method utilizes BF3 as a lewis acid catalyst which is mild enough not to
disturb the shiff base moiety of A-007. D-glucose is completely protected and activated to tetraO-acetyl-a-D-glucopyranosyl trichloroacetimidate in three steps in 48% overall yield, using
literature procedures with minor modifications (Scheme 2.4).10 The first step of prodrug

33

synthesis involved Schmidt’s glucosylation10 of A-007 with 2,3,4,6-tetra-O-acetyl--Dglucopyranosyl trichloroacetimidate,11 followed by sodium hydroxide hydrolysis in mixture of
dichloromethane and methanol.
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Scheme 2.4. Synthesis of prodrug 5

Synthesis of Positive A-007 prodrugs
Amino acid glycine derivatives have been synthesized as the positive A-007 prodrugs. The
trifluoroacetic acid salt 3 was prepared by the acylation of A-007 with Boc-glycine in the
presence of dicyclohexylcarbodiimide, followed by trifluoroacetic acid deprotection in dichloro
methane.9 The hydrochloric acid salt 4 was prepared in a similar manner as the trifluoroacetic
acid salt, except that the Boc-deprotection was carried out with methanolic HCl instead of
trifluoroacetic acid (Scheme 2.5).
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Scheme 2.5. Synthesis of positive A-007 prodrugs

Spectroscopic study of A-007 prodrugs
The simplest possible prodrug of A-007 is its sodium salt (1Na). This compound will be
converted into free A-007 under physiological conditions. Unfortunately, even this double
sodium salt is not soluble in water in high concentrations. While at an elevated temperature
(50°C) 10 mM water solution can be formed, upon cooling, a red colored precipitate forms at
room temperature. It is reasonable to speculate that because A-007 is a surfactant by nature,
molecular aggregates could form in aqueous media. This should be reflected in chemical shift of
the aromatic protons of 1Na versus its concentration. However, our spectroscopic studies
revealed no noticeable difference in chemical shift of 1 mM and 10 mM concentration of 1Na in
water media (Fig. 2), suggesting that A-007 does not form molecular aggregates, such as
micelles.13

The formation of micelles in aqueous media is a desirable property for these

prodrugs, because micellar stability can be a function of concentration. Ideally, a prodrug should
be stable at higher aqueous concentrations, above the critical micellar concentration (CMC) and
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it hydrolyzes easily at lower or below CMC concentrations. In this way, the prodrug can be
stored at higher concentrations and upon administration it slowly hydrolyzes in the blood stream.

Figure 2.2. 1H NMR spectra of aqueous 1Na.

Ideally, compounds to be used as prodrugs should be water soluble or have the ability to
form cyclodextrin inclusion complexes. To test the capability of 1Na to be used as a prodrug of
A-007, we analyzed the capacity of 1Na to form a cyclodextrin inclusion complex with 
and -cyclodextrins. We prepared a 10 mM solution of 1Na with -cyclodextrin, and observed
that the solution stayed clear for several days, a dramatic improvement considering that the
precipitate forms in approximately 30 min from 10 mM 1Na without -cyclodextrin. (A 10 mM
solution was made by mixing together A-007 with sodium hydroxide in D2O and sonicated at
50°C for 5 min. A solution that is 0.1 mM is the highest water concentration of 1Na that remain
stable for several days.) Table 2.1 gives a list of solubilities of A-007 prodrugs and their cyclodextrin inclusion complexes.
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Table 2.1: List of solubilities of A-007 prodrugs and their -cyclodextrin inclusion complexes.
Entry
#

Prodrug

Max. Aqueous
solubility
0.1mM

Solubility with
saturated
aqueous -CD
10mM

1

1Na

2

Clog P
5.03 +/- 0.57

2Na

0.2mM

12mM

4.51 +/- 0.61

3

3

10mM

>25mM

3.46 +/- 0.62

4

4

10mM

>22mM

3.46 +/- 0.62

5

5

2.8mM

14mM

0.49 +/- 0.60

6

6

0.5mM

21mM

4.55 +/- 0.6

To determine whether a strong cyclodextrin inclusion complex is formed, it is necessary
to observe changes in the spectroscopic pattern of the compound/complex, where these changes
should be reflected by changes in the NMR chemical shifts. In our analyses, we found no
noticeable change in chemical shifts of aromatic protons of 1Na in combination with - or cyclodextrins. This can be explained by the fact that the -cyclodextrin cavity is too small to
encapsulate the phenol moieties of 1Na, while the  cyclodextrin cavity is too large to forms
strong inclusion complexes with 1Na. On the other hand it is well documented that cyclodextrin forms a strong inclusion complex with phenol groups,14 and this observation
corresponds to our spectroscopic data of 1Na and -cyclodextrin. We observed a significant
chemical shift in the NMR spectra of free 1Na and 1Na in aqueous -CD (Figures. 2.3 & 2.4).
The chemical shift changes for 1Na reached saturation at 2:1 ratio -CD and 1Na. This implies
the possibility of a ternary cyclodextrin complex formation between one molecule of 1Na and
two molecules of -CD.24
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Figure 2.3. 1H NMR spectra of aqueous -cyclodextrin of 1Na (10 mM).

Figure 2.4. 1H NMR spectra of aqueous -cyclodextrin of 1Na (10 mM).
Because our one-dimensional NMR spectroscopic study of -CD complexation with 1Na
is not conclusive, additional spectroscopic investigation is essential. There are two additional
spectroscopic methods that can shed more light on the nature of the complex, electron spray
mass spectroscopy (ES-MS) and the two-dimensional nuclear Overhauser spectroscopy
(NOESY). Electron spray mass spectroscopy (ES-MS)15 is an important tool used for the
characterization of non-covalent binding and using this spectroscopic technique, the ternary
complex signal at 1331.1 m/z was observed in the -cyclodextrin and 1Na water solution. This
signal corresponds to the molecular mass of two cyclodextrins and one 1Na (Figure 2.5).
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Figure 2.5. Negative ES-MS spectra of 1Na (0.01 mM) and -cyclodextrin (0.03 mM).

Two-dimensional NOESY (Nuclear Overhauser Spectroscopy) can be used to
demonstrate that two protons or groups of protons are in proximity, as the protons must be within
3.5Å of each other.16 This spectroscopic method is a valuable tool to study -cyclodextrin
inclusion complexes with A-007 prodrugs. Using NOESY, we found that the 2D NOESY spectra
of our -cyclodextrin complex with 1Na showed intense cross peaks indicating interactions
between -cyclodextrin and phenol moiety of 1Na (Figure. 2.6). These two cross peaks indicate
the presence of these groups in the vicinity of 2–5 Å. However there are no cross coupling
signals between -cyclodextrin hydrogens and the hydrogens of the 2,4-dinitrophenyl moiety of
1Na, suggesting that this part of the 1Na molecule is not encapsulated in the -cyclodextrin
cavity. In summary, all spectroscopic studies, including the 1D NMR, 2D NOESY, and ES-MS,
indicate that there is the formation of a ternary inclusion complex that substantially increases the
water solubility of the simple A-007 prodrug, 1Na.
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Figure 2.6. 2D NOESY spectra of 1Na (10 mM) in aqueous -cyclodextrin (30 mM).

Figure 2.7. 1H NMR spectra of 2Na (10 mM) in aqueous -cyclodextrin.

Our second compound, the sodium salt 2Na, does not strictly belong to the group of
hydrolysable A-007 prodrugs because it cannot be directly converted into A-007 itself.
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Nevertheless, we chose to include this compound in our study due to the fact that phenol ethers
metabolize via oxidative O-dealkylation, resulting in the formation of a free phenol group, or in
our case to A-007.23 In addition, the corresponding acid 2 also has anticancer activity that is
similar to the original A-007. Unfortunately, the low solubility of this acid also hampers its oral
or intravenous administration. Using carboxylic acid salts as a polar group of 2Na, we expected
this compound to possess physical properties similar to surfactants, lending it capable of forming
molecular assemblies similar to taxol prodrugs reported by Nicolaou and coworkers.17 First, we
explored the change of the NMR chemical shift of 2Na versus its concentration in pure water.
There was a substantial downfield chemical shift observed in the spectra when the concentration
of 2Na increased from 1 mM to 10 mM, while the saturation was achieved after the 10 mM
concentration (after CMC).

Figure 2.8. 2D NOESY of 2Na (10 mM) in aqueous -cyclodextrin (30 mM).
In the aqueous cyclodextrin solution of 2Na we expected to observe the appropriate
NMR chemical shift changes when the cyclodextrin inclusion complex is formed. There were no
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noticeable changes when either -cyclodextrin or -cyclodextrin was added to aqueous 2Na (10
mM). This observation did not come as a surprise as the -cyclodextrin cavity is too small (4.7–
5.3 Å) while -cyclodextrin cavity is too big (7.5–8.3 Å) to form strong inclusion complexes
with 2Na.18 However, there was a substantial difference with -cyclodextrin (Figure. 2.7). This
difference is profound on the chemical shift of the phenol moiety of the prodrug, indicating that
this part of the molecule interacts with -cyclodextrin. As was the case with 1Na, the cyclodextrin titration of 10 mM solution of 2Na suggests that a ternary (one molecule of 2Na
and two molecules of -cyclodextrin) complex is formed. This was based on the fact that after a
ratio of 1:2 was reached, further increases of -cyclodextrin did not produce noticeable chemical
shift changes in the NMR spectra of 2Na.
Two-dimensional NOESY spectra clearly support our assumption that the ternary cyclodextrin inclusion complex with 2Na is formed (Figure. 2.8). There are several NOE cross
couplings between the two phenol moieties of prodrug 2Na and the cyclodextrin hydrogens.
However, we observed no cross coupling between hydrogens from the 2,4-dinitrophenyl moiety
of 2Na and the -cyclodextrin hydrogens. Furthermore, cross coupling between the methylene
hydrogens of the acetic acid moieties and -cylcodextrin hydrogens was observed as well. All of
these cross couplings strongly suggest that the formation of a ternary -cyclodextrin inclusion
complex with 2Na in water media as demonstrated in Figure 2.8.
Another prodrug which behaves exactly similar to 1Na and 2Na is prodrug 6. This is the
succenic acid derivative of A-007 used as its ammonium salt which is more stable and more
water soluble than the corresponding free acid. The behavior of 6 towards different
cyclodextrins is similar to the other negative prodrugs 1Na and 2Na, in that there were no
noticeable changes when either -cyclodextrin or -cyclodextrin was added into aqueous 6 (10
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mM). However, there was a substantial difference with -cyclodextrin (Figure. 2.9). This
difference is profound on the chemical shift of the phenol moiety of the prodrug, indicating that
this part of the molecule interacts with -cyclodextrin.

Figure 2.9. 1H NMR spectra of aqueous -cyclodextrin of 6 (10 mM).

Two-dimensional NOESY spectra of 6 clearly supported our assumption that the ternary
-cyclodextrin inclusion complex is formed (Figure. 2.10). There are several NOE cross
couplings between the two phenol moieties of prodrug 6 and the cyclodextrin hydrogen.
However, we observed no cross coupling between hydrogens from the 2,4-dinitrophenyl moiety
of 6 and the -cyclodextrin hydrogens. Furthermore, cross coupling between the methylene
hydrogens of the succenic acid moieties and -cylcodextrin hydrogens was observed as well. All
of these cross couplings strongly suggest that the formation of a ternary -cyclodextrin inclusion
complex with 6 as demonstrated in Figure 2.10.
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Figure 2.10. 2D NOESY of 6(1 mM) in aqueous -cyclodextrin (3 mM).

The previously described prodrugs (1Na, 2Na and 6) are salts and therefore are
negatively charged organic molecules that revert to the corresponding target low water soluble
drugs upon acidification. At physiological pH (7.4) these prodrugs must be used in combination
with -cyclodextrin. To ensure a proper drug delivery using prodrugs, it is of crucial importance
to explore ‘neutral’ (less pH sensitive) A-007 prodrugs. A second very important point in the
design of the A-007 prodrug is its timely release to the targeted area. Therefore, the half-life of
drug released from the prodrug is an important factor in drug design.19 The ideal prodrug is the
one that is instantly transformed into the target drug at the site in which biological activity is
desired.
Glucosides of active biological compounds are very often used in ESPT (Enzyme specific
prodrug therapy) strategy.20 Due to differing physiological conditions enzyme groups such as
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glucoronidases show activity in excess in cancer cells compared to normal cells. Several
prodrugs have been developed taking advantage of the excessive activity of these enzymes in
tumor tissues. This strategy provides the means to selectively deliver an active drug to its
intended target from an inactive glycoside prodrug. This condition is of particular importance in
targeting cancer cells.

Figure 2.11. Negative ES-MS of diglucoside 5 (0.01 mM) and aqueous -CD (0.03 mM).

Considering this, our glucoside 5 should be an ideal prodrug for A-007. After delivery of
the glucoside 5 to the vicinity of the cancer cell, the free drug A-007 should be delivered by
enzymatic glycoside bond cleavage. To further support this hypothesis, it was also determined in
vitro that prodrug 5 has slightly higher anticancer activity than the original A-007. However, the
solubility of 5 is still relatively low (~2 mg/1 mL of water). The solubility of this compound is
fivefold higher in the presence of -cyclodextrin (from ~2 mg/1mL of water to 10 mg/1 mL of
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aqueous -CD). Even so, we could not observe substantial change of aromatic NMR chemical
shift of 5 with any of the three cyclodextrins. However, in the ES-MS spectra of 5 in aqueous cyclodextrin, there is a weak signal that corresponds to the complex between one -CD and one
molecule of 5 (Figure. 2.11). The only plausible explanation is that inter-molecular interactions
between 5 and -cyclodextrin occurred between glucose moieties of 5 and the outside wall of cyclodextrin. That will increase the solubility of 5 in -CD, show the molecular associate signal
in ES-MS, but have no influence on the chemical shift of aromatic signals that are relatively far
away from the molecular interactions.

Figure 2.12. 1H NMR spectra of aqueous -cyclodextrin of 3 (10 mM).

Figure 2.13. 1H NMR spectra different concentration of aqueous -cyclodextrin of 3.
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To explore the influence of cationic A-007 prodrugs on delivery (half-life), solubility, and
anticancer activity, we prepared and studied the physical properties of glycine derived prodrugs 3
and 4. The NMRs indicated the formation of -cyclodextrin inclusion complexes (Figure 2.12
and 2.13). These compounds are hydrolysable prodrugs sensitive to the moisture and their
stability in aqueous media might be questionable, based on the shelf-life of the compounds.21
Considering that these compounds have surfactant-like properties, it is reasonable to expect that
they might be able to form molecular aggregates similar to micelles in aqueous media.
Aggregation was nicely demonstrated by following the NMR chemical shift for aromatic protons
versus concentration of 4 in water media (Figure. 2.14). We observed a substantial downfield
chemical shift with increasing concentration, with the maximal effect observed at 10 mM. At this
concentration, aqueous 4 is stable at room temperature for long periods (at least three months).
We assume that at this concentration, 4 forms molecular aggregates similar to micelles (Figure.
2.14), which slow down the hydrolysis of the ester group.

Figure 2.14. Dependence of concentration of 4 on the chemical shift.

47

Figure 2.15. 1H NMR showing hydrolysis of 4.

To confirm this assumption, we also explored the water stability of 4 at 1 mM
concentration (Figure. 2.14, 2.15). Almost instantly, hydrolysis of the two ester groups of 4
started and the precipitation of A-007 could be observed. Due to the exceptionally low water
solubility of A-007, we were not able to obtain the NMR spectra of pure A-007 in water, and the
additional signals in the NMR spectra of 4 after one and two days (fig 2.15) correspond to the
mono ester of A-007 (partially hydrolyzed product of 4). The NMR spectra of 4 with progress of
time were used for computing the half-life of this. The half-life was determined by evaluating the
decline of prodrug peak intensity (integration) versus time. It was determined that the half-life of
4 as a 1 mM concentration at room temperature was around 24 hours. As mentioned above, at a
10 mM concentration the formation of the precipitate was not observed even after a few months
at 5°C. The comparative stabilities of 4 after 1, 2 and 3 days is shown in figure.2.16.
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Figure 2.16. 1H NMR depicting concentration dependence of stability of 4.

Prodrug 3 behaves similar to prodrug 4 in that there is a noticeable difference in the
chemical shift of the 3 protons in aqueous -cyclodextrin, indicating strong interactions between
-cyclodextrin and 3. Unfortunately, we were not able to record a reliable two-dimensional
NOESY NMR spectra due to fact that 3 hydrolyzed in water media. In the NMR sample there are
three components (3, monoester of A-007, and A-007) in complex with -cyclodextrin. The
molar ratio of these three components varies with the progression of the NMR recording time.
This is clearly demonstrated on the one-dimensional spectrum of 3 in water and -cyclodextrin
(Figure. 2.17). Even for the freshly prepared sample of 3in water, the NMR spectra (acquired
after 10 min) shows the presence of partially hydrolyzed 3. Full hydrolysis of 3 generates A-007
that immediately precipitates from the solution.
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Regardless of the fact that the characterization of the -cyclodextrin inclusion complex
with 3 is hard to evaluate by two-dimensional NMR spectroscopy, we believe that the 1H NMR
spectra supports the formation of the -cyclodextrin inclusion complex. Furthermore, this
prodrug half-life (~4.5 hours in aqueous -cyclodextrin) seems to be ideal for pharmacological
study of this prodrug 3.

Conclusion
Several interesting A-007 prodrugs were prepared through ester, ether, and acetal
linkages of polar molecules to A-007. All the prodrugs have significantly higher water solubility
as compared to original A-007. To further increase their water solubility, alter their water halflife, and biodelivery, cyclodextrin inclusion complexes were studied. Through one-dimensional
NMR, two-dimensional NOESY, and negative ES-MS spectroscopy studies, it was demonstrated
that inclusion complexes with -cyclodextrin were formed for all but A-007 glucoside 5. It
seems that the -cyclodextrin cavity is too small and the -cyclodextrin cavity is too large to
form stable inclusion complexes with these studied A-007 prodrugs. It was postulated that cyclodextrin forms a 2:1 inclusion complex with the studied A-007 prodrugs. None of the three
studied cyclodextrins form inclusion complexes with the diglucoside of A-007, although they
slightly increase the prodrug water solubility. This prodrug was prepared for targeted cancer
therapy (ESPT).

50

Experimental
Melting points were taken on an Electrothermal IA 9000 Digital Melting Point Apparatus and are
uncorrected. The 1H and 13C NMR spectra were run on Varian 300 MHz Gemini2000, Varian
400 MHz Unity, Varian 500 MHz Unity and in CDCl3, DMSO-d6 as solvent and internal
standard. When D2O is used as solvent then DMSO in D2O (in a sealed capillary inside the
NMR tube) is used as the internal standard (2.5 ppm). Two-dimensional NOESY spectra were
recorded on Varian INOVA 500MHz spectrophotometer with D2O as a solvent and internal
standard (4.80 ppm). The mass spectra were recorded on a Micromass Quattro 2 Triple
Quadropole Mass Spectrometer. The prepared ammonium A-007 prodrugs are hydroscopic and
decompose by ester hydrolysis. However under dry conditions they can be stored for at least
several months. All compounds have melting points higher than 200°C and decompose before
melting. For ammonium compounds 3 and 4 carbon NMR spectra were not reported because
they decompose in solution during NMR acquisition time. For these compounds 1H NMR
samples were prepared immediately before recording the spectrum.

4, 4’ Dihydroxybenzophenone 2, 4 dinitrophenyl hydrazone (1)
MeOH suspensions (300 mL) of substituted 2,4 dinitrophenylhydrazine (29.3g, 0.148 mol) and
concentrated sulfuric acid (20 mL) were stirred at 50°C. After the hydrazine dissolved, a MeOH
solution (300 mL) of the 4, 4’ dihydroxybenzophenone (0.1 mol) was added to the hydrazine and
the resulting reaction mixture was stirred at 50°Cfor additional 30 min. The reaction mixture was
concentrated to 1/4 of its original volume under vacuum and diluted with water (500 mL). The
precipitates were separated by filtration and washed with 3% aqueous NaHCO3 (3 x 100 mL)
and water (3 x 50 mL). Products were recrystallized from MeOH, EtOH, or glacial AcOH. The
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product was obtained as deep-red crystals in 78% yield. M.p. 270-272 °C. IR: 3506 (N-H), 3288
(N-H), 2921 (Ar-H), 1614 (C=N), 1592, 1503, 1417, 1336, 1311, and 1139 cm-1. 1H NMR
(DMSO-d6, 300 MHz):  11.13 (1H, s), 10.05 (1H, s), 9.99 (1H, s), 8.78 (1H, d, J= 2.7 Hz), 8.36
(1H, dd, J1 = 9.6 Hz, J2 =2.7 Hz), 8.12 (1H, d, J= 9.6 Hz), 7.47 (2H, d, J= 8.7 Hz), 7.22 (2H, d,
J= 8.4 Hz), 7.01 (2H, d, J= 8.1 Hz), 6.81 (2H, d, J= 8.4 Hz). 13C NMR (DMSO-d6, 100 MHz):
 156.19, 155.31, 152.33, 140.47, 133.27, 126.50, 126.35, 126.02, 125.50, 124.07, 119.46,
118.19, 112.97, 112.90, and 111.91 ppm. Anal. Calcd for C19H14N4O6: C, 57.87; H, 3.58; N,
14.21. Found: C, 57.42; H, 3.81; N, 13.88.

Ethyl {4-[[(2,4-dinitrophenyl)hydrazono]-( 4-ethoxycarbonyl methoxyphenyl)-methyl]phenoxy}- ethanoate (2Et)
An acetone (500 mL) suspension of A-007 (3.94 g, 0.01 mol), potassium carbonate monohydrate
(3.12 g, 0.01 mol), and ethyl 2-bromoacetate (3.34 g, 0.02 mol) was sonicated at room
temperature for 2 h and heated at reflux overnight. The solvent from dark red suspension
was evaporated to the solid residue. The solid residue was mixed with CH2Cl2 (200 mL), stirred
at room temperature for 2 h, and the insoluble material was separated by filtration. The filtrate
was washed with 10% potassium carbonate, dried over anhydrous magnesium sulfate and
evaporated to deep red solid residue (5.3 g, 94%). According to the NMR spectroscopy product
was more than 96% pure and was used in next step without further purification.
1

H NMR (300 MHz, CDCl3)  11.30 (1H, s), 9.09 (1H, d, J = 2.4 Hz), 8.35 (1H, dd, J1 = 9.3, J2

= 2.4 Hz), 8.18 (1H, d, J = 9.3 Hz), 7,64 (2H, d, J = 9 Hz), 7.32 (2H, d, J = 8.4 Hz), 7.30 (2H, d,
J = 8.7 Hz); 7.17 (2H, d, J = 8.4 Hz), 6.94 (2H, d, J = 9.0 Hz), 4.76 (2H, s), 4.69 (2H, s), 4.37
(2H, q, J = 6.9 Hz), 4.31 (2H, q, J = 6.9 Hz), 1.36 (3H, t, J = 6.9 Hz), 1.34 (3H, t, J = 6.9 Hz);
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13

C NMR (100 MHz, CDCl3) d 168.7, 159.8, 159.4, 155.2, 144.7, 138.0, 130.6, 130.1, 129.9,

129.6, 124.9, 123.7, 116.8, 116.3, 114.8, 65.6, 65.5, 14.4. Anal. Calcd for C27H26N4O10 (MW
566.52): C, 57.24; H, 4.63; N, 9.89. Found: C, 57.08; H 4.77, N 9.72.

(4-{(4-carboxymethoxy-phenyl)-[(2,4- dinitro-phenyl)-hydrazono]-methyl}-phenoxy)-acetic
acid (2)
Water (150 mL), sodium hydroxide (1.6 g, 0.04 mol), and MeOH (150 mL) were mixed with
CH2Cl2 (150 mL) solution of crude A-007 ester (5.3 g, 9.3 mmol). This solution was stirred at
room temperature for 4 h. The reaction mixture was concentrated to 1/3 of its original volume at
40°C and reduced pressure, diluted with water (100 mL), and neutralized with concentrated
hydrochloric acid (10 mL). The solid material was separated by filtration, washed with water (3
x 100 mL), and dried at 110°C for a few hours to afford a product that was pure by NMR
spectroscopy (4.5 g, 95%).
1

H NMR (DMSO-d6, 400 MHz) d 11.12 (1H, s), 8.79 (1H, d, J = 2.4 Hz), 8.34 (1H, dd, J1 = 9.6

Hz, J2 = 2.4 Hz), 8.17 (1H, d, J = 9.6 Hz), 7.54 (2H, d, J = 8.8 Hz), 7.38 (2H, d, J = 8.4 Hz),
7.20 (2H, d, J = 8.4 Hz), 6.99 (2H, d, J = 8.4 Hz), 4.81 (2H, s), 4.73 (2H, s); 13C NMR (DMSOd6, 100 MHz) d 169.93, 169.90, 159.6, 159.0, 154.6, 144.1, 137.1, 130.1, 130.0, 129.6, 129.3,
123.8, 122.9, 116.6, 115.8, 114.7, 64.7, 64.6. Anal. Calcd for C23H18N4O10 (MW 510.41): C,
54.12; H, 3.55; N, 10.98. Found: C, 53.98; H, 3.63; N, 10.87.
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tert-butoxycarbonylamino-acetic acid 4-{[4-(2-tert-butoxycarbonylamino-acetoxy)phenyl]- [(2,4-dinitro-phenyl)-hydrazono]-methyl}-phenyl ester (3BOC)
tert-Butoxycarbonylamino-acetic acid (175 mg, 1 mmol), A-007 (197 mg, 0.5 mmol), and
dicyclohexylcarbodiimide (248 mg, 1.2 mmol) were taken in 20 mL of dry CH2Cl2.
The reaction mixture was stirred at 0°C for 1 h and then at room temperature overnight. The
progress of the reaction was monitored by proton NMR spectroscopy. The reaction mixture was
concentrated to half of the original volume and filtered. The white residue was discarded and the
filtrate was further concentrated and subjected to column chromatography on a silica gel column
with CH2Cl2 and EtOAc (10:1) producing pure product (140 mg; 40%). 1H NMR (CDCl3, 400
MHz) 11.20 (1H, s), 9.01 (1H, d, J = 2.8 Hz), 8.33 (1H, dd, J1 = 9.6 Hz, J2 = 2.0 Hz), 8.14 (2H,
d, J = 9.6 Hz), 7.43 (2H, d, J = 8.8 Hz), 7.38 (2H, d, J = 8.4 Hz), 7.15 (2H, d, J = 8.8 Hz), 5.28
(2H, m), 4.22 (2H, d, J = 4.8 Hz), 4.18 (2H, d, J = 4.4 Hz), 1.48 (9H, s), and 1.47 (9H, s); 13C
NMR (CDCl3, 100 MHz) 169.1, 168.9, 155.9, 153.6, 152.2, 152.0, 144.5, 136.4, 134.3, 130.1,
129.9, 129.8, 129.3, 123.5, 121.8, 116.7, 80.5, 42.8, 28.4. Anal. Calcd for C33H36N6O12 (MW
708.67): C, 55.93; H, 5.12; N, 11.86. Found: C, 55.73; H, 5.12; N, 11.77.

3,3’-(4,4’-((2-(2,4-dinitrophenyl)- hydrazono)methylene)bis(4,1-phenylene)bis(oxy))bis- (2oxoethylammonium trifluoroacetate) (3)
A mixture of CH2Cl2–trifluoroacetic acid (9 mL:1 mL) was cooled to 0°C and 3BOC was added
(354 mg, 0.5 mmol). The reaction mixture was stirred at 0°C for 1 h and solvent was evaporated
under a stream of nitrogen resulting in red crystalline product (361 mg; 98%). 1H NMR
(DMSO-d6, 400 MHz) d 11.04 (1H, s), 8.83 (1H, d, J = 2.4 Hz), 8.48 (3H, m), 8.83 (3H, m),
8.26 (2H, d, J = 9.3 Hz), 7.78 (2H, d, J = 8.8 Hz), 7.66 (2H, d, J = 8.4 Hz), 7.55 (2H, d, J = 8.4
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Hz), 7.32 (2H, d, J = 8.8 Hz), 4.21 (2H, m), 4.16 (2H, m). Anal. Calcd for C27H22F6N6O12.2H2O
(MW 772.52): C, 41.98; H, 3.39; N, 10.88. Found: C, 42.02; H, 3.37; N, 10.75.

3,3’-(4,4’-((2-(2,4-dinitrophenyl)- hydrazono)methylene)bis(4,1-phenylene)bis(oxy))bis- (2oxoethylammonium chloride) (4)
A CH2Cl2 (0.2 mL) solution of 3BOC (45 mg; 0.06 mmol) was injected into an ice cold MeOH
(2 mL) solution of hydrochloric acid (made by the addition of 0.2 mL of oxalyl chloride). A red
hygroscopic precipitate was immediately formed. The product was separated by filtration,
washed with CH2Cl2 (3 x 0.5 mL), and dried under nitrogen to produce a product that was pure
by NMR spectroscopy (33 mg, 95%). 1H NMR (DMSO-d6, 400 MHz) d 11.04 (1H, s), 8.33 (1H,
d, J = 2 Hz), 8.45 (1H, dd, J1 = 9.6 Hz, J2 = 2.0 Hz), 8.26 (1H, d, J = 9.6 Hz), 7.77 (2H, d, J =
8.4 Hz), 7.64 (2H, d, J = 8.0 Hz), 7.56 (2H, d, J = 8.4 Hz), 7.32 (2H, d, J = 8.4 Hz), 4.18 (2H, s),
4.13 (2H, s). Negative ES-MS m/z 507.4 (M-2HCl-H+), 450.3 (M-3HCl-COCH2NH2+), 393.4
(M-2HCl- 2COCH2NH2-H+); Anal. Calcd for C23H22Cl2N6O8. 2H2O (MW 617.39): C, 44.74; H,
4.24; N, 13.61. Found: C, 44.56; H, 4.31; N, 13.45.

Penta-O-acetyl-D-glucopyranose (10): D-glucose (20 g, 110 mmol) was refluxed in pyridine
(150 mL) for 1 hour. Acetic anhydride (100 mL) was added and the mixture was refluxed an
additional 2 hours. The resulting solution was cooled to room temperature, poured over ice (300
mL) and stirred until the product solidified, about 2 hours. The solid was filtered, washed with
water, and recrystallized from ethyl acetate/hexanes to give 10 as a white solid (36 g, 83 %
yield). 10β: D-glucose (5.0 g, 28 mmol), sodium acetate (4.0 g, 50 mmol), and acetic anhydride
(30 mL) were stirred at 100°C for 3 hours. The mixture was cooled to room temperature, poured
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over ice (150 mL) and stirred for 2 hours. The resulting white solid was filtered and washed with
water and recrystallized from methanol to give 10β as a white solid (3.7 g, 38 % yield). 1H NMR
of 10β (400 MHZ, CDCl3): δ 5.72 (1H, d, J = 4.0 Hz), 5.26 (1H, t, J = 9.2 Hz), 5.14 (1H, t, J =
8.8 Hz), 5.13 (1H, t, J = 10.0 Hz), 4.30 (1H, dd, J1 = 6.2 Hz, J2 = 2.2 Hz), 4.12 (1H, dd, J1 = 6.3
Hz, J2 = 1.0 Hz), 3.84 (1H, m), 2.12 (3H, s), 2.09 (3H, s), 2.04 (6H, s), 2.01 (3H, s). 13C NMR of
10β (100 MHz, CDCl3): δ 170.7, 170.3, 169.8, 169.5, 168.9, 89.1, 69.9, 69.2, 67.9, 61.5, 20.9,
20.8, 20.7, 20.6, 20.5.

2,3,4,6-Tetra-O-acetyl–D-glucopyranose(11): D-glucose penta acetate (10 g, 26 mmol) and 2aminoethanol (3.9 g, 64 mmol) were dissolved in ethyl acetate (250 mL) and DMSO (2.5 mL)
and stirred at room temperature overnight. The mixture was washed with water (3 x 150 mL),
dried over sodium sulfate and concentrated to give 11 as colorless syrup (6.2 g, 70% yield). This
product was used immediately in the further reactions without further purification. 1H NMR of
11α (300 MHz, CDCl3): δ 5.51 (1H, t, J = 9.9 Hz), 5.45 (1H, d, J = 1.5 Hz), 5.06 (1H, t, J = 9.9
Hz), 4.89 (1H, dd, J1 = 5.03 Hz, J2 = 1.8 Hz), 4.26 – 4.06 (3H, m), 2.07 (3H, s), 2.06, (3H, s),
2.01 (3H, s), 2.00 (3H, s). 13C NMR of 11α (100 MHz, CDCl3): δ 171.2, 170.5, 170.4, 169.9,
95.3, 73.0, 72.5, 71.9, 68.4, 68.2, 20.8, 20.7, 20.6, 20.6. 13C NMR of 11β (100 MHz, CDCl3): δ
171.2, 170.5, 170.4, 169.9, 90.0, 71.2, 70.0, 68.6, 67.0, 62.0, 20.8, 20.7, 20.6, 20.6.
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Tetra-O-acetyl-α-D-glucopyranosyl trichloroacetimidate (12):
2,3,4,6-Tetra-Oacetyl–D-glucopyranose(11) (2.0 g, 3.3 mmol), K2CO3 (1.1 g, 8.2 mmol), and
trichloroacetonitrile (5 mL) were stirred at room temperature in dichloromethane (20 mL) for 48
hours. The resulting suspension was filtered through silica gel using a 1:1 mixture of CH2Cl2 and
Et2O (150 mL). The filtrate was concentrated to give 12 as a pale yellow solid (2.0 g, 83 %
yield). 1H NMR (400 MHz, CDCl3): δ 8.67 (1H, s), 6.52 (1H, d, J = 1.8 Hz), 5.53 (1H, t, J = 9.6
Hz), 5.15 (1H, t, J = 10.0 Hz), 5.10 (1H, dd, J1 = 6.8 Hz, J2 = 2.0 Hz), 4.24 (1H, dd, J1 = 6.2 Hz,
J2 = 2.0 Hz), 4.18 (1H, m), 4.10 (1H, dd, J1 = 6.0 Hz, J2 = 1.0 Hz), 2.05 (3H, s), 2.02 (3H, s),
2.00 (3H, s), 1.99 (3H, s). 13C NMR (100 MHz, CDCl3): δ 170.9, 170.3, 170.2, 169.8, 161.0,
93.0, 70.2, 70.0, 69.9, 67.9, 61.5, 20.8, 20.8, 20.6.

4,4’-dihydroxybenzophenone-2,4-dinitrophenylhydrazone bis(2,3,4,6-tetra-O-acetyl-Dglucopyranoside) (5Ac)
2,3,4,6-Tetra-O-acetyl--D-glucopyranosyl-trichloroacetimidate (370 mg, 0.75 mmol) and A007 (118 mg, 0.3 mmol) were stirred under an atmosphere of nitrogen in anhydrous CH2Cl2 (20
mL) with 3Å molecular sieves for 1 h. The solution was cooled in an ice-bath for 30 min before
BF3-OEt2 (2 mL) was added and stirred for 1 min the ice-bath followed by 1 h at room
temperature. The solution was added to an ice cold saturated aq NaHCO3 solution (100 mL) with
vigorous stirring and then extracted with ether (2 x 75 mL). The organic layers were combined
and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure
and the residue was purified by flash column chromatography (CH2Cl2 –CH3CO2Et 10:1) to give
5Ac as red crystalline solid (86 mg; 40%).
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1

H NMR (CDCl3, 400 MHz)  11.28 (1H, s), 9.09 (1H, d, J = 2.8 Hz), 8.37 (1H, dd, J1 = 2.8 Hz,

J2 = 9.6 Hz), 8.17 (1H, d, J = 9.2 Hz), 7.61 (2H, d, J = 8.8 Hz), 7.31 (2H, d, J = 8.8 Hz), 7.25
(2H, d, J = 8.8 Hz), 5.40–5.10 (6H, m), 4.30 (2H, m), 4.20 (2H, t), 3.9 (2H, m), 2.13 (3H, s),
2.09 (3H, s), 2.08 (3H, s), 2.075 (6H, s), 2,071 (3H, s), and 2.065 (3H, s). Negative ES-MS
1011.8 [M-H-] ; positive ES-MS 1035.8 [M+Na]+. Anal. Calcd for C45H48N2O23 (MW 1012.88):
C, 53.36; H, 4.78; N, 5.53. Found: C, 53.25; H, 4.88; N, 5.42.

4,4’-dihydroxybenzophenone-2,4-dinitrophenylhydrazone bis(-D-glucopyranoside) (5)
Octa-acetate 5Ac (101 mg, 0.1 mol) was dissolved in 2:1 MeOH–CH2Cl2 (30 mL). Sodium
hydroxide (1 M) was added to a pH 9–10. The solution was stirred at room temperature
overnight, neutralized with acidic Dowex resin, and evaporated. The solid residue was dried
under reduced pressure at room temperature to give 68 mg (95%) of red crystalline product. 1H
NMR (DMSO-d6, 400 MHz) d 11.13 (1H, s), 8.80 (2H, d, J = 2.4 Hz), 8.40 (2H, dd, J1 = 9.6
Hz, J2 = 2.4 Hz), 8.19 (2H, d, J = 9.6 Hz), 5.54 (1H, d, J = 4.8 Hz), 5.48 (1H, d, J = 4.8 Hz),
5.18 (4H, m), 4.99 (1H, d, J = 7.2 Hz), 4.92 (1H, D, J = 7.4 Hz), 4.74 (1H, t, J = 5.6 Hz), 4.67
(1H, t, J = 5.6 Hz), 3.2 (4H, m); 13C NMR (DMSO-d6, 100 MHz)  159.4, 159.0, 154.9, 144.5,
137.6, 130.6, 130.3, 129.7, 129.6, 125.0, 123.4, 117.8, 117.0, 116.6, 100.6, 100.3, 77.3, 76.8,
73.6, 73.5, 70.0, 61.0. Positive ES-MS 731.5 [M+Na]+; Negative ES-MS 717.4 [M-H]. Anal.
Calcd for C31H34N4O16 (MW 718.62) C, 51.81; H, 4.77; N, 7.80. Found: C, 51.65; H, 4.88; N,
7.68.

Succinic acid mono-t-butyl ester (8)
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To a mixture of succinic anhydride (3g, 30 mmol), N-hydroxysuccinimide(1g, 9 mmol) and
DMAP (0.35 g, 2.86 mmol) in toluene (50 mL) were added tert-butyl alchohol (5 mL) and
triethyl amine (9mmol, 1.25 mL). The brownish solution was refluxed for 24 h. The solution
was cooled and diluted with ethyl acetate (50 mL) was washed with 10% citric acid (2 x 50 mL)
and brine, dried over anhydrous Na2SO4 , and concentrated to give a brown oil, which on
recrystallization from diethyl ether/petroleum ether (1:3) afforded pure 8 (4.1g, 78%). 1H NMR
(300 MHz, CDCl3)  2.65-2.50 (m, 4H), 1.45(s, 9h). ESI-MS: m/z [M-H]- =173.1. 13C NMR
(DMSO-d6, 100 MHz)d 150.3, 141.9, 117.4.

Succinic acid 4-{[4-(3-tert-butoxycarbonyl-propionyloxy)-phenyl]-[(2,4-dinitro-phenyl)hydrazono]-methyl}-phenyl ester tert-butyl ester (6tBu)
Succinic acid mono-tert-butyl ester (8) (3.13g), A-007 (2.5g), and dicyclohexylcarbodiimide
(3.92g) were taken in 50 mL of dry CH2Cl2. The reaction mixture was stirred at 25°C for 1 h
and then at room temperature overnight. The progress of the reaction was monitored by proton
NMR spectroscopy. The reaction mixture was concentrated to half of the original volume and
filtered. The white residue was discarded and the filtrate was further concentrated and subjected
to column chromatography on a silica gel column with CH2Cl2 and EtOAc (7:1) producing pure
product (2.24 g; 50%). 1H NMR (400 MHz, CDCl3) δ 11.26 (s, 1H), 9.09 (d, J = 2.5, 1H), 8.38
(dd, J = 2.5, 9.6, 1H), 8.19 (d, J = 9.6, 1H), 7.71 (d, J = 8.7, 2H), 7.422 (q, 4H), 7.166(d,J=8.8,
2H), 2.80 (m, 8H), 1.45 (m, 18H); 13C NMR (100 MHz, CDCl3) δ 171.4, 171.0, 170.9, 153.9,
152.6, 152.3, 144.6, 138.3, 134.1, 130.2, 129.9, 129.7, 129.3, 129.0, 123.6, 122.0, 116.7, 30.4,
30.3, 29.7, 29.7, 28.3. Anal. Calcd for C35H38N4O12(MW 706.70) C, 59.48; H, 5.42; N, 7.93.
Found: C, 59.36; H, 5.49; N, 7.83.
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Succinic acid mono-(4-{[4-(3-carboxy-propionyloxy)-phenyl]-[(2,4-dinitro-phenyl)hydrazono]-methyl}-phenyl) ester (6)
A mixture of CH2Cl2–trifluoroacetic acid (9 mL:1 mL) was cooled to 0°C and 6tBu was added
(200 mg, 0.28 mmol). The reaction mixture was stirred at 0°C for 8 h and solvent was
evaporated under a stream of nitrogen resulting in red amorphous product. It is stirred in 5 mL
of ice cold hexane at 0°C for 10 minutes. Hexane is reduced to half its volume under a slow
stream of nitrogen. The product is filtered under vacuum to yield pure product as seen in NMR
(160 mg; 98%). 1H NMR (400 MHz, D2O) δ 10.43 (s, 1H), 9.09 (s, 1H), 8.42 (d, J = 16, 1H),
8.11 (d, J = 12.2, 1H), 7.63 (d, J = 8, 2H), 7.23 (d, J = 16.2, 2H), 6.92 (d, J = 8.7, 2H), 6.72 (d, J
= 8.4, 2H), 2.61(m, 8H); 13C NMR (100 MHz, D2O) δ 177.4, 169.1, 169.3, 155.9, 155.8, 155.0,
146.1, 135.9, 131.0, 138.2, 121.6, 121.1, 128.3, 128.4, 128.1, 116.5, 116.1; Anal. Calcd for
C27H22N4O12 (MW 594.48) C, 54.55; H, 3.73; N, 9.42; Found: C, 51.43; H, 4.16; N, 8.89.
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Chapter III. Chemoselective debenzylation by Catalytic Hydrogen Transfer
Reactions in the presence of the Nitro and Imino Functionalities.

Abstract
It is impossible to envision any synthetic task of preparation of complex natural products
without protecting groups in the course of their preparation. Removal of the protecting group is
sometimes a very demanding process due to presence of functionalities in the molecules that are
sensitive to the deprotection reaction conditions. In an attempt to synthesize hydrophilic A-007
prodrugs, we have had a similar problem. To circumvent this problem, we explored
chemoselective benzyl deprotection methodologies and determined several simple solutions with
variety of chemoselectivities towards aliphatic/ aromatic benzyl groups, nitro groups and
hydrazone moieties in good yields. For debenzylation of A-007 prodrugs, catalytic
hydrogenation as well as use of strong acids was avoided in deference to the sensitivity of nitro
group and the lability of the hydrazone and ester moieties.

Introduction
Despite promising anticancer activity,1-9 due to its very low solubility in water, A-007
cannot be delivered either orally or intravenously. To be able to use it orally or intravenously the
drug should be labile-bound to nontoxic water soluble compounds called carrier molecules.
Several options for carrier molecules include saccharides and amino acids.10-13 Target structures
of these simple A-007 prodrugs from each of these families are presented in Scheme 3.1.
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Prodrug 1 is a saccharide derivative and prodrug 2 is lactic acid saccharide derivative of
A-007. Using conventional protection groups to connect saccharide and lactic acid moieties is
hampered by the acid-base sensitivity of ester group of 2, and the acid sensitivity of acetal and
hydrazone group of 1 and 3. Benzyl protection of the alcohol moiety would be ideal but 2,4dinitrophenylhydrazone moiety of A-007 cannot withstand reduction conditions required for
benzyl group removal. Therefore, if we have the capability to selectively remove the benzyl
protection group from 3, 4 and 5, then a road to preparation of oligosaccharide and
peptidosachharide derivatives of A-007 will be established.
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HO
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NH
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Bn=benzyl (C6H5CH2-)

NO2

Figure 3.1. A-007 saccharide and amino acid saccharide prodrugs

Considering the availability of both the 2,3,4,6-tetra-O-benzyl--D-glucopyranosyl
trichloroacetimidate14-18 and benzyl lactate19, as well as availability of synthetic methodology for
their coupling with A-007, one can assume that preparation of prodrugs 1 and 2 is a simple
synthetic task (Figure 3.1). However, removal of the benzyl protection group from 4 and 5 is
daunting task considering that the A-007 moiety contains easy to reduce functionalities (nitro
and hydrazine). Therefore, broadly used debenzylation methods such as catalytic
hydrogenation20, 21 cannot be applied in these cases. The presence of acetal, ester, amino, and
hydrazine groups preclude the use of a strong acid as catalyst for dibenzylation.22-25 There are a
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few literature indications that benzyl protection can be removed through catalytic hydrogen
transfer, but26, 27 to the best of our knowledge a thorough study of benzyl deprotection in
presence of easily reduced functionalities has not yet been performed. For this reason, we
explored benzyl deprotection methodologies. The goal was to select a suitable catalyst and
develop an optimized catalytic procedure in which the level of the nitro-reduced and hydrazone
reduced product was minimized. A variety of palladium catalysts with different sources of
hydrogen were employed to explore these possibilities. The effect of different variables on the
activity and selectivity of the debenzylation were investigated attempting to establish a suitable
one-pot reduction method for chemoselective debenzylation. Our study indicated that with
proper selection of the catalyst, hydrogen source and control of the reaction conditions, the
selectivity for the desired debenzylation product can be achieved as high as 95%. In addition, we
also determined several simple solutions to obtain variety of other chemoselectivities (nitro
reduction in preference to benzyl, aromatic debenzylation in preference to aliphatic
debenzylation etc.) in good yields.
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Scheme 3.1. Retrosynthetic path for prodrugs 4 and 5.
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Results and discussion
In order to know the selectivity of different debenzylation conditions, we needed to first
synthesize substrates 4 and 5. At the start of this investigation, we did not have these compounds
available and we needed to develop a method first before pursuing this synthetic pathway.
Hence we needed model substrates which provided the required functionalities whose relative
reducibility were to be determined. For this purpose, we designed the three model compounds
shown in table 3.1. Compound 6 can be used to test under a particular set of reduction
conditions, the chemoselective reduction of nitro group over debenzylation or vice versa .
Similarly, compound 8 can determine selectivity of the reducing agent towards the hydrazine
functional group, in addition to the nitro group. The compound that we finally planned to
perform the debenzylation, includes the benzyl group on a sugar moiety, hence analogues
compound 7 is one of the model compounds included.

6.

7.
NO2
O

8.
H OBn

O

H O
BnO
BnO

H
H

O
N

N

H
NO2

OBn O
NO2

Table 3.1: Model compounds.

Transfer Hydrogenation with Formic Acid Analogues
The first transfer hydrogenation reagent we choose was used formic acid as the hydrogen
source.26, 27 Transfer hydrogenation using formic acid as hydrogen donor is simple and is of
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interest because it avoids some of the inconvenient aspects of conventional hydrogenation
procedures. As compared to hydrogen, formic acid is very soluble in most common solvents. It
reacts rapidly with palladium on charcoal at room temperature even without the presence of a
hydrogen acceptor to give a hydrogenated palladium, PdnH, and carbon dioxide.27 Transfer
hydrogenation with formic acid28 and palladium thus appears to proceed in two separate and
distinct steps as follows:

HCOOH + 2n Pd

2 PdnH + CO2

2 PdnH

AH2 + 2n Pd

+A

HCOOH + A

2AH2 + CO2

The simplicity of this procedure makes it very attractive considering no special
hydrogenating equipment is necessary. We explored the novelty of this reaction on the three
model compounds that were previously prepared (Table 3.1). Unfortunately, these conditions
seemed too harsh for the reduction sensitive functionalities in our target substrates. Under these
conditions, both the the nitro and benzyl groups were reduced in both model compounds 6 and 8.
Model compound 7 was completely debenzylated, indicating that while formic acid is a good
debenzylating agent, it does not offer the required chemoselectivity with respect to the other
reduction sensitive functionalities in question. We then attempted to see if chemoselectivity
could be achieved by using lower molar equivalents of formic acid and by using shorter reaction
times. These changes did not yield the required chemoselectivity either.

In an attempt to investigate the potential of ammonium formate29,30a,b as a milder
derivative of formic acid, we performed the reactions on the model compounds with ammonium
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formate30b,31 as the hydrogen source. Again, as in the case of formic acid, chemoselectivity
could not be achieved by using lower molar equivalents or using shorter reaction times. We
finally succeeded in achieving the desired chemoselective debenzylation using ammonium
acetate as the hydrogen source, in the case of aromatic benzyl ethers. Under these conditions
aliphatic benzyl ethers remain unaffected. This was clear as under these conditions, compounds
having benzyl group in the form of aromatic benzyl ethers namely 6 and 8 got completely
debenzylated, while 7 remained unchanged. The results of the hydrogen transfer chemoselective
studies with formic acid analogues are shown in table 3.2. Compounds 6 and 8 having benzyl
groups present in the form of aromatic benzyl ethers are completely reduced chemoselectively
leaving nitro group unchanged. On the other hand Compound 7, which has benzyl groups
protecting aliphatic alcohols are completely unaffected under similar conditions.
These results can be explained based on the fact that the aromatic ring lies flat on the
metal surface for optimal coordination.31, 32 In compounds where the substrate is an aromatic
benzyl ether, the planar geometry facilitates the effective binding with the metal surface and
hence the benzylic group in such compounds is preferentially cleaved. On the other hand,
aliphatic alcohols could have an adverse steric effect that would interfere with the planar
geometry required for effective binding which would reduce its affinity for the metal surface as
compared to its phenolic counterpart. Our experiments show that the affinity of the palladium
metal to the substrate is proportional to the number of substrate occupied active sites on the
palladium surface, which, in turn, determines the ease of the reduction process. If this were to be
true, one would anticipate that the 2-naphthylmethyl (NAP) group with its flat extended aromatic
system should have a high affinity to the palladium surface and should be deprotected
preferentially to the benzyl group31,33. Indeed literature indicates that the hydrogenolysis of ether
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9 shows that the NAP group can be selectively deprotected in the presence of a benzyl group
(Scheme 3.3).

O

O

9

Pd/C, H2

O

OH

EtOH

Scheme 3.3: Selective deprotection of NAP vs. Benzyl group.
The transfer hydrogenation reactions with ammonium acetate as the hydrogen source is
very promising considering that it can not only be an extremely simple, mild chemoselective
reduction method for benzyl reduction over nitro group, but it can also be used as a method of
chemoselective debenzylation of aromatic benzyl ethers over aliphatic benzyl ethers.
Unfortunately, the major disadvantage of this method is that the reaction must be carried out for
relatively long times at refluxing temperature with potential damage particularly to other
temperature sensitive functional groups. In order for this promising deprotection method to be of
any practical significance, it is important to bring down the reaction time.
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Table 3.2: Benzyl reductions with formic acid derivatives.
O-Bn derivative

A formic acid derivative
10% Pd/C, Methanol, reflux under N2
80-85%

Entry
#

Substrate

Hydrogen
source

Eq of
Hydrogen
source

1

6

HCOONH4

5 Eq

0.5

2

7

HCOONH4

5 Eq

2.5

3

8

HCOONH4

5 Eq

3.5

4

6

HCOONH4

1 Eq

5

5

7

HCOONH4

1 Eq

56

6

8

HCOONH4

1 Eq

15

7

6

CH3COONH4

20 Eq

120

8

7

CH3COONH4

20 Eq

120

9

8

CH3COONH4

20 Eq

144

Debenzylated product

Time
(hours)

Result
Complete –NO2 reduction and
Debenzylation
Complete Debenzylation
Complete Debenzylation, –NO2 ,
–C=N– reduction in progress
Parallel reduction of –NO2 and –Bn
group
–Bn group untouched
–NO2 reduction started before
Debenzylation and –C=N–
reduction
Complete Debenzylation, –NO2
untouched
Benzyl group still present
Complete Debenzylation, –NO2,
–C=N– untouched

Recently there have been reports of microwave-induced organic reaction enhancement
(MORE) chemistry techniques34 leading to reaction rapidity and improved yields. These reports
provoked us to test the feasibility of our debenzylation method under microwave irradiation. We
employed this deprotection procedure successfully to enhance reaction rapidity. The selectivity
is retained and the corresponding deprotection products are formed in up to 75% yield. The
reduction in overall reaction time is drastic, considering similar reactions done under reflux
conditions take several days as compared to reactions performed in microwave, which only take
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few minutes. There is a difference in using the microwave method. Methanol/ethanol solvent
that is normally used in formic acid based transfer hydrogenation reactions do not yield good
results. A simple modification of reaction conditions i.e. replacement of ethanol with high
boiling solvents, such as ethylene glycol yielded good results.35 The reaction is a one pot
synthesis and purification involves a simple filtration followed by the aqueous workup. The
results are summarized in Table 3.3. Unfortunately, in the target prodrugs 4 and 5 the benzyl
groups are in the form of aliphatic benzyl ethers on a sugar moiety, hence this method cannot be
applied to our target prodrugs. Despite that, this transfer hydrogenation method is excellent for
chemoselective aromatic ether debenzylations over aliphatic benzyl ethers and also over nitro
reductions.
The above promising results encouraged us to look for low cost alternatives to perform
this reaction. The use of low-cost metals such as magnesium36, zinc37 and lead38 used for
deprotection of N-Bn groups is known in literature39. To our knowledge such methods for
debenzylation of O-Bn groups is not known. We decided to explore this avenue with the goal to
select a suitable low-cost debenzylation catalyst that can retain the reactivity as well as
selectivity of the Pd/C catalyst.
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Table 3.3: Benzyl reductions with ammonium acetate under microwave conditions.

O-Bn derivative

Ammonium acetate, Alcohol
10% Pd/C, 60-75%
microwave

Debenzylated product

Entry #

Substrate

Solvent

Result

1

6

Methanol

No change

2

7

Methanol

No debenzylation

3

6

Ethanol

No change

4

7

Ethanol

No debenzylation

5

6

Isopropyl alcohol

No change

6

7

Isopropyl alcohol

No debenzylation

7

6

Ethylene glycol

Debenzylation, –NO2 untouched

8

7

Ethylene glycol

No Debenzylation

9

8

Ethylene glycol

Debenzylation

Initially, the reaction was performed under exactly similar conditions, except the catalyst
Pd/C was replaced with Zn. The results of this change were very interesting. With Zn, the
chemoselectivity was completely opposite to that of palladium/carbon. The nitro group is very
sensitive under these conditions and gets reduced completely to the amine while the benzyl
group remains unchanged. Even upon continuing the reaction for longer times, the benzyl group
remains unchanged both from aliphatic and aromatic systems, indicating zinc is not good catalyst
for debenzylations, at least under these conditions. Zinc catalyzed reactions always seem to
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reduce nitro groups in preference to benzyl groups. The same reaction can be performed with
stronger reagents (sources of hydrogen) with much higher reaction rates even at room
temperature. For instance, the reaction performed with zinc and pyridinium acetate is
instantaneous even at room temperature. The reduction with zinc and acetic acid combination is
very fast as well. We also tried to explore this reaction with other inexpensive metals namely,
iron and nickel. These metals also gave similar results as zinc, except that the reactions of both
these metals are much slower and needed extended periods of refluxing. All our attempts to
carry out the reactions at room temperature with these metals (iron and nickel) failed. The
results of the zinc, iron and nickel catalyzed reductions are summarized in Table 3.4.
In summary, transfer hydrogenation with formic acid derivatives and palladium is a good
chemoselective debenzylation method for aromatic benzyl ethers over aliphatic benzyl ethers and
nitro groups. The reaction rates have been successfully reduced employing the MORE34
technique. It was also realized that chemoselective nitro reduction can be achieved by
employing zinc and formic acid derivatives as the hydrogen source. Unfortunately, our target
prodrugs 4 and 5 are aliphatic benzyl ethers, and this debenzylation method is not a good choice.
Therefore, we continued to explore other transfer hydrogenation methods.
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Table 3.4: Zinc, iron and nickel catalyzed reductions.

O-Bn derivative

Ammonium acetate
Methanol, Reflux, >95%

Debenzylated product

Metal catalyst

Entry
#
1

Reaction conditions

Effect on 6

Time (hours)

Zn/CH3COONH4, CH3OH, reflux

-NO2 reduced to -NH2, Benzyl group intact

8

2

Zn/pyridinium acetate, 25°C

-NO2 reduced to -NH2, Benzyl group intact

Instantaneous

3

Zn/NH4Cl, 25°C

-NO2 reduced to -NH2, Benzyl group intact

7

4

Zn/ HCOONH4, 25°C

-NO2 reduced to -NH2, Benzyl group intact

7

5

Zn/CH3COOH, 25°C

-NO2 reduced to -NH2, Benzyl group intact

3

6

Zn/CH3COONa, CH3OH, reflux

-NO2 reduced to -NH2, Benzyl group intact

8

7

Zn/ CH3COONa , CH3OH, 25°C

No change

>20

8

Fe/ NH4Cl, reflux

-NO2 reduced to -NH2, Benzyl group intact

10

9

Fe/ NH4Cl, 25°C

No change

>20

10

Fe/ HCOONH4, reflux

-NO2 reduced to -NH2, Benzyl group intact

12

11

Fe/ HCOONH4, 25°C

No change

>20

12

Fe/ CH3COONH4, reflux

No change

>20

13

Ni/ NH4Cl, reflux

-NO2 reduced to -NH2, Benzyl group intact

13

14

Ni/ NH4Cl, 25°C

No change

>20

15

Ni/ HCOONH4, 25°C

No change

>20

16

Ni/ HCOONH4, reflux

No change

>20
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Catalytic transfer hydrogenation using alcohols

Heterogeneous, catalytic, transfer hydrogenolysis with alcohols is a known debenzylation
procedure in literature. This method is used to deprotect benzyl ethers of poly-ols and has been
utilized in carbohydrate chemistry as well.40, 41 The reaction itself is very simple. The substrate
is treated with 10% Pd/C and refluxed in 2-propanol. The reaction conditions are very mild and
the reaction is very slow and very selective (Table 3.5).
We explored this reaction for its selectivity and the results indicate that the O-benzyl
group is selectively removed in the presence of the nitro group, as observed in the model
compounds. Under the specified conditions, aliphatic benzyl groups are removed as well. The
reaction is very clean and go to completion in all the three model compounds as seen in entries 1,
2, 3 of Table 3.5. The nitro and hydrazone moieties remain untouched. However, long reaction

times were necessary. To solve this problem, 3-methyl butanol was employed as a higher
boiling solvent, with better results, in that the reaction times are reduced from over 48 hours to
14 hours. Attempts to further reduce the reaction time using cyclohexanol were derogatory in
that under such high temperature, sugar derivative 2 degraded. Hence the choice of solvent is
very important in order to tailor the reaction conditions for optimal results.
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Table 3.5: Transfer hydrogenation reactions with alcohols.
O-Bn derivative

Alcohol, reflux
10% Pd/C, 70-75%

Debenzylated product

Entry #

Substrate

Alcohol

Time

Result

1

6

2-propanol

2 days

Complete Debenzylation, –NO2
untouched

2

7

2-propanol

3 days

Complete Debenzylation

3

8

2-propanol

8 days

Complete Debenzylation, –NO2
untouched

4

6

3-methyl
butanol

14 hr

Complete Debenzylation, –NO2
untouched

5

7

3-methyl
butanol

14 hr

Complete Debenzylation

6

8

3-methyl
butanol

14 hr

–NO2 almost untouched, 50%
Debenzylation

7

7

Cyclohexanol

14 hr

Sugar degraded

The kinetic, thermodynamic, and stereo chemical data on transfer hydrogenation
reactions and their mechanisms are poorly understood.42 There are many explanations regarding
the mechanism of this reaction. In general, heterogeneous catalysis can be difficult to interpret
mechanistically, because of difficulties in preparing and reproducing uniform catalytic surfaces.
In addition, the fact that hydrogen can form ionic and covalent hydrides and that it can also
dissolve in palladium without there being any bond formation, complicates the mechanism of
these reactions.
It is reported in literature,40 that transfer hydrogenation with alcohols can take place
between adsorbed species, and oxidative addition of the hydrogen donor to palladium, followed
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by coordination of the substrate and transfer of hydrogen occurs in two steps, with the second
one formally involving a five-membered transition state (Scheme 3.4).

H

CR2 + Pd

H

Pd

H

CR2

OH

Pd

CR2

A

H

OH

OH

H2A + Pd + R2C

O

Pd

CR2

A

OH

HA

Pd
C

H

O

R
R

Scheme 3.4. Transfer hydrogenation with alcohols.42

If alcohol were to be the hydrogen donar in this reaction, then the by-product of the
reaction would be toluene and acetone, toluene being the reduced product of benzyl group, while
acetone being the oxidation product of 2-propanol. In practice however, we did not observe the
formation of these side products. Hence we concluded that this might not be the real mechanism.
An alternative explanation of mechanism of debenzylation with alcohols is believed to
occur via oxidation of benzyl group43. In this, the O-benzyl protecting group acts as hydrogen
donor.
CH

O

H

OH
R

O

C

Pd

CH

R

H

O

R

O
O
H

H

Pd H

Pd
H

CH

H
C

+

+

R OH

O

+ Pd

+
O

H
R

Pd H

O

Scheme 3.5.: Transfer hydrogenation with alcohols via oxidation of benzyl group.43
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Initially the reaction was attempted in ethanol. There was a clear progress of the reaction
with ethanol but the reaction was impractically slow. Replacing ethanol with 2-propanol gave
good results. The improvement in the reaction rate could be due to one or both of two major
factors that change with the replacement of the solvent. One factor is that 2-propanol is a higher
boiling alcohol and under reflux conditions it offers higher reaction temperature which could
result in accelerated reaction rate. The second factor is that 2-propanol, being a secondary
alcohol, can form a more stable secondary radical (Scheme 3.4). If the reaction were to go
through mechanism shown in Scheme 3.4, it must proceed faster in 2-propanol verses a primary
alcohol of comparable boiling point. To determine whether this was the mechanism, the reaction
was repeated with 3-methyl butanol, a higher boiling but primary alcohol. The reaction
progressed much faster indicating that the reaction is not probably going through the mechanism
one(Scheme 3.4), as mechanism one would have favored secondary alcohol 2-propanol over
primary alcohol 3-methyl butanol. Further, benzaldehyde was isolated from the reaction
mixture. This happens to be the by-product of reaction only when the reaction goes through
mechanism two(Scheme 3.5) which involves oxidation of benzyl group to benzaldehyde. In
summary it can be concluded that transfer hydrogenation with propanol follows oxidative
debenzylation mechanism.
Another interesting mechanistic aspect worth noting is that, the planar geometry
requirement does not seem to be as critical in these alcohol assisted debenzylation reactions as it
is in ammonium acetate assisted debenzylation. This conclusion can be made based on the fact
that alcohol assisted debenzylations proceed with equal ease in aliphatic compounds as well as
aromatic systems, while this is not the case with ammonium acetate assisted debenzylations. Our
experiments with p-methoxybenzyl protected nitrophenol further corroborated this point. Both
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the above debenzylation methods have been tried on p-methoxybenzyl protected nitrophenol
with interesting results.
NO2

NO2

O

O
6

O

9

Figure 3.2. Model compounds 6 and 9

Table 3.6. Relative reaction times for the debenzylation of model compounds in different
debenzylation methods.
Entry #

Substrate

Debenzylation

Time

method

(hours)

Result

1

6

CH3COONH4

120

Complete Debenzylation, –NO2 untouched

2

9

CH3COONH4

170

Complete Debenzylation, –NO2 untouched

3

6

2-propanol

48

Complete Debenzylation, –NO2 untouched

4

9

2-propanol

6

Complete Debenzylation, –NO2 untouched

The aromatic ring lies flat on the metal surface for optimal coordination44,45. It is possible
that substitution on the aromatic ring could have an adverse steric effect that would interfere with
the planar geometry required for effective binding and thus reduce its affinity for the metal
surface. This seems to be the case considering the time taken for debenzylation of 6 is much
more than for 9 as seen entries 1 and 2 of Table 3.6. This may explain why the least substituted
benzyl group, although not electronically favored, can still be preferentially cleaved.44,45 This is
the true for ammonium acetate assisted debenzylation. The effect of this seems to be much
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lower in alcohol assisted debenzylations. In alcohol assisted debenzylations the electronic effect
seems to the deciding factor for the rate of debenzylation.
Unfortunately, again like in ammonium acetate debenzylations, the disadvantage with
this method is that the reaction must be carried out for relatively long times at reflux temperature
with potential damage particularly to other temperature sensitive functional groups. Based on
the success we achieved in applying the microwave-induced organic reaction enhancement
(MORE) chemistry techniques,34 we decided to attempt it for the alcohol assisted debenzylation
method as well. The results are shown in Table 3.8. We met with partial success in model
compounds 6 and 8 with 2-propanol, in that the reaction rates are increased dramatically.
Unfortunately, even before the reactions go to completion, degradation of the product starts. The
degradation rate was so rapid in the higher alcohols 3-methyl butanol and cyclohexanol, that no
appreciable amounts of products were observed. With compound 7 there was no product
formation. Prolonged exposure of compound 8 only results in complete degradation of the
substrate. The degradation was even faster with higher boiling alcohols.

Table 3.8.: Microwave assisted transfer hydrogenation reactions in alcohols.
Entry
#
1

Substrate

Alcohol

Time

Result

6

2-propanol

12 min

60% Debenzylation, –NO2 untouched Further
microwaving degrades the substrate

2

7

2-propanol

55 min

No debenzylation
Further microwaving degrades the substrate

3

8

2-propanol

32 min

50% Debenzylation
Further microwaving degrades the substrate
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To summarize, alcohol assisted debenzylation can be successfully employed for
debenzylation reactions. The reaction times were high with 2-propanol, but they can brought
down drastically by choice of higher boiling point alcohol. The choice of alcohol is such that the
boiling point should be high enough to increase the speed of the reaction while at the same time
not so high that degradation of substrate and product occur. Among the alcohols tried 2-methyl
butanol seemed to be a good choice, as the reaction time is reasonably low and products can be
obtained in pure form with no degradation. Attempts to further speed up the reaction through
microwave induced reaction techniques were not successful.
Among other transfer hydrogenations, the most important method is using cyclohexene as
a hydrogen source. The major advantage of this debenzylation method is that the time required
is much less than that for the usual catalytic hydrogenation and also the products formed are of
greater purity. Unfortunately, information regarding the relative selectivity of this reduction
method with respect to nitro reduction verses debenzylation is not available. Hence we decided
to explore this method in detail.

Transfer hydrogenation with Cyclohexene

Transfer hydrogenation with cyclohexene is a simple and convenient method for removal
of all protecting groups that are normally removed by catalytic hydrogenation.46-48 The substrate
is dissolved in a mixture of ethanol and cyclohexene (acetic acid may be added to assist
dissolution) and the solution is refluxed with stirring in the presence of palladium-charcoal or
palladium black.49-51 The work up involves a simple filtration.
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It is known in literature that the nitro group is reducible under these conditions.52-56 We
explored the possibility of using the same method under milder conditions. The various
possibilities tried included lower temperature, lower catalyst loading, poisoned catalysts and
limiting the concentration of hydrogen source. The results are indicated in Table 3.9.
We initially tried to determine if time based selective debenzylation is possible. It was
noticed that under the specified conditions, the nitro reduction and debenzylation occurs
simultaneously as can be concluded from entries 1, 2 and 3 of Table 3.9.
Next, we tried to carry out the reaction under milder temperature conditions. The reaction
was attempted at room temperature, but at this temperature, there is absolutely no progress of the
reaction. Hydrogen generation is supposed to occur through disproportionation of cyclohexene
to benzene and cyclohexane. This reaction seems to have an activation energy barrier that
cannot be reached under room temperature conditions. Hence there is no hydrogen available to
carry out the reduction and neither the nitro group nor the benzyl group is reduced.
Ordinarily, cyclohexene transfer hydrogenations are carried out using cyclohexene
alcohol mixtures as a solvent, where cyclohexene is used in large excess.55 This is typical to
many transfer hydrogenation reactions because, the hydrogen generated from the reagent used as
hydrogen source is typically never used with 100% efficiency.56,57 Nevertheless, we performed
this reaction with stochiometric amount of cyclohexene, in order to understand the selectivity
pattern of this transfer hydrogenation method. Under these conditions, it was noted that there is
absolutely no reaction in any of the model compounds. We then increased the molar ratio to four
equivalents. At this concentration of cyclohexene there was selectivity towards benzyl
reduction. Model compound 6 is completely debenzylated before the unwanted nitro reduction
starts. Additionally, compound 7, the aliphatic system, is effectively debenzylated in a short
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period of time. Entries 4, 5 and 6 (Table 3.9) indicate the fate of compounds 6, 7 and 8
respectively under these conditions. Unfortunately, the nitro reduction in compound 8 starts
when debenzylation is only 70% complete. Despite that, these results are promising and can be
further improved, if there is a way to retard the nitro reduction.
We attempted to usethe poisoned palladium catalyst - Lindlar’s catalyst, to determine if
retardation of nitro reduction could occur. Unfortunately, with this catalyst even the
chemoselectivity proved to be different. Nitro reduction precedes debenzylation in the case of
aromatic debenzylations, as seen in entry 7 of Table 3.9. Debenzylation of aliphatic benzyl
ethers does not occur under these conditions. This is evidenced by model compound 7 entry 8 in
Table 3.9. In compound 6 there is complete reduction of nitro group even before debenzylation
starts and in compound 8 the reductions occur simultaneously.
It is a known fact that activity and sometimes even the selectivity of surface catalysts
depends on the surface topography of the catalyst used, which in turn depends on the method
employed to make the catalyst. The activity of the catalyst is structure specific. We tried using
Pd/C catalyst of different loadings and types to see if one of the methods could carry out
complete debenzylation before the nitro reduction starts. Several different catalysts were used
but the one that ultimately gave the required chemoselectivity was the 5% Pd/C wet paste. This
catalyst has the required selectivity when used in 4 equivalents concentration versus the number
of benzyl groups in the substrate. The debenzylation is very fast and clean and is complete
within half an hour with no competing reaction. The results of the reduction method are shown
in Table 3.9 entries 10 and 11. This is the excellent method for chemoselective debenzylation
considering the reaction is fast, simple, clean, and is a one pot synthesis with no special
hydrogenation equipment needed. Purification involves a simple filtration.

84

Table 3.9. Transfer hydrogenation reactions with cyclohexene.
4 Eq Cyclohexene, 5% Pd/C (wet paste)
O-Bn derivative
Ethanol, reflux under N2, >95%

Debenzylated product

Entry
#

O-Bn
derivative

Eq of
Cyclohexene

Time
(hours)

Catalyst

Result

1

6

Large excess

3

5% Pd/C wet

Complete Debenzylation, –NO2 reduced
by 50%

2

7

Large excess

1

5% Pd/C wet

Complete Debenzylation

3

8

Large excess

3

5% Pd/C wet

70% –NO2 reduction, 50% C=N reduced
while debenzylation was 50%

4

6

4Eq

2

5% Pd/C wet

Complete Debenzylation,
–NO2 untouched

5

7

4 Eq

6

5% Pd/C wet

70% Debenzylation

6

8

4 Eq

6

5% Pd/C wet

At 70% Debenzylation, nitro reduction
starts

7

6

Large excess

12

5% Lindlar’s
catalyst

Complete –NO2 reduction, 5%
Debenzylation

8

7

Large excess

12

5% Lindlar’s
catalyst

No Debenzylation

9

8

Large excess

15

5% Lindlar’s
catalyst

50% Debenzylation, –NO2 reduction
starts

10

7

4 Eq

½

5% Pd/C –
wet, paste

>95% Debenzylation

11

8

4Eq

1

5% Pd/C –
wet paste

95% Debenzylation with in ½ hr, within
this time –NO2 is untouched

12

4

4Eq

½

5% Pd/C –
wet, paste

95% Debenzylation
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Conclusion
In the course of the preparation of ester-saccharide derivatives of A-007 as anticancer drugs, we
faced the problem of selective removal of benzyl groups without affecting either acidic or
reduction sensitive functionalities present within the A-007 molecule. For this reason, we
explored benzyl deprotection methodologies and determined several simple solutions which gave
a variety of chemoselectivities in excellent yields. Catalytic hydrogenation, as well as the use of
strong acids, was avoided in deference to the sensitivity of the nitro group and the lability of the
hydrazone and ester moieties. The selective deprotection methods developed include
debenzylation of aromatic benzyl ethers in preference to aliphatic benzyl ethers, benzyl ethers in
preference to nitro groups, and nitro groups in preference to benzyl ethers. The selective
deprotection methods developed are mild, simple, one pot methods with no special
hydrogenation equipment needed. In addition, the above methodologies developed are very
general and can be applied to a variety of substrates.
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Experimental
Melting points were taken on an Electro thermal IA 9000 Digital Melting Point Apparatus and
are uncorrected. The 1H and 13C NMR spectra were run on Varian 300 MHz Gemini2000 and on
Varian 400 MHz Unity in CDCl3, DMSO-d6, or D2O as solvent and internal standards. A
commercially available, domestic microwave oven (GE, model #: JES738WJ02) was used in all
experiments. All the chemicals mentioned are from Aldrich chemical company unless otherwise
mentioned. The catalyst that works best for cyclohexene reductions was Pd on 5% charcoal
paste with 50-65% water content from Alfa Aeser. Cyclohexene is always freshly distilled
before each reduction unless used from a freshly opened bottle. Pd/C used in transfer
hydrogenation methods with formic acid analogues as hydrogen source can be reused at least
three times with no loss in activity, while Pd/C used in alcohol and cyclohexene methods reused
up to five times with no loss in activity.

Preparation of N-[Bis-(4-benzyloxy-phenyl)-methylene]-N'-(2,4-dinitro-phenyl)-hydrazine
(3):

A mixture of A007 (1g, 2.5 m mol) and benzyl chloride (0.416g. 3.3 m mol ) is refluxed in a 1:1
mixture of methanol and 1.5% aqueous NaOH (50mL). The reaction can be monitored visually
through change in color of the reaction mixture. At the beginning, the reaction mixture is a clear
dark red solution. As the reaction progresses, bright red product is formed as precipitate and
reaction mixture clears up until it completely becomes colorless. The product is a bright red
precipitate which can be filtered out and washed with ice cold methanol. Pure product is
obtained in 98% yield, no further purification is necessary.
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Melting point: The compound degrades beyond 200°C before it melts. 1H NMR (400 MHz,
CDCl3) d 11.3(1H, s), 9.09(1H, d, J =4 Hz), 8.32(1H, dd, J=4, 2.4 Hz), 7.63(1H, d, J =8 Hz),
7.49-7.22(14H, m), 5.18 (2H, s), 5.13(2H, s);

13

C NMR (100 MHz, CDCl3) 160.9, 155.8, 144.8,

137.9, 136.6, 135.4, 130.1, 129.9, 128.98, 128.94, 128.5, 128.4, 127.9, 127.7, 124.2, 123.8,
116.8, 116.4, 115.0, 70.4.

Preparation of 4,4’-dihydroxybenzophenone-2,4-dinitrophenylhydrazone bis( 2,3,4,6-tetraO-benzyl--D-glucopyranoside) (4):

2,3,4,6-Tetra-O-benzoyl-α-D-glucopyranosyl)-trichloroacetimidate (4a) (5.55g, 0.75 mmol) and
A-007 (118 mg, 0.3 mmol) were stirred under an atmosphere of nitrogen in anhydrous CH2Cl2

(20 mL) with 3Å molecular sieves for 1 h. The solution was cooled in an ice-bath for 30 min
before BF3-OEt2 (2 mL) was added and stirred for 1 min the ice-bath followed by 1 h at room
temperature. The solution was added to an ice cold saturated aq NaHCO3 solution (100 mL) with
vigorous stirring and then extracted with ether (2 x 75 mL). The organic layers were combined
and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure
and the residue was purified by flash column chromatography (with a solvent system - 20:1
dichloromethane –ethyl acetate ) to give 4 as red crystalline solid in 20% yield. MP: The
compound degrades at 200°C before it melts. 1H NMR (DMSO-d6, 400 MHz) 7.82(2H, d, J
=6.4 Hz), 7.64-7.14(55H, m), 7.02(2H, d, J =6.24 Hz), 5.18-3.56 (14H, m), 4.59(16H, s); 13C
NMR (DMSO-d6, 100 MHz),  160.9, 161.1,155.5, 147.8, 139.6,
137.15,
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Preparation of 2,3,4,6-Tetra-O-benzoyl-α-D-glucopyranosyl)-trichloroacetimidate (4a):

Tetrabenzoyl-D-glucopyranose (4b) (2.0 g, 3.3 mmol), K2CO3 (1.1 g, 8.2 mmol), and
trichloroacetonitrile (5 mL) were stirred at room temperature in dichloromethane (20 mL) for 48
hours. The resulting suspension was filtered through silica gel using a 1:1 mixture of CH2Cl2 and
Et2O (150 mL). The filtrate was concentrated to give 4a as a pale yellow oil (2.0 g, 83
% yield). 1H NMR (300 MHz, CDCl3): δ 8.62 (1H, s) 8.02 (2H, d, J = 3.9 Hz), 7.93 (4H, d, J =
5.7 Hz), 7.85 (2H, d, J = 4.2 Hz), 7.56 – 7.25 (12H, m), 6.82 (1H, d, J = 2.0 Hz), 6.25 (1H, t, J =
9.9 Hz), 5.79 (1H, t, J=9.9 Hz), 5.60 (1H, dd, J1 = 5.1 Hz, J2 = 1.8 Hz), 4.62 (2H, d, J = 5.1 Hz),
4.46 (1H, dd, J1 = 6.5 Hz, J2 = 3.0 Hz);

13

C NMR (100 MHz, CDCl3): δ 166.2, 165.8, 165.6,

165.4, 160.7, 133.7, 133.5, 133.4, 130.1, 129.91, 129.86, 129.7, 129.0, 128.73, 128.66, 128.60,
128.55, 128.51, 93.3, 90.9, 70.9, 70.3, 68.8,62.6.

Preparation of 2,3,4,6-Tetra-O-benzoyl-D-glucopyranose (4b): Pentabenzoyl--D-

glucopyranose (4c) (10 g, 14 mmol) and 2-aminoethanol (2.0 g, 36 mmol) were stirred at room
temperature in ethyl acetate (150 mL) and DMSO (2 mL) overnight, during which time the initial
suspension formed a solution. The resulting solution was washed with water (3 x 150 mL) and
the organic layer was dried over sodium sulfate and concentrated. The residue was purified by
flash column chromatography (CH2Cl2 followed by Et2O) to give 4b as a white solid (6.0 g, 70
% yield). 100 mg of the product was recrystallized from diethyl ether/hexanes for 1H and 13C
NMR analysis. 1H NMR (300 MHz, CDCl3) 4b-β: δ 8.19- 7.82 (8H, m), 7.57-7.19 (12H, m),
6.23 (1H, t, J=9.9 Hz), 5.72 (2H, m), 5.30 (1H, dd, J1=6.45 Hz, J2=1.2 Hz), 4.66 (2H, m), 4.46
(1H, dd, J1=8.6 Hz, J2=2.4 Hz), 3.12 (1H, d, J=1.3 Hz). 13C NMR of 4b-β (CDCl3): δ 166.6,
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166.13, 166.10, 165.5, 133.6, 133.5, 133.3, 130.1, 130.0, 129.8, 129.7, 129.6, 129.2, 129.1,
129.0, 128.9, 128.8, 128.6, 128.5, 128.46, 90.6, 72.5, 70.4, 69.6, 67.8, 63.0.

Preparation of Penta-O-benzoyl-β-D-glucopyranose (4c):

D-glucose (5.0 g, 28 mmol) was refluxed in pyridine (100 mL) for 1 hour. The solution was then
added to benzoyl chloride (20mL) which had been heated to 65°C. After the mixture was cooled
to room temperature, water (400 mL) was added and stirred until the product solidified,
approximately 30 minutes. The solid was filtered and washed with water and recrystallized from
ethyl acetate to give 4c as a white solid (11 g, 56 % yield). 1H NMR (300 MHz, CDCl3): δ
8.01 (4H, d, J = 4.0 Hz), 7.89 (4H, d, J = 3.8 Hz), 7.84 (2H, d, J = 3.9 Hz), 7.53 – 7.21 (15H, m),
6.28 (1H, d, J=3.9 Hz), 6.02 (1H, t, J = 9.3 Hz), 5.83 (2H, q, J=12.9 Hz), 4.64 (1H, dd, J1 = 6.0
Hz, J2 = 1.4 Hz), 4.49 (1H, dd, J1 = 8.1 Hz, J2 = 2.1 Hz), 4.394 (1H, m). 13C NMR (300 MHz,
CDCl3): δ 166.3, 165.8, 165.30, 165.28, 164.8, 134.0, 133.7, 133.6, 133.5, 133.3, 130.4, 130.0,
129.99, 129.96, 129.7, 128.9, 128.84, 128.82, 128.7, 128.62, 128.59, 128.5, 92.9, 73.3, 73.0,
71.0, 69.2, 62.8.

Preparation of 1-Benzyloxy-4-nitro-benzene (6)

A mixture of nitro phenol (13.9g, 0.1 mol) and benzyl chloride(5.75 mL, 0.05 mol) is refluxed in
a 1:1 mixture of methanol and 1.5% aqueous NaOH. The reaction is stopped after 4 hours and
product is extracted into methylene chloride. The organic layers are washed (x 3) with aqueous
NaHCO3 and dried with sodium sulfate. The product formed is 98% pure by NMR and hence
used with no further purification. The product is obtained in 95% yield upon concentrated under
vacuum .
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MP: 107°C; 1H NMR (400 MHz, CDCl3)  8.21(2H, d, J =4.8 Hz), 7.43-7.37(m, 5H), 7.04(2H,
d, J =4.8 Hz); 13C NMR (100 MHz, CDCl3) d 163.8, 141.8, 135.6, 129.0, 128.7, 128.7, 127.7,
127.2, 126.1, 115.0, 70.8.

Synthesis of methyl 2,3,4,6-tetra-O-benzyl--D-glucopyranoside (7)

Methyl glycoside (25 g) is dissolved at 55°C in 300 mL of 33% aq NaOH solution.
Tetrabutylammonium bromide(TBABr, 32 g) is added and benzyl chloride (77 mL) is added
dropwise over 1h. The reaction mixture is stirred at 55°C for 4.5 h and then at room temperature
overnight. 200 mL of toluene are added, the phases are separated and the organic phase is
washed with water until it is neutral. It is concentrated in vacuo and purified by flash
chromatography (toluene-ethyl acetate, 35:1) to yield 36 g (63 mmol, 75%) of the fully protected
product as a colorless syrup. 1H NMR (400 MHz, CDCl3) m), 5.39(1H, s), 5.013.39(17H, m); 13C NMR (100 MHz, CDCl3)  139.01, 138.75, 138.48, 138.38, 138.13, 134.67,
133.25, 130.29, 129.96, 129.92, 129.21, 128.62, 128.00, 127.84,104.91, 98.41, 84.84, 82.52,
82.33, 80.03, 78.07, 77.86, 75.95, 75.88, 75.22, 75.04, 74.94, 73.67, 73.58, 72.30, 70.24, 69.12,
68.66, 68.34, 66.88, 55.35.

Preparation of N-[Bis-(4-benzyloxy-phenyl)-methylene]-N'-(2,4-dinitro-phenyl)-hydrazine
(8):

A mixture of A007 (1g, 2.5 m mol) and benzyl chloride (0.416g. 3.3 m mol ) is refluxed in a 1:1
mixture of methanol and 1.5% aqueous NaOH (50mL). The reaction can be monitored visually
through change in color of the reaction mixture. At the beginning, the reaction mixture is a clear
dark red solution. As the reaction progresses, bright red product is formed as precipitate and
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reaction mixture clears up until it completely becomes colorless. The product is a bright red
precipitate which can be filtered out and washed with ice cold methanol. Pure product is
obtained in 98% yield, no further purification is necessary.
MP: The compound degrades beyond 200°C before it melts. 1H NMR (400 MHz, CDCl3) 
11.3(1H, s), 9.09(1H, d, J =4 Hz), 8.32(1H, dd, J=4, 2.4 Hz), 7.63(1H, d, J =8 Hz), 7.497.22(14H, m), 5.18 (2H, s), 5.13(2H, s);

13

C NMR (100 MHz, CDCl3) 160.9, 155.8, 144.8,

137.9, 136.6, 135.4, 130.1, 129.9, 128.98, 128.94, 128.5, 128.4, 127.9, 127.7, 124.2, 123.8,
116.8, 116.4, 115.0, 70.4.

Preparation of 1-(4-methoxy Benzyloxy)-4-nitro-benzene (9)

p-methoxybenzyl alcohol(1.38g, 10mmol) is taken in 15 mL of anhydrous ether. To this mixture
thionyl chloride(1.5 mL, 20mmol) is added drop wise. The reaction mixture is stirred at room
temperature for 3 hours and then the solvent is evaporated under nitrogen. A dark purple residue
of p-methoxy benzyl chloride is formed. To this 20 mL of methanol is added. In a separate
container p-nitrophenol (1.39g, 10mmol) is dissolved in 20 mL of 1% aqueous NaOH. This
mixture is added dropwise to the methanol solution of p-methoxy benzyl chloride drop wise with
stirring. As the addition process is still in progress golden yellow flakes of product is formed.
The precipitate is filtered and then washed with ice cold water to give pure product in 96% yield.
MP : 125 º C; 1H NMR (400 MHz, CDCl3) d 8.21(2H, d, J =9.2 Hz), 7.36(2H, d, J =8.8 Hz),
7.02(2H, d, J =9.2 Hz), 6.94(2H, d, J =2.2 Hz), 5.09(2H, s), 3.83(3H, s);

13

C NMR (100 MHz,

CDCl3) d 164.0, 160.0, 142.1, 135.4, 129.5, 127.6, 126.1, 115.0, 114.4, 70.7, 55.5.
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General procedures for reductions

The number of moles of substrate indicated is with respect to number of benzyl groups. (Not
the number of moles of substrate.)

General procedure for reductions with ammonium salts:

A suspension of substrate (0.5 m mol) and an equal weight of 10% Pd/C in dry methanol (15
mL) was added to anhydrous ammonium salt and then refluxed under nitrogen for the times
indicated in Table 2.2. The catalyst was filtered out and washed with methanol. The combined
washings and the filtrate are filtered through a celite pad (1 inch wide and 1 inch long) and
concentrated under vacuum. The column was washed with a methanol-dichloromethane mixture
and then the combined washings were evaporated under vacuum to obtain the product. The
number of moles of ammonium salt used and reaction times are indicated in Table 2.2. The
yields of the reduction products are in the range 80-85%.

Microwave-Assisted reduction procedure with ammonium salts:

A suspension of substrate (0.5 mmol) and an equal weight of 10% Pd/C in ethylene glycol (15
mL) and ammonium salt (10 mmol) in an Erlenmeyer flask was allowed for microwave
irradiation 160 power. A filter funnel was placed over the Erlenmeyer flask to prevent any
accidental spillage. A “heat sink” was maintained to control the microwave energy input into the
reaction mixture. After the reaction, the reaction mixture was cooled and then the catalyst was
filtered out. The filtrate was diluted with water and extracted with ether or ethyl acetate, and the
organic layer was washed twice with saturated brine solution and finally with water. The organic
layer was dried over anhydrous sodium sulphate, filtered and then followed up with evaporation
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of the organic layer followed by purification either by preparative TLC or by column
chromatography. The yields of the reduction products are in the range 60-75%.

General procedure for reduction reactions using Zn/Fe/Ni metals:

A suspension of substrate (10 mmol), ammonium salt (80 mmol), and metal dust (1g) in
methanol (15 mL) was stirred at temperatures indicated in Table 3.4 until the completion of the
reaction(monitored by TLC). After the completion of the reaction the reaction mixture was
filtered through a celite pad, washed with solvent and then the combined filtrate and washings
were evaporated under vacuum. The residue was taken into chloroform or ether, washed twice
with saturated brine solution and finally with water. The organic layer was dried over anhydrous
sodium sulphate, filtered and evaporation of the organic yields the pure product in >95% yield.

General procedure for debenzylation reactions with alcohols:

A solution of O-benzyl derivative(1.5 mmol with respect to # of benzyl groups) in 10 mL of
alcohol (indicated in Table 3.5) was added to a stirred suspension of 10% Pd/C (1 gm) in
refluxing 2º alcohol (10 mL) and the mixture was boiled under reflux for the times indicated in
Table 3.5. After the completion of the reaction (monitored by TLC), the catalyst was collected
and washed with solvent alcohol. The combined filtrate and washings were evaporated under
vacuum and then the residue was fractioned by column chromatography (7:5 hexane-ethyl
acetate mixture) or preparative TLC to obtain the debenzylated product in 70-75% yield.
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General procedure for reductions with Cyclohexene:

A mixture of O-benzyl derivative (0.5 m mol), 5% Pd/C wet paste (an equal weight of Pd/C is
added per benzyl group), dry ethanol (20 mL) and cyclohexene (amount of cyclohexene used is
as indicated in Table 3.9) were refluxed with stirring under air. At the end of times indicated (in
Table 3.9), the catalyst was filtered off under suction to separate the catalyst, followed by
filtration through a celite pad (1 inch wide and 0.25 inch long). The flash column is then washed
with ethanol. The combined filtrate and washings were evaporated under vacuum to obtain pure
products, which needed no further purification, in about 95% yield.

Reduction products:

p-aminophenol:

MP: 248 º C; 1H NMR (400 MHz, CDCl3) 6.97(2H, d, J =8.8 Hz), 6.77 (2H, d, J =8.8 Hz). 13C
NMR (100 MHz, CDCl3) 164.1, 139.8, 126.3, 116.1.

4, 4’-Dihydroxybenzophenone 2, 4,diaminophenyl hydrazone:

The compound degrades beyond 200°C before it melts. 1H NMR (400 MHz, CDCl3) 7.62(1H,
d, J =6 Hz), 7.54(1H, s), 7.42(1H, d, J =6.2 Hz), 7.34(2H, d, J =8 Hz), 7.14(2H, d, J =8 Hz),
6.92(2H, d, J =8 Hz), 6.72(2H, d, J =8 Hz);

13

C NMR (100 MHz, CDCl3)158.5, 1 57.5, 136.9,

133.9, 131.4, 130.4, 123.6, 123.1, 116.8, 105.8, 101.1.

methyl glycoside:

1

H NMR (400 MHz, CDCl3) 4.38(1H, d, J =4.38 Hz), 3.94-3.23(6H, m),

3.57(3H, s); 13C NMR (100 MHz, CDCl3 73.21, 71.70, 71.34, 69.67, 60.06, 55.13.
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p-nitrophenol: MP: 115 º C; 1H NMR (400 MHz, CDCl3) 8.182(2H, d, 9.2), 6.91(2H, d, 8.8);
13

C NMR (100 MHz, CDCl3) 164.1, 139.8, 126.3, 116.1.

N-(4,4’ -Dihydroxybenzhydrylidene)-N-(2,4-dinitrophenyl) hydrazine:

MP: 270-272 °C. 1H NMR (DMSO-d6, 300 MHz):  11.13 (1H, s, NH), 10.05 (1H, s, OH), 9.99
(1H, s, OH), 8.78 (1H, d, J = 2.7 Hz), 8.36 (1H, dd, J1= 9.6, J2 =2.7), 8.12 (1H, d, J= 9.6), 7.47
(2H, d, J =8.7 Hz), 7.22 (2H, d, J= 8.4) , 7.01 (2H, d, J =8.1), 6.81 (2H, d, J= 8.4), 13C NMR
(DMSO-d6, 300 MHz):  156.19, 155.31, 152.33, 140.47, 133.27, 126.50, 126.35, 126.02,
125.50, 124.07, 119.46, 118.19, 112.97, 112.90, 111.91.

p-benzyloxy aniline: MP: 55º C; 1H NMR (DMSO-d6, 400 MHz): m),

6.81(2H, d, J =8.4 Hz), 6.64(2H, d, J =8.8 Hz), 4.98(2H, s);

13

C NMR (DMSO-d6, 100 MHz):

140.36, 137.72, 128.73, 128.02, 127.72, 116.63, 116.40, 116.28, 70.97.

4,4’-dihydroxybenzophenone-2,4-dinitrophenylhydrazone bis(-D-glucopyranoside) (1)

The compound degrades at 200°C before it melts. 1H NMR (DMSO-d6, 400 MHz) 11.13 (1H,
s), 8.80 (2H, d, J = 2.4 Hz), 8.40 (2H, dd, J1 = 9.6 Hz, J2 = 2.4 Hz), 8.19 (2H, d, J = 9.6 Hz),
5.54 (1H, d, J = 4.8 Hz), 5.48 (1H, d, J = 4.8 Hz), 5.18 (4H, m), 4.99 (1H, d, J = 7.2 Hz), 4.92
(1H, D, J = 7.4 Hz), 4.74 (1H, t, J = 5.6 Hz), 4.67(1H, t, J = 5.6 Hz), 3.2 (4H, m);
13

C NMR (DMSO-d6, 100 MHz) d 159.4, 159.0, 154.9, 144.5, 137.6, 130.6, 130.3, 129.7, 129.6,

125.0, 123.4, 117.8, 117.0, 116.6, 100.6, 100.3, 77.3, 76.8, 73.6, 73.5, 70.0, 61.0.
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Chapter IV. Electrospray Ionization Mass Spectroscopy Study of
Cyclodextrin Complexes with A-007 Prodrugs.

Abstract
Electrospray mass spectroscopic study of several A-007 prodrugs in aqueous cyclodextrin (CD), -cyclodextrin (CD), and -cyclodextrin (CD) was performed.
Acetic acid derivative of A-007 should be metabolized in vivo before it becomes A-007, while on
the other hand, glycine attached A-007 prodrugs have surfactant like physical properties and they
are slowly hydrolyzed in the aqueous cyclodextrins by releasing free A-007. ESI-MS
spectroscopic study gives insight into the process of prodrug hydrolysis in the presence of
cyclodextrins and also on the influence of cyclodextrins on timely A-007 prodrug release.
Formation of various molecular aggregates and cyclodextrin inclusion complexes of A-007
prodrugs and their hydrolyzed products was demonstrated by ESI-MS spectroscopy.

Introduction
One of the challenges of utilizing A-007 as potent anticancer drug is to overcome its low
water solubility that limits the A-007 anticancer application only to cancer cases where topical
application is possible.1 This problem can be solved with pharmacologically acceptable A-007
prodrugs that have good water solubility and low toxicity. Furthermore good prodrug should be
slowly transformed under physiological conditions into free A-007. This task is delicate and
should be controlled due to fact that fast A-007 release in blood plasma will cause its
precipitation resulting in possible blood vessel blockage. Recent studies on amino acid derived
camptothecin derivatives2 as potent anticancer prodrugs stimulated us to explore water soluble
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A-007 anticancer prodrugs.3 To further our knowledge on A-007 prodrugs and influence of -

cyclodextrin (CD), -cyclodextrin (CD), and -cyclodextrin (CD) on prodrug stability
Electrospray Mass Spectroscopic (ESI-MS) study was performed. Structures of four A-007
prodrugs that were selected for ESI-MS spectroscopic study are presented in Figure 4.1.
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Figure 4.1. Structures of A-007 and its prodrugs for ESI-MS spectroscopic study.

Acetic Acid derivative 2 is not in classical sense the A-007 prodrug because it should be first
metabolized by liver enzyme oxidation4 into corresponding hemiacetal that upon hydrolysis will
produce free A-007. Neither A-007 nor 2 have sufficient water solubility to be administrated
alone as anticancer drug. Therefore for successful administration of the A-007 prodrugs
additional water solubilizing agents must be added. Besides increasing the prodrug solubility,
these materials should also deliver the drug as well as control rate of the prodrug transformation
into free A-007 drug to avoid its precipitation in the blood vessels. -Cyclodextrin (CD), cyclodextrin (CD), and -cyclodextrin (CD), are commonly used as host molecules to
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increase solubility and deliver aromatic drugs and prodrugs.5 We decided to use the same
approach to alter physical properties of our prodrugs.

Results and Discussion
It is well established that p-substituted phenols can form strong complexes with cyclodextrin.6 These complexes are well organized in solid crystalline state.7 In mixtures with
ratio of A-007 and CD 1:15, the negative ESI-MS shows mostly ions of free A-007 and
CD, and molecular aggregates of CD by itself (Figure 4.2). The most intensive signals are

485.6 [CD-2H]2-, 393.5 [A007-H]-, and 972.1 [CD-H]-. However there is a small intensity
signal (2.5%) at 1169.5 that corresponds to ternary complex, [A-007+2CD-2H]2-, between
A007 and two molecules of CD. Interestingly this A007 inclusion complex with CD is of
lower intensity than the ternary complex of CD self-complexation at 1458.6 indicating its
very low concentration in the solution. If we assume that intensity of the cyclodextrincomplexed A007 and free A007 are proportional to their concentration in the gas phase then
there is only 5% (2.5/55x100) A007 in the ternary CD complex.
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Figure 4.2. Negative ESI-MS spectra of aqueous A007 in presence of -cyclodextrin

Similar pattern of molecular aggregation was observed in negative ESI-MS spectra of A007 in aqueous -cyclodextrin (CD) (Figure 4.3) with noticeable difference in relative

intensity of ternary complex of one molecule of A-007 with two molecules of CD) in
comparison with ESI-MS signal for complex between three molecules of CD. This indicates
that CD forms stronger complex with A-007 in comparison with  CD. This finding is also
in the agreement with our 1H-NMR spectroscopic study of CD inclusion complexes with A007. This study also reveals that bulk of A007 molecule still resides in water media rather than

in cyclodextrin cavity.
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Figure 4.3. Negative ESI-MS of aqueous A007 in CD.

As it is the case with CD and CD dominant signals in ESI-MS of A-007 in aqueous
CD are for free A007 and CD molecular ions (Figure 4.4). However there are some

spectroscopic patterns that distinguish this MS from other two. One is the presence of MS signal
that corresponds to mass of molecular complex between one A-007 and three molecules of
CD. This can be easily explained with the fact that CD has the largest cavity in comparison

with CD and CD and can easily accommodate dinitrophenyl moiety of A-007. The ESIMS spectroscopic study results can be very well related to solubility studies where the drug
includes a tri-substituted phenyl moiety. For instance similar approach with CD was used by
Kamigauchi and coworkers to extract some alkaloids containing tri-substituted phenyl moiety
from their natural materials by aqueous cyclodextrins.8 In this finding the best results were
obtained with aqueous CD due to alkaloid-cyclodextrin complementarily size.
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Figure 4.4. Negative ESI-MS spectra of A007 in CD

As discussed previously compound 2 is an acetic acid derivative of A007 and it is prodrug
that by itself has similar anticancer activity as A-007. It can be administered as a aqueous
sodium bicarbonate salt intravenously. For an oral administration, cyclodextrins delivery
approach should be utilized due to fact that in low pH stomach environment salt of 2 will
become again free acid 2. It is also possible that it can be metabolized into its oxalic hemiacetal
by the liver enzyme that can upon entering into blood stream hydrolyze into A-007. The ESIMS spectroscopic study of this compound in aqueous cyclodextrins indicates formation of
inclusion complexes. If we assume that intensity for the cyclodextrins complexed 2 and free 2
corresponds their molar ratio in gas phase then we can estimate the molar percentage
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cyclodextrins complexation of 2. There should be around 40% of 2 in 1:1 complex with CD
(one molecule of A007 and two molecules of CD) and around 3% in 1:2 complex with CD
(Figures 4.5). The signals that are used for the comparison are 254.5 [M-2H]2-, 740.6 [CD+M2H]2-, and 1227.5 [2CD+M-2H]2- (Figure 4.5). Considering the size of the phenyl group and
the cyclodextrins cavity, it seems that CD has a required complementarily to form inclusion
complexes with polar 1,4-disubstituted benzene.9 This is perfectly reflected in presence of
signals for high order cyclodextrins complexing of 2 (Figure 4.6). Particularly presence of
signals at 1304.4 for [3CD+M-3H]3- and signal at 1389.2 [2CD+M-2H]2-. Possibility of
formation high order complexes with 2 is even more emphasized in negative ESI-MS spectra of
2 in aqueous CD (Figure 4.6). On the other hand there is no substantial complex formation

between prodrug 2 with three molecules of CD however these kind of complex are observed
between prodrug  and both CD and CD due to larger cavities (Figure 4.6).

Figure 4.5a. Negative ESI-MS spectra of 2 in -cyclodextrin
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Figure 4.5b. Negative ESI-MS spectra of 2 in -cyclodextrin

Figure 4.5c. Negative ESI-MS spectra of 2 in -cyclodextrin
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Figure 4.6. Relative intensity of ESI-MS
signals of multi-cyclodextrin complexes
with prodrug 2.

Compounds 3 and 4 are classical examples of cationic prodrugs. They both under
physiological conditions metabolize into our A-007 drug. They also have surfactant like
properties, hydrophobic and hydrophilic parts of molecule. Physical properties of these
kind of molecules are sensitive to their solution concentration. This is due to formation
of micelle type molecular aggregates.10 Our earlier 1H-NMR spectroscopic study
demonstrates that stability of 3 and 4 in water media depends on its water concentration.
At relatively high concentration (10 mM) of both these prodrugs are stable at room
temperature for several months. However at lower concentration (below 0.1 mM) they
both hydrolyze into A-007 with half-life time of ~24 hour. Due to surfactant like
properties of both 3 and 4 these can be stored as high concentrated water solutions for
long time and administrated as such to patients via intravenous injection. Naturally after
the injection, concentration will become much lower than critical micellar concentration
and compounds 3 and 4 will slowly hydrolyze into our targeted A-007 drug.
Cyclodextrins can substantially alter both the prodrug solubility as well as prodrug half-
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life time. In our case, 0.1 mM solution of 3 in 1 mM -CD has half-life about five hours
as determined by 1H-NMR spectroscopy. However 1H-NMR spectroscopic study was
hampered by existence of many molecular species and subsequently even many more
molecular aggregates in aqueous solution of 3 and cyclodextrins. Because the exchange
rate between many molecular aggregates is much faster than the NMR time scale an
average chemical shift was observed for all of these molecular aggregate. On the other
hand EMI-MS spectroscopy is capable to give us signals for every molecular species
present in an aqueous media.11
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Figure 4.7. Three molecular species originated from 3 and 4 that are present in aqueous
cyclodextrin

Considering the two step hydrolysis of 3 and 4 there are at least three molecular
species present in their negative ESI-MS of their cyclodextrin solutions (Figure 4.7). It
also seems that cyclodextrins catalyze the hydrolysis of the ester groups which makes it
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practically difficult to record ESI-MS of 3 and 4 and cyclodextrins without its hydrolyzed
products. Furthermore all of these three ionic species are capable to form self assembly
molecular aggregates, molecular aggregates with each other, and above all, they can form
inclusion complexes with cyclodextrins (Figure 4.7). This will all result in complex ESIMS spectra of 3 and 4 in aqueous cyclodextrins. A few structures of molecular
aggregates of 3 and 4 and their hydrolyzed products are presented in Figure 4.8.
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Figure 4.8. Structure of a few prodrug 3 and 4 multi-molecular complexes

Signals of three possible molecular species (molecular ion at 507.3, partially
hydrolyzed molecular ion at 450.2, and fully hydrolyzed molecular ion at 393.5) and their
molecular aggregates are present in negative ESI-MS spectra of 3 or 4 in aqueous cyclodextrin (CD) (Figures 4.9). Recent spectroscopic studies on linear ammonium
threading molecules with -cyclodextrin show formation of cyclodextrin complexes with
formation of rotaxanes.12 The attached two glycine moieties to the A-007 forms
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ammonium treading that can form inclusion complex with A-007 as evidenced by signal
at 994.6 that corresponds to complex of -CD with two molecular ions of ammonium
prodrugs 3 and 4 (Figure 4.9). Naturally presence of CD complex with fully
hydrolyzed 3 and 4 is observed as well (signal at 682.7 for complex of molecular double
ion of A007 with one CD). The negative ESI-MS spectra of 3 or 4 in aqueous CD
also represents dispersion of various molecular ions and molecular ion aggregates of
prodrugs 3 and 4 (Figure 4.9).

Figure 4.9. The negative ESI-MS spectra of aqueous 3 in CD and CD
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Figure 4.10. Positive ESI-MS spectra of 3 in aqueous CD

Interestingly positive ESI-MS spectra of aqueous cyclodextrin solutions of 3 and 4
are remarkably similar to negative ESI-MS spectra adjusted for molecular weight of
proton, ammonium, and sodium ion. That was perfectly demonstrated on positive ESIMS spectra of 3 in aqueous CD (Figure 4.10). Noticeable are signals for CD
inclusion complex with two 3 at 1136.0 and CD inclusion complex of partially
hydrolyzed 3 at 882.9. All the other signals corresponds either to molecule 3 (signal at
509.7), partially hydrolyzed 3 (signal at 487.6), fully hydrolyzed 3 (signal at 395.5) or
their various molecular associates (Figure 4.10).
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Conclusion.
Water soluble A-007 prodrug interactions with cyclodextrin, cyclodextrin, and
cyclodextrin were studied with ESI-MS spectroscopy. Cyclodextrins were used for

several purposes; to solubilize the prodrug, change stability of the prodrug and prodrug
carrier. It was demonstrated that in cyclodextrin water solution half-time of prodrug 3
was decreased to around 4-5 hours which is the ideal for in vivo drug release. It was also
demonstrated that during prodrug hydrolysis various molecular associates were formed
that can substantially alter drug absorption and release capability. Therefore
cyclodextrins seems to be crucial for both drug delivery as well as controlling the drug
release by altering the prodrug half-life time in blood plasma.
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Experimental
All cyclodextrins, solvents and chemicals were obtained from Sigma-Aldrich and
are used without further purification. Preparation procedures and characterization A007
prodrugs were reported previously. A aqueous solution were sonicated for freshly
prepared to eliminated large percentage of hydrolyzed A007 drugs and sonicated for a
few minutes to insures homogeneity All the mass spectrometric analysis was performed
on an Applied Biosystems/MDS SCIEX (Foster City, CA, USA) 3200 QTRAP hybrid
quadrupole/linear ion trap mass spectrometer with direct infusion of each prodiginine
sample in aqueous methanol (50/50) spiked with 0.1% formic acid at a flow rate of 4
L/min. Positive-ion and negative mode ES-MS was used for the analysis, with the

Turbo VTM("superscript") source settings for A-007 or its derivatives optimized as
follows: ionspray voltage 5.5 kV, declustering potential 60 V, source temperature 120°C,
GS1 40, and curtain gas 10. Ultrahigh grade (99.999%) nitrogen was utilized as
nebulizing gas and drying gas.
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Chapter V. Attempts Towards the Synthesis of the Tetramic Acid
Antibiotic - Magnesidin
Abstract
Magnesidin, the tetramic acid natural product, is a drug candidate for gingivitis and other
novel anti-bacterial applications. The key step in the synthetic strategy of Magnesidin
and other tetramic acids is the ring opening of an oxazolone ring with an activated ester.
In this context, an efficient two-step synthetic procedure for the preparation of numerous
variations of oxazolone rings from N-protected glycine and either aliphatic or aromatic
aldehydes was developed. The major problem associated with Magnesidin synthesis is
the volatile nature of key intermediate oxazolone. This problem has been circumvented
by the design and synthesis of a tag molecule, which serves as a synthetic equivalent of a
resin/solid support with the aim of restoring homogeneous reaction conditions and
anchoring the volatile molecule to the solution phase.

Introduction
Attempts to synthesize Magnesidin and Magnesidin-like compounds by methods
analogous to those reported in the literature for 3-acetyl tetramic acids1,2, through the
intermediate N-alkanoyl-acetylamino acid ethyl ester or the azlactone either met with
failure or gave the desired compounds in very poor yields. The presence of the olefhinic
moiety at position 5 of the five membered Magnesidin tetramic acid ring 1(Figure. 5.1)
makes it aromatic in nature and synthetically inaccessible through the traditional methods
of tetramic acid synthesis. Our approach to the synthesis of Magnesidin involved a new
route through the ring opening of advanced intermediate 5 (Scheme5.1) with -keto ester.
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The -keto ester is used as a multicoupling reagent3, utilizing the both the electrophilic
carbonyl and nucleophilic active methylene carbon to perform the required synthesis.
Once the condensation product formed by the nucleophilic attack of active methylene
carbon of -keto ester with intermediate 5 is in place, we envisioned a possibility of
intramolecular cyclization by the elimination of alcohol to make the Magnesidin ring.

Results and Discussion
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Figure. 5.1. Structure of Magnesidin.

Initial Retrosynthetic Analysis of Magnesidin

The synthetic approach for Magnesidin can be seen in the retrosynthetic analysis
depicted in Scheme 5.1. It was envisioned that the synthesis of Magnesidin would
commence from the straightforward reaction of the commercially available amino acid
threonine4 (Scheme 5.1). As per the retrosynthetic analysis, the benzoylation of
carboxylate6 protected threonine would yield compound 6. Subsequent ring closure of
compound 6 by intramolecular condensation under basic conditions would provide key
oxazolone ring 5. Making the oxazolone ring sets the stage for incorporating the -keto
ester moiety to make the tetramic acid core. The nucleophile generated by proton
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abstraction from a -keto ester can open the oxazolone ring to make the basic tetramic
acid skeleton. A sequence of required substitutions (Scheme.5.1) would then make the
tetramic acid Magnesidin.
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Scheme 5.1. Initial Retrosynthetic analysis of Magnesidin.
First Attempt to Synthesize Magnesidin

Substituted threonine 11 was prepared from commercially available amino acid 8
in 88% yield over three steps following literature procedures4,5 with minor modifications
(Scheme 5.2). In the first step, threonine was esterified to yield 9. This compound is
commercially available but it can be synthesized very cost effectively.
The esterification is carried out in order to protect the carboxylic acid from
chemoselective benzoylation of the amine group in the following step to make compound
11. The ester formed as its hydrochloride salt needs to be free-based for the subsequent

benzoylation to occur. Ordinarily, a simple wash with a mild aqueous base like sodium
bicarbonate would suffice, but considering that we have a hydroxyl moiety in 11, the
molecule is hydrophilic and is lost upon aqueous work up. Therefore, we decided to
continue to the next step, namely benzoylation of amine, taking care to use two
equivalents of the base triethylamine. The extra base scavenges the HCl from the
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ammonium salt to make triethylamine hydrochloride which is insoluble in
dichloromethane and can be filtered out after crystallization. Benzoylation is done with
benzoyl chloride and triethyl amine on 11. The reaction completes in two hours, and the
reaction mixture is subsequently left overnight, to crystallize out triethylamine
hydrochloride, which is easily filtered off. The aqueous work up is completed to obtain
the pure product. The ester deprotection was achieved under reflux conditions with ethyl
acetate as the solvent and a mixture of acetic acid/hydrochloric acid as the reagent. The
deprotection was initially attempted under milder conditions at room temperature and
with acetic acid as the reagent, but under these conditions the expected hydrolysis did not
occur. After a standard work up and purification, the product was obtained in 88% yield
over the 3 steps on a multigram scale. Unfortunately, as expected, we could not make
the oxazolone ring under dehydration conditions using acetic anhydride and sodium
acetate from compound 11. Our subsequent attempts to carry out this transformation
using stronger conditions, by varying the temperature and base, did not bring about the
required transformation.
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Scheme 5.2. Attempted synthesis of oxazolone ring.
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To our surprise, we could not find in the literature a reliable general procedure for
the preparation of oxazolone ring of this general structure. These oxazolone rings are
important precursors in the synthesis of -unsaturated acids and various other valuable
pharmaceuticals.6,7 Therefore, it was important to develop an industrially viable
synthetic procedure that was inexpensive and capable of producing the product in high
yields. To meet these requirements, a simple, preferably one-pot synthesis should be
developed using readily available starting materials. The procedure we developed adheres
to these requirements.
N-Protected glycine and the corresponding aldehydes were chosen as the optimal
starting reagents for these reactions. A suspension of N-protected glycine is stirred with
sodium acetate and acetic anhydride at 0°C and into this suspension, the aldehyde is
added. The reaction mixture is stirred at 0°C for two hours and then it is refluxed until the
reaction goes to completion, which is monitored by NMR. The first step in this reaction
is the formation of 2-R-4H-oxazol-5-one 14, which readily condenses with the aldehyde
to form the required oxazolone ring 15.
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Scheme 5.3: Synthesis of oxazolone ring.
To fully understand and demonstrate the scope of this condensation, the reaction
progression between N-acetylglycine and 1,4-benzenedicarbaldehyde was followed by
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NMR spectroscopy8 (Figure.5.2). The first step in the reaction is the formation of 2methyl-4H-oxazol-5-one (B), which readily condenses with 1,4-benzenedicarbaldehyde
(C) to form the monocondensation product (D). The reaction continues, and the final
double condensation product (E) is formed. According to our NMR studies, the
conversion appears to be nearly quantitative. Similar reaction conditions were used for
the preparation all the oxazolones listed in Table. 5.1.

Figure 5.2. HNMR data showing the reaction progression for the preparation of
oxazolone ring.

With a general method for the synthesis of numerous variations of oxazolone
rings in hand, the next step was to open the oxazolone ring with a -keto ester to make
the tetramic acid skeleton. To have a better understanding of the nature and scope of the
ring opening of the oxazolone ring with a nucleophile, we decided to study the behavior
of oxazolone ring with hydroxyl and methoxy nucleophiles.8
Opening the oxazolone ring with hydroxy and alkoxy groups leads to the
formation of N-protected -unsaturated -amino acids and esters, respectively. As
discussed earlier, these compounds are of high commercial importance. A variety of
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asymmetric synthetic methods for amino acid preparation have been developed and are
available in literature.9-15 One method of importance involves hydrogenation of an
enamide using chiral transition-metal catalysts. Perhaps one of the best examples using
enamides as a starting material16, 17 is enantioselective synthesis of [(S)-2-amino-3-(3,4dihyroxyphenyl)propanoic acid] (L-DOPA),18 which involves a rhodium hydrogenation
catalyst containing a chiral phosphorus ligand reacting with an enamide. Unfortunately,
large-scale manufacturing of -unsaturated amino acids has proven to be problematic.
Theoretically, amino acids are ideal starting materials for the preparation of these
compounds. For instance, L-threonine methyl ester is an excellent starting material for
the preparation of Z-2-(N-acetylamino) butenoate.19 However, there is no general
synthetic procedure using amino acids as precursors. Now that we have a general
procedure to make oxazolone ring, it will not only make an excellent general method to
make --unsaturated acids and esters, but also it will give insight into behavior of
oxazolone ring towards different nucleophiles.
The ring opening of oxazolone ring was achieved very easily. A methanol
solution of oxazolone and sodium methoxide was stirred at room temperature for 15 min.
The solvent was evaporated, and the residue was partitioned between 10% aqueous
ammonium chloride (100 mL) and methylene chloride. After standard workup, the oily
residue was recrystallized from petroleum ether to give the pure product N-protected
unsaturated -amino acids ester (Scheme 5.4). The corresponding N-protected
unsaturated amino acids were prepared under similar conditions except, the

solvent used was a 1:1 mixture of methanol and water and the base used was sodium
hydroxide. To this end, our method of opening an oxazolone ring with an appropriate
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nucleophile, served as an excellent general method to synthesize -acetylamino- and benzoylamido--unsaturated acids and esters. The starting materials are inexpensive,
and the reaction procedures are very simple. The products are purified by simple
recrystallization from methanol. Therefore, this method is applicable to large-scale
(industrial) preparation of these valuable intermediates for use in the pharmaceutical
industry.
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Scheme 5.4: Synthesis of -acetylamino-, -benzoylamido--unsaturated acids and
esters.
To determine the stereochemistry of the double bond generated in the course of
the condensation reaction, X-ray structural analysis was performed with 4-Ethylidene-2phenyl-4H-oxazol-5-one (15-I-g) (Figure. 5.3). X-ray analysis proved that this isomer
was the major isomer (more than 95%) of the condensation reaction. Our X-ray
crystallographic study confirms that the stereochemistry of the major isomer formed
during condensations of 14 with aldehyde has Z-configuration of the newly formed
double bond of oxazolone. Therefore, in preparation of both esters and acids, which are
prepared by ring opening of oxazolone, the stereochemistry of the double bond must be
preserved.
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Table 5.1. Oxozolones (15-I), -acetylamino- and -benzoylamino--unsaturated
acids (15-III) and esters (15-II) synthesized and their Isolated yields.
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R2

15-I

%Yield
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%Yield

5-III

%Yield
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1-naphthyl

e

80

e

80

e

92

C6H5

2-furyl

f

90

f

89

f

96

C6H5

CH3

g

95

g

90

g

91

C6H5

1-naphthyl

h

84

h

87

h

92

C6H5

C6H5

i

90

i

90

i

96

C6H5

3,4,5-(MeO)3C6H4

j

80

j

80

j

93

C6H5

4-(Me2N)C6H4

k

90

k

90

k

91

126

Figure 5.3. Ortep drawing of the X-ray determined structure of 15-I-g (Table 5.1)
(Courtesy of E.D. Stevens, University of New Orleans)

We established that it was possible to open oxazolone rings with nucleophiles
under basic conditions. Our next step was to establish a method for opening the
oxazolone ring with an activated ester to make the desired tetramic acid skeleton. (Figure
5.4)
In an attempt to open the oxazolone ring with the anion of -keto ester, we stirred
a mixture of 3-oxo-decanoic acid methyl ester in methonol and sodium methoxide, while
4-ethylidene-2-phenyl-4H-oxazol-5-one was added and stirring continued. After several
hours there was no trace of our desired product formed. The reaction conditions were
varied and checked for the progress of the reaction. Refluxing the reaction mixture,
changing solvents, trying stronger base did not help to bring about the desired
transformation.
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Figure 5.4. Expected reaction of oxazolone with anion of -ketoester.
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We figured the electron withdrawing benzoyl group on amine nitrogen was
deactivating the amine group and preventing its nucleophilic activity, consequently
interfering with ring closure. We speculated that if the benzoyl group was replaced by an
electron donating group or at least with a group that is low in electron withdrawing
ability, this transformation should be feasible. Hence we decided to replace benzoyl
group with ethoxycarbonyl group (Scheme.5.5, compound 18). The rationale for the
replacement benzoyl group was twofold. First, this replacement allowed for us to
determine if it is indeed the benzoyl group that is preventing the ring closure by
decreasing the nucleophilicity of amine nitrogen. Second, it allowed us to continue with
the standardized oxazolone route with few steps.
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N

O
OC2H5
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H

N

O
18
OC2H5

a. Ethyl chloroformate/ NaOH+NaOH, 70% b. Ac2O, 99% c. Acetone, 99% d. Diethyl melonate/NaOEt

Scheme 5.5. Synthesis of ethoxy-substituted oxazolone ring.

To obtain the amino-substituted glycine 17 (Scheme 5.5.), a solution of the
glycine in aqueous NaOH was stirred and ethyl chloroformate and aqueous NaOH was
added dropwise. The mixture was stirred at 0°C and washed with ether.20 After a
standard workup the compound was directly used to make the required oxazolone ring 18
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with ethoxy substituent on the ring nitrogen. A suspension of 2-Ethoxycarbonylaminoethanoic acid, acetaldehyde, sodium acetate and acetic anhydride was stirred at 0° C first
and then under reflux, essentially following the method developed to make oxazolone
rings. The reaction mixture was then mixed with water and stirred at room temperature.
After the workup, the NMR of both the organic and aqueous layers were almost void of
any product. There was a trace amount oxazolone 18. We then realized because of the
very small size of oxazolone 18, it was a very volatile molecule which vaporized even at
room temperature. A molecule so volatile is difficult to manipulate and hard to work
with. Use of higher temperatures, even room temperature is precluded because of the low
molecular weight. Hence it was determined that further attempts to carry out the required
transformation via this route would most likely be unsuccessful.

Second Attempt to Synthesize Magnesidin

We decided to start with an open chain threonine derivative and introduce an
active methylene group containing alkyl side chain on amine. This procedure serves two
purposes. First, the substituent at 3rd position of the product Magnesidin ring can be
introduced directly by choosing the appropriate alkyl side chain. Second, the early
introduction of the heavy alkyl chain increases the molecular weight of the intermediates,
such that the intermediates are rendered non-volatile and are therefore easy to handle.
This precludes the volatility problem encountered in the previous synthetic attempts and
since the reaction involves fewer steps, it is expected that this synthetic route would be
more efficient.
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Scheme 5.6. Third Retrosynthetic Analysis of the Magnesidin.

We started with the inexpensive amino acid threonine and made the
corresponding methyl ester by Fisher esterification. The next step was to condense keto-decanoic acid with threonine methyl ester under DCC coupling conditions. The
intended next step was the dehydration to make the olefhinic moiety and subsequent ring
closure to make the tetramic acid core. Unfortunately, the expected dehydration with
acetic anhydride and sodium acetate did not happen. Instead the free hydroxyl group of
threonine was acetylated. The ring closure did not happen either, as evident by the NMR.
Assuming the dehydration could be achieved at a later stage under high temperature
dehydration conditions, the compound was separated and the ring closure was tried with
the stronger base sodium methoxide. Under these conditions instead of the expected ring
closure, the acetyl group was lost and compound 19 was regenerated. At this stage, it
was realized even if we could protect the free hydroxyl group of threonine methyl ester in
the form of silyl ether, it would not be successful as a synthetic scheme, considering mild
basic conditions, namely acetic anhydride and sodium was unable to accomplish ring
closure. Using strong basic conditions might lead to ring closure but selectivity is lost
considering there are multiple acidic protons (Figure 5.5) resulting in the possibility for
multiple enolic forms and hence too many byproducts. Therefore it is important to use a
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method which avoids strong basic conditions and minimizes the possible enolic forms
and hence multiple product formation. One possibility is carrying out dehydration before
using the base to close the ring. This has been tried in Scheme 5.9.
OP

O
O
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O

Figure 5.5. Possible deprotonation sites upon using a strong base.
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Scheme 5.7: Second Attempt to Synthesize Magnesidin

Third Retrosynthetic Analysis of the Magnesidin

Our literature search indicated that ring closure to make tetramic acid under
extremely mild conditions can be achieved with Meldrum’s acid21 (2,2-dimethyl-1,3-
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dioxane-4,6-dione, Scheme 5.8). Meldrum’s acid is an exceptionally acidic methylene
compound,22 that has been used by Yonemitsu et.al as a versatile agent for various
syntheses which involve the reactions of nucleophiles generated from an active
methylene group under extremely mild conditions.22-27 For instance, -keto esters were
obtained by acylation of meldrums acid using acyl chlorides in dichloromethane in the
presence of pyridine.

This gave the corresponding acyl meldrums acid almost

quantitatively. Alcoholysis of acyl meldrums yields the corresponding -keto
esters(Scheme 5.8). On the other hand a new process for the acylation of Meldrum’s acid
with chiral N-protected amino acids was developed by Jouin et al24. In this process, the
N-protected amino acids were activated with isopreopenyl chloroformate and it was
shown that the acyl Meldrum’s acids could be readily converted to the corresponding
chiral N-protected-substituted tetramic acids by heating in an organic solvent. A variant
of this method was recently reported by Sandris et,al20 which described a particularly
simple and convenient acylation reaction of Meldrum’s acid via the imidazolides of Nprotected glycine 21 and the transformation of the acylated compounds 22 to the
corresponding N-protected tetramic acids 23.
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a.1,1'-Carbonyldiimidazole and Meldrum's acid in DCM at RT, 86-93% b. CHCl3, EtOAc, Reflux, 75-96%

Scheme 5.8. Meldrum’s acid mediated synthesis of tetramic acids.
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Based on the successful ring closure by Sandris et al20 to make tetramic acid
under mild basic conditions, and our requirement to avoid strong basic conditions, a new
retrosynthetic analysis was designed. Considering the difficulties in the dehydration step
we faced, it was also made sure that the synthetic scheme was designed such that
olefhinic moiety was already in place, before condensation with Meldrum’s acid was
attempted.
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Scheme 5.9. Third Retrosynthetic Analysis of the Magnesidin.

The synthesis was started with the previously prepared threonine methyl ester.
The diamide 24 (Scheme 5.10) was prepared successfully in 97% yield from the
threonine methyl ester by simple reflux with acetic anhydride and sodium acetate.28
Mono-amide 25 was made by hydrolysis of 24 using triethylamine as a base and
methanol. Under these conditions exclusive mono-deacetylation occurs in 97% yield.
The methyl ester 25 was hydrolyzed to give free acid 26 in 98% yield. Once we had the
olephenic moiety in place, the stage is set for condensation with Meldrum’s acid.
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Scheme 5.10. Third Attempt to Synthesize Magnesidin.

Unfortunately, condensation of acid 26 with meldrums acid as described
by Sandris et al. did not proceed as expected product 27 was observed. Surprisingly,
there was no trace of starting acid 26. Consequently, it was suspected that instead of the
expected condensation with Meldrum’s acid, the acid 26 self condensed to form 4ethylidene-2-methyl-4H-oxazol-5-one 28 (Scheme 5.11). We reasoned that the presence
of olefhinic moiety in the acid 26 could be the reason for the preferred self condensation
over condensation with Meldrum’s acid. The rationale for this reasoning was that due to
the presence of olefhinic moiety in acid 26 the oxazolone 28 (scheme 5.11) is almost like
aromatic furan system, considering each of the carbons involved in the ring is sp2
hybridized, and all other criteria for aromaticity is met. So a possible aromatic ring
formation by the self condensation process should be preventing the condensation
reaction with Meldrum’s acid.
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Scheme 5.11. Self condensation of 25.

Fourth Retrosynthetic Analysis of the Magnesidin

Based on the synthetic strategies tried thus far, it was deemed that the oxazolone
method was very promising. For this method to work two things should be taken care of.
First, for the successful ring opening of oxazolone ring with nucleophile generated from
an active methylene group and subsequent ring closure to tetramic acid, it is important
that the substituent on ring nitrogen is not very electron withdrawing in nature. Second,
the oxazolone ring is heavy such that the molecule is non-volatile at room temperature.
Theoretically, this problem can be overcome by covalently attaching the volatile
oxazolone ring to a solid support. However, despite the many benefits offered by solid
phase approach, the heterogeneous nature of the insoluble polymers and reaction
conditions often results in a series of problems including problems with loading capacity,
inability to use conventional spectroscopic techniques for reaction monitoring, unequal
distribution of and/or access to the reaction sites, solvation problems and inefficient
coupling rate. Soluble polymer support such as polyethylene glycol polyvinyl alcohol
and other ingenious variants of these polymers have limitations such as low loading
capacity, limited solubility during the reaction processes, aqueous solubility, and
insolubility in ether solvents etc. Hence we decided to develop an alternative
methodology, a tag molecule, which serves as a synthetic equivalent of a resin/solid
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support with the aim of restoring homogeneous reaction conditions while at the same
time anchoring the volatile molecule in the solution phase. Figure 5.6 shows the tag
molecule which we developed, to be attached to the oxazolone ring. Our plan is to
synthesize the tag molecule first and then attach the oxazolone ring to this tag, to solve
the volatility problem.
The design of the molecular tag is done such that it can be used as soluble support
for organic synthesis. Substrates anchored on molecular tag are expected to retain their
reactivity, as in solution reactions, and allowed the use of conventional spectroscopic
analysis during the synthetic process. Ideally, the constitution of molecular tag should be
such that excess reagents and by-products in the multistep reactions can be removed
easily by simple recrystallization. Also, the presence of huge aromatic moiety would
make it easy to identify spectroscopically. Considering all the above factors the
molecular tag has been designed as seen in Figure.5.6.

OH
CH2

O

N

O

Tag molecule

Figure 5.6: Tag molecule.
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Fourth Retrosynthetic Analysis of the Magnesidin
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Fourth Attempt to Synthesize Magnesidin
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Scheme 5.13. Synthesis of tag molecule.
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The synthesis of the tag molecule was started by condensation of commercially
available, inexpensive Benzo[de]isochromene-1,3-dione (29) and p-amino toluene as
starting materials. The product had physical properties that easily set it apart from both
starting materials. In our spectral analyses, there were clear differences in the chemical
shift for the benzylic proton signals of the condensation product and the starting p-amino
toluene. The ratios of these signals were used to determine the percentage of reaction
conversion. Through our experimentation, we determined that the best solvent for this
reaction is toluene and pyridine. With toluene as solvent a non nucelophilic base such as
triethyl amine is required while with pyridine use of another basic reagent is precluded.
Compound 31 (Scheme 5.13) was brominated under benzylic bromination conditions
using NBS. The dibromination product is a very common side product of this reaction.
The ratio of the mono and dibenzylation product and the extent of reaction strongly
varied with the nature of the solvent and temperature applied. The extent of formation of
dibenzylation product was dramatically reduced by using flash light instead of high
temperature conditions. Furthermore, the cost of reaction is reduced by replacing the
carbon tetrachloride generally used for allylic bromination reactions, with chloroform.
Our attempts for direct hydrolysis of the 32(Scheme 5.13) to alcohol under mild
conditions did not yield fruitful results. It was important to avoid harsh conditions to
prevent hydrolysis of amide linkage. Consequently, we avoided the direct hydrolysis of
the benzyl bromide 32, and tried to circumvent the problem by generating an ester at the
benzylic position(compound 33), which was hydrolyzed subsequently to yield alcohol 34.
After thoroughly exploring different reaction conditions, acetylation has been achieved
with a simple sonication at room temperature with sodium acetate in dimethylsulfoxide as
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solvent. Acetate 33 was hydrolyzed exclusively to obtain required alcohol (the tag
molecule) in quantitative yield, with no side reactions. Thus we successfully achieved
the synthesis of tag molecule.
Attaching the tag molecule synthesized to oxazolone ring, followed by ring
opening of oxazolone with a -keto ester should make the required tetramic acid
Magnesidin. Since we already developed general methods to make oxazolone ring and
also to perform the ring opening of oxazolone ring with a nucleophiles, we believe the
synthetic attempts to make Magnesidin will be successful by this route.

Conclusion
The synthesis of the Magnesidin is a very challenging endeavor. The structure of the
molecule is very pH sensitive and exists in multiple tautomeric forms and it is almost
impossible to lock into one particular form. This coupled with its very small size makes
the synthesis complicated. Through this work, it has been determined that the most
efficient approach to the synthesis of the Magnesidin is via the ring opening of
corresponding oxazolone ring with an anion generated from active methylene of a ketoester. To this end, a simple one-pot synthesis to make oxazolone rings has been
developed. The method can be used as a general synthetic procedure for making the
synthons of a variety of tetramic acids. Definitive characterization of one of oxazolone
rings, 4-ethylidene-2-phenyl-4H-oxazol-5-one was achieved by X-ray crystallography.
Further the synthetic reaction developed was stereoselective with the major isomer
formed during condensations being Z-isomer. The method is industrially viable method
with readily available starting materials. Furthermore, an efficient two-step synthetic
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procedure for the preparation of numerous variations of N-protected -unsaturated amino acids and their corresponding esters from N-protected glycine and either aliphatic
or aromatic aldehydes was developed. The reaction involved cyclization of the Nprotected glycine into oxazolone, condensation with the aldehyde, and ring opening with
a base. All the products mentioned are produced in good to excellent yields.
Additionally, it was deemed that in order to successfully synthesize Magnesidin
from an oxazolone ring, the major challenge is anchoring the volatile oxazolone ring to
the solution phase. Theoretically this problem can be overcome by covalently attaching
the volatile oxazolone ring to a solid support. However, considering many limitations
this method offers such as low loading capacity, limited solubility during the reaction
processes etc., we developed an alternative methodology, a tag molecule, which serves as
a synthetic equivalent of a resin/solid support with the aim of restoring homogeneous
reaction conditions while at the same time anchoring the volatile molecule in the solution
phase. In addition to above mentioned advantages, the tag molecule imparts crystalinity
to the attached molecule, which intern simplifies the purification procedures.

Experimental Section
All NMR reaction following experiments were performed on 500 MHz UNITY500
Varian NMR instrument by taking samples from the reaction mixture containing 0.02
mol Nacetylglycine, 20 mL acetic anhydride, 3 g sodium acetate, and 0.01 mol of 1,4benzenedicarbaldehyde. The NMR sample was prepared as DMSO-d6 solution. All
DMSO-d6 samples were clear solutions. Elemental analysis was performed by Atlantic
Microlab, Inc. Melting points were taken on an Electrothermal IA 9000 Digital Melting
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Point Apparatus and are uncorrected. X-ray structure determination was performed on
Bruker SMART 1KCCD automated diffractometer. Crystals of compound 7g were
obtained by slow crystallization from a diluted methanol solution of 7g.

L-Threonine Methyl Ester Hydrochloride (9)

Methanol(250 mL) was cooled at 0 °C, and thionyl chloride(18 mL; 0.25 mol) was added
dropwise. To the resultant solution of HCl in methanol was added L-threonine (30 g;
0.25 mL), and the reaction mixture was heated under reflux for 1h. The solvent was
removed in vacuo, another 250mL of a solution of HCl in methanol, prepared in the same
manner as before, was added, and the reaction mixture was heated under reflux for
another 1h. The solvent was removed in vacuo to yield the title compound (42g; 98%) as
white solid: MP160-163 °C. 1H-NMR (300 MHz, CD3OD)  1H, dq, J=6.5; 4.2
Hz), 3.92 (1 H, d, J=4.2 Hz), 3.84 (3H, s), 1.31(3H, d, J=6.5Hz); 13C-NMR (75 MHz,
CD3OD) 

N-Benzoyl L-Threonine Methyl Ester (10)

A crude L-threonine methyl ester (39.49 g, 0.3 mol) was dissolved in 300 mL of
methanol and then transferred to the round bottom flask equipped with magnetic stirrer
and cooling ice bath. A solution was chilled to 0°C and a total of 64.1 g (0.63 mol, 3 eq.)
was added to the flask. A total of 30.9 g (0.21 mol) of benzoyl chloride was added to the
solution and resulting mixture stirred at 0°C for 1 hour. After this period of time the
solvent was removed on rotavap to yield a viscous semi-solid. A total of 300 mL of cold
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water was added to the residue and organic material was extracted with ethyl acetate
(2.times.300 mL). The organic phase was separated, washed with brine (200 mL) and
dried over sodium sulfate. The solvent was removed on rotavap to yield 52.02 g (98%) of
clear yellow oil. Obtained oil was crystallized from 200 mL of ether to give a white
crystalline solid, which was filtered off, washed with hexane (2 x 100 mL) and dried
under suction. An additional drying in a vacuum desiccator yielded 42.35 g (84.7% yield)
of clear syrup. 1H-NMR (300 MHz, CDCl3) : 7.82 (2H, d, J=7.3 Hz), 7.43 (1H, t, J=7.3
Hz), 7.40 (2H, t, J=7.3 Hz), 7.2 (1H, bd, J1=9.0 Hz), 4.78 (1H, dd, J=2.4 Hz, J=8.7 Hz),
4.42 (1H, dq, J=2.6 Hz, J=6.3 Hz), 3.42 (1 H, s), 3.78 (3H, s),1.25 ( 3H, d, J=6.3 Hz);
13

C-NMR (75 MHz, CDCl3) : 171.2, 167.1, 133.3, 131.4, 128.6, 127.5, 66.3, 63.1, 51.1,

17.4.

N-Benzoyl L-Threonine (11)

N-Benzoyl Threonine Methyl Ester (10g, 45 mmol) was dissolved in 110 mL of 10:1
mixture of acetic acid and 30% hydrochloric acid and refluxed for 3 hours with stirring.
After the methyl group completely disappeared in the proton NMR, the reaction was
stopped. The solvent was removed in vacuo and washed with water (100 mL x 3). The
residue was coevoporated with 100 mL of toluene (x 3). The toluene suspension was
filtered under vacuum to give the 9.12 g of pure product as a white precipitate (95%
yield). Mp 146°C, 1H-NMR (300 MHz, DMSO-d6)  8.07(2H, d, J=8), 7.89(2H, d, J=8),
7.48-7.59(2H, m), 4.47(1H, dd, J=9,3), 4.28-4.21(1H, m), 1.17(3H, d, J=6);

13

C-NMR

(300 MHz, DMSO-d6) 166.4, 171.8, 133.6, 131.2, 128, 127.1, 66.4, 58.6, 20.04.
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General Procedure for Preparation of Oxazolone (15-I):
Preparation of 2-Methyl-4-(3,4,5-trimethoxybenzylidene)-4H-oxazol-5-one (15-I-c)

A suspension of N-acetylglycine (5.9 g; 0.05 mol), sodium acetate (4.1 g; 0.05 mol), and
acetic anhydride (30 mL) was stirred at room temperature for 30 min. Into the white
suspension, 3,4,5-trimethoxybenzaldehyde (8.3 g; 0.05 mol) was added. The resulting
suspension was stirred at room temperature for 1 h and then at 60°C for 5 h. The reaction
mixture became a brown solution that upon cooling to room temperature again became a
suspension. This suspension was mixed with water (1 L) and stirred at room temperature
for a half an hour. The insoluble material was separated by filtration, washed with water
(3 x 30 mL), and recrystallized from methanol (250 mL).

General Procedure for Preparation of (15-II):
Preparation of Methyl (Z)-2-Benzoylaminobut-2-enoate (15-II-g)

The methanol (20 mL) solution of 3g (1.87 g; 0.01 mol) and sodium methoxide in
methanol (2 mL of 25% CH3ONa in CH3OH) was stirred at room temperature for 15 min.
Solvent was evaporated, and the residue was partitioned between 10% aqueous
ammonium chloride (100 mL) and methylene chloride (150 mL). The organic layer was
washed with water (3 x 100 mL), dried over anhydrous sodium sulfate, and evaporated to
an oily residue. The oily residue was dissolved in hot petroleum ether (500 mL) from
which white needles of product crystallized.

General Procedure for Preparation of (15-III):
Preparation of 2-Acetylamino-3-phenylacrylic Acid (15-III-b)
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Into aqueous (200 mL) sodium hydroxide (4.0 g; 0.1 mol), a solution of methanol (200
mL) and 4-benzylidene-2-methyl-4H-oxazol-5-one (18.7g; 0.1 mol) was added. The
reaction mixture was stirred at room temperature for 30 min, followed by methanol
evaporation at reduced pressure. The remaining clear water solution was acidified with
10% hydrochloric acid to pH 3 and left at room temperature overnight. The formed
crystalline product was separated by filtration, washed with cold water (3 x 50 mL) and
dried at 110°C for 30 min to afford pure product.

2-Phenyl-4-(2,4,6-trimethoxy-benzylidene)-4H-oxazol-5-one (15-Ia)

Yield: 92%, product was obtained as orange amorphous solid. MP:

170.5-171.5°C. 1H

NMR (400 MHz, CDCl3) δ 8.07(2H, d, J = 8 Hz),7.56-7.46(4H, m), 6.16(2H, s),
3.88(6H, s), 3.86(3H, s); 13C NMR (100 MHz, DMSO-d6) δ 187.9, 164.5, 160.9, 132.6,
128.9, 127.9, 126.6, 126.4, 105.5, 90.9, 55.9.

2-Benzoylamino-3-(2,4,6-trimethoxy-phenyl)-acrylic acid methyl ester (15-IIa)

Yield: 80%, product was obtained as orange crystalline solid. MP: 135-136.5 °C. 1H
NMR (400 MHz, CDCl3) δ10.30(1H, s), 8.54(1H, s), 7.77 (2H, d, J = 8 Hz); 7.477.28(4H, m), 6.12(2H, s), 3.81(6H, s), 3.76(3H, s); 13C NMR (100 MHz, DMSO-d6) δ
187.6, 165.6, 162.4, 158.5, 134.1, 131.7, 128.5, 127.2, 126.3, 121.4, 105.0, 91.1, 56.2.

2-Benzoylamino-3-(2,4,6-trimethoxy-phenyl)-acrylic acid(15-IIIa)

Yield: 87%, product was obtained as red crystalline solid. MP: 138-139°C.
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1

H NMR (400 MHz, CDCl3) δ 10.25(1H, s), 8.57(1H, s), 7.74(2H, d, J=7.2 Hz), 7.43-

7.33(4H, m), 6.08(2H, s), 3.77(6H, s), 3.71(3H, s); 13C NMR (100 MHz, DMSO-d6) δ
187.5, 165.5, 164.8, 163.9, 162.3, 158.3, 133.8, 131.5, 129.7, 128.4, 128.0, 127.0, 126.1,
121.5, 104.6, 90.9, 90.1, 56.0, 55.2, 52.1.

4-Benzylidene-2-methyl-4H-oxazol-5-one (15-Ib)

Yield: 90% product was obtained as off white amorphous solid. MP: 148-150°C. 1H
NMR (400 MHz, CDCl3) δ 7.32-8.20(5H, m), 7.16(1H, s), 2.45 (3H, s); 13C NMR (100
MHz, CDCl3) δ 133.3, 132.4, 131.7, 131.3, 129.1, 55.9, 15.8.

Methyl (Z)-2-(N-acetylamino)-3-phenylpropenoate (15-IIb)

Yield: 90% product was obtained as white amorphous solid. MP: 121-122°C.
1

H NMR (300 MHz, CDCl3) δ 7.63-7.21(6H, m) , 7.12(1H, s), 3.84(3H, s), 2.11(3H, s);

13

C NMR (100 MHz, CDCl3) δ 168.8, 165.7, 133.7, 132.3, 129.4, 129.6, 128.6, 124.2,

52.7, 23.3.
2-Acetylamino-3-phenylacrylic Acid (15-IIIb)

Yield: 93%, product was obtained as white amorphous solid. MP: 190°C.
1

H NMR (DMSO-d6, 300MHz) 9.5 (1H, s, NH), 7.62 (2H, d, J = 7.2 Hz), 7.41 (2H, t, J

= 6.0 Hz), 7.35 (1H, t, J = 7.2 Hz). 7.24 (1H, s), and 1.91 (3H, s); 13C NMR (DMSO-d6,
100 MHz) d 169.4, 166.5, 133.8, 131.2, 129.8, 129.2,128.6, 127.5, and 22.6 ppm. Anal.
calcd. for C11H11NO3 (MW 205.21): C, 64.38; H, 5.40; N, 6.83. Found: C, 64.26; H, 5.49;
N, 6.89.
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2-Phenyl-4-thiophen-3-ylmethylene-4H-oxazol-5-one (15-Ic)

Yield: 92%, product was obtained as yellow solid. MP: 176-177°C;
1

H NMR (400 MHz, DMSO-d6) δ 8.20-8.05(2H, m), (1H, d,J = 4.5 Hz), 7.6(1H, d, J =4

Hz), 7.55-7.45(3H, m), 7.44(1H, s), 7.12(1H, s); 13C NMR (100 MHz, DMSO-d6) δ
171.9, 160.0, 138.9, 138.8, 135.6, 135.4, 133.2, 129.8, 128.8, 128.5, 128.1, 120.3.

2-Benzoylamino-3-thiophen-3-yl-acrylic acid methyl ester (15-IIc)

Yield: 82%, product was obtained as pale yellow solid. MP: 187-188°C;
1

H NMR (400 MHz, DMSO-d6) δ 9.84(1H, s), 8.2-7.9(2H, m), 7.93(1H, s), 7.8-7.5(5H,

m), 7.2-7.1(1H, m), 3.71(3H, s); 13C NMR (100 MHz, CD3OD) δ 165.2, 164.9, 133.1,
132.8, 132.0, 130.4, 129.9, 128.3, 127.1, 126.9, 127.1, 119.0, 114.8, 48.9.

2-Benzoylamino-3-thiophen-3-yl-acrylic acid (15-IIIc)

Yield: 96%, product was obtained as pale yellow solid. MP: 237-238°C; 1H NMR
(400 MHz, DMSO-d6) δ 9.7(1H, s), 8.1-7.9(2H, m), 7.88(1H, s), 7.7-7.4(5H, m), 7.156.95(1H, m); 13C NMR (100 MHz, CD3OD) δ 171.2, 169.3, 135.2, 133.1, 132.2, 131.4,
129.6, 129.4, 129.1, 128.1, 127.0, 126.3, 121.1, 120.1.

2-Methyl-4-thiophen-3-ylmethylene-4H-oxazol-5-one (15-Id)

Yield: 93%, product was obtained as yellow needles. MP: 132-133 °C;
1

H NMR (400 MHz, DMSO-d6) δ 7.65(1H, d, J =4.5Hz), 7.55(1H, d, J = 4 Hz),

7.35(1H, s), 7.12(1H, m), 2.4(3H, s); 13C NMR (100 MHz, CD3OD) δ171.8, 168.9, 136.6,
133.0, 129.1, 128.4, 119.2, 19.1.
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2-Acetylamino-3-thiophen-3-yl-acrylic acid methyl ester (15-IId)

Yield: 90%, product was obtained as yellow powder. MP: 118-119°C; 1H NMR (400
MHz, DMSO-d6) δ 9.35(1H, s), 7.81(1H, D, J=5 Hz), 7.77(1H, s), 7.45(1H, d, J =4 Hz),
7.1-7.2(1H, m), 3.71(3H, s), 2.05(3H, s); 13C NMR (100 MHz, CD3OD) δ168.4, 163.1,
136.0, 134.9, 123.1, 122.9, 119.1, 116.5, 52.1, 20.9.

2-Acetylamino-3-thiophen-3-yl-acrylic acid (15-IIId)

Yield: 88%, product was obtained as yellow crystalline solid. MP: 230-231 °C; 1H
NMR (400 MHz, DMSO-d6) δ 9.24(1H, s), 7.76(1H, s), 7.66(1H, d, J=4.5Hz), 7.43(1H,
d, J=4.5Hz), 7.07(1H, m), 2.02(3H, s); 13C NMR (100 MHz, CD3OD) δ 169.9, 169.1,
132.8, 132.1, 129.1, 128.0, 120.3, 120.1, 19.9.

4-Naphthalen-2-ylmethylene-2-phenyl-4H-oxazol-5-one (15-Ie)

Yield: 80%, product was obtained as white crystalline solid. MP: 159-160°C. 1H NMR
(300 MHz, CDCl3)  8.404 (s, 1H); 8.38-8.34 (m, 1H); 7.94-7.83 (m, 3H); 7.59- 7.50 (m,
2H); 7.307 (s, 1H); 2.449 (s, 3H). 13C NMR (100 MHz, CDCl3)  168.0; 166.1; 134.5;
133.9; 133.3; 132.8; 131.6; 131.1; 129.3; 128.7; 128.2; 127.9; 127.8; 126.8; 15.8.

Methyl 2-Acetamido-3-(2-naphthyl) propenoate (15-IIe)

Yield: 80%, product was obtained as white crystalline solid. MP: 153-154°C.
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1

H NMR (DMSO-d6)  9.773 (s, 1H), 8.170 (s, 1H), 7.95-7.91 (m, 3H), 7.779 (d, 1H, J=

8.79 Hz), 7.58-7.55 (m, 2H); 7.335 (s, 1H); 3.738 (s, 3H), 2.051 (s, 3H),13C NMR (100
MHz, DMSO-d6)  169.5, 165.6, 133.0, 131.1, 130.9, 130.1, 128.4, 128.0, 127.5, 127.1,
126.9, 126.6, 126.4, 52.2, 22.5.

2-Acetylamino-3-naphthalen-2-yl-acrylic acid (15-IIIe)

Yield: 92%, product was obtained as white amorphous solid. MP: 184-186°C.
1

H NMR (100 MHz, DMSO-d6) 9.83(1H,s), 8.05-7.51(8H, m); 2.21(3H, s); 13C NMR

(100 MHz, DMSO-d6)  166.5, 165.9, 134.5, 132.9, 133.1, 131.7, 131.0, 130.8, 129.9,
126.5, 126.1, 125.4, 124.1, 18.3.

2-Phenyl-4-furon-3-ylmethylene-4H-oxazol-5-one (15-If)

Yield: 90%, product was obtained as a white solid. MP: 170-171°C; 1H NMR (400
MHz, CDCl3) δ 8.16 (d, 2H), 7.69-7.51 (5H, m), 7.19 (1H, s), 6.66(1H, dd, J1=0.4,
J2=0.4); 13C NMR (CDCl3, 100 MHz) d 167.3, 163.2, 150.7, 146.9, 133.4, 130.6, 129.1,
128.5, 125.8, 120.3, 118.5, 115.5, 114.0.

2-Benzoylamino-3-furon-3-yl-acrylic acid methyl ester (15-IIf)

Yield: 89%, MP: 136-137 °C. 1H NMR (CDCl3, 300 MHz) d = 8.28(1H, s), 7.957.85(2H, m), 7.6-7.46(4H, m), 7.08(1H, s), 6.58(3H, d, J =3.6 Hz), 6.47(1H, dd, J
=3.4Hz, J =1.6 Hz), 3.84(3H, s); 13C NMR (CDCl3, 100 MHz) d 165.6, 165.4, 123.0,
116.2, 115.4, 133.5, 132.2, 128.7, 1.
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2-Benzoylamino-3-furon-3-yl-acrylic acid (15-IIIf)

Yield: 96%, MP: 231-232 °C. 1H NMR (400 MHz, DMSO-d6) δ 12.74 (1H, s), 9.84
(1H, s), 8.00 (2H, d, J = 7.5 Hz), 7.83 (1H, s), 7.56 (3H, m), 7.28 (1H, s), 6.83 (1H, d, J =
3.4), 6.61 (1H, d, J = 3.4); 13C NMR (100 MHz, DMSO-d6) δ 165.7, 149.2, 145.2,
133.5, 131.6, 128.3, 127.5, 124.2, 120.6, 115.3, 112.4, 75.0.

4-Benzylidene-2-methyl-4H-oxazol-5-one(15-Ig)

Yield: 95%, product obtained as yellow needles. MP: 148-150°C; 1H NMR (CDCl3,
300 MHz)  7.32-8.20(5H, m), 7.16(1H, s), 2.45(3H, s); 13C NMR (CDCl3, 100 MHz)


2-Acetylamino-3-phenyl-acrylic acid methyl ester(15-IIg)

Yield: 90%, product was obtained as white crystalline solid. MP: 79-80°C.
1

H NMR (CDCl3, 400 MHz)  7.87 (2H, d, J = 7.2 Hz), 7.63 (1H, broad s), 7.54 (1H, t, J

= 7.2 Hz), 7.46 (2H, t, J = 7.2 Hz), 6.89 (1H, q, J = 7.6 Hz), 3.78 (3H, s), and 1.84 ppm
(2H, d, J = 7.6 Hz). 13C NMR (CDCl3, 100 MHz) d 165.4, 165.1 133.9, 133.8, 132.0,
128.6, 127.4, 126.0, 52.4, 15.0.

2-Benzoylamino-but-2-enoic acid (15-IIIg)

Yield: 91%, white amorphous solid. MP: 135.5-137.5°C;
1

H NMR (400 MHz, DMSO-d6) δ 9.54(1H, s), 8.21(2H, d, J =8.4 Hz), 7.98-7.44 (3H,

m), 6.68(1H, q, J =6.8 Hz), 1.72(3H, d, J =6.8 Hz).

13

C NMR (100 MHz, DMSO-d6) δ

171.9, 165.7, 133.9, 133.8, 133.0, 131.6, 131.5, 128.3, 127.7, 127.6, 13.6.
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4-Benzylidene-2-naphtyl-4H-oxazol-5-one (15-Ih)

Yield: 84%, product obtained as yellow needles. MP: 164-165°C.
1

H NMR (400 MHz, DMSO-d6) 8.9(2H, d, J =8.4 Hz), 8.43(2H, d, J =8.4 Hz), 8.17-

7.66 (9H, M); 13C NMR (100 MHz, DMSO-d6) 201.1, 167.9, 164.2, 134.0, 133.8,
133.6, 132.6, 132.2, 132.1, 129.4, 129.3, 129.1, 128.6, 127.6, 127.1, 126.4, 125.9, 125.7,
122.9.

2-Benzoylamino-3-naphtyl-acrylic acid methyl ester (15-IIh)

Yield: 87%, product obtained as off white crystalline solid. MP: 118-118.5°C.
1

H NMR (400 MHz, CDCl3) 8.78(1H, s), 8.04-7.37 (13H, m), 3.94(3H, s); 13C NMR

(100 MHz, CDCl3)  165.9, 165.7, 133.8, 133.6, 132.3, 131.4, 131.1, 129.7, 129.0, 128.9,
128.8, 128.5, 128.2, 127.9, 127.6, 127.2, 127.0, 126.5, 125.2, 124.4, 53.0.

2-Benzoylamino-3-naphtyl-acrylic acid (15-IIIh)

Yield: 92%, product obtained as off-white crystalline solid. MP: 213.5-215°C. 1H NMR
(400 MHz, DMSO-d6) (1H,S), 8.03-7.45(13H, m);

13

C NMR (100 MHz, DMSO-

d6) d 166.7, 166.1, 134.8, 133.5, 133.1, 131.7, 131.0, 130.8, 129.9, 129.7, 128.5, 128.3,
127.6, 126.6, 126.5, 126.1, 125.4, 124.1.

4-Benzylidene-2-phenyl-4H-oxazol-5-one(15-Ii)

Yield: 90%, MP 160-161°C.
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1

H NMR (300 MHz, CDCl3)  8.12-7.44(10H, m), 7.24(1H, s); 13C NMR (100 MHz,

DMSO-d6)  172.8, 161.1, 141.0, 140.6, 133.2, 132.9, 132.5, 130.3, 129.8, 128.9, 128.1,
126.2, 22.1.

Methyl (Z)-2-(N-benzoylamino)-3-phenylpropenoate (15-IIi)

Yield: 90%, MP 140.5-141.5°C.
1

H NMR (300 MHz, CDCl3)  7.88-7.82, 7.56-7.41 and 7.34-7.28(10H, m), 3.83(3H, s);

13

C NMR (100 MHz, CDCl3)  165.8, 165.6, 133.8, 133.5, 132.1, 131.8, 129.6, 129.4,

128.7, 128.6, 127.4, 124.2, 52.7.

2-Benzoylamino-3-phenyl-acrylic acid (15-IIIi)

Yield: 96%, MP 233-235°C.
1

H NMR (300 MHz, DMSO-d6)  9.24(1H, s), 8.10-7.95, 7.75-7.25(12H, 2m); 13C NMR

(100 MHz, DMSO-d6)  167.5, 162.4, 133.1, 132.4, 130.4, 128.3, 127.56,


2-Phenyl-4-(3,4,5-trimethoxy-benzylidene)-4H-oxazol-5-one (15-Ij)

Yield: 80%, product obtained as Pale yellow crystalline solid. MP 152-153°C. 1H NMR
(300 MHz, CD3OD)  7.54 (2H, s), 7.09 (1H, s), 3.90 (6H, s), 3.85 (3H, s), 2.41 (3H, s);
13

C NMR (100 MHz, CD3OD) 176.2, 161.7, 153.4, 152.9, 138.3, 133.4, 132.6, 131.9,

129.2, 129.1, 128.3, 127.3, 125.8, 125.6, 115.5, 110.0, 108.1, 95.6, 75.7, 73.3, 61.3, 61.0,
57.2, 56.4, 56.3.
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2-Benzoylamino-3-(3,4,5-trimethoxy-phenyl)-acrylic acid (15-IIj)

Yield: 80%, product obtained as white crystalline solid, MP: 202-203°C;
1

H NMR (300 MHz, CD3OD)  7.47 (1H, s), 6.95 (2H, s), 3.86 (6 H, s), 3.80 (3H, s),

2.13 (3H, s); 13C NMR (CDCl3, 100 MHz) d, 165.9, 165.5, 152.6, 138.7, 133.9, 133.1,
132.0, 128.7, 128.5, 127.7, 127.5, 125.5, 107.6, 105.4, 60.1, 55.8, 55.6, 52.2, 51.9.

2-Benzoylamino-3-(3,4,5-trimethoxy-phenyl)-acrylic acid (15-IIIj)

Yield: 93%, product obtained as pale yellow amorphous solid. MP: Decomposes beyond
200°C before melting. 1H NMR (300 MHz, CD3OD) 9.93(1H, s), 8.0(2H, d, J=1.8),
7.59-7.44(3H, m), 7.05(1H, s), 6.69(1H, s), 3.65(3H, s), 3.64(6H, s);

13

C NMR (CDCl3,

100 MHz) d, 154.1, 152.6, 128.5, 127.5, 114.9, 107.5, 60.0, 55.6.

4-(4-Dimethylamino-benzylidene)-2-phenyl-4H-oxazol-5-one (15-Ik)

Yield: 90%, product obtained as bright red crystalline solid; MP: 213-215 °C. 1H NMR
(CDCl3, 400 MHz) , 8.16-8.13(3H, m), 7.56-7.50(5H, m), 7.21(1H, s), 6.75(2H, d, J
=8.8 Hz), 3.11(6H, s); 13C NMR (CDCl3, 100 MHz) , 168.8, 162.0, 160.8, 152.4, 135.0,
135.0, 133.6, 132.5, 129.2, 129.0, 128.5, 128.0, 126.5, 121.9, 121.3, 112.0, 40.2.

2-Benzoylamino-3-(4-dimethylamino-phenyl)-acrylic acid (15-IIk)

Yield: 90%, product obtained as red crystalline solid. MP: 180-181°C.
1

H NMR (400 MHz, DMSO-d6) δ 9.86 (1H, s), 8.00 (2H, d, J = 7.2 Hz), 7.54 (m, 5H),

7.40(1H, s), 6.69 (2H, d, J = 8.9 Hz), 3.69 (3H, m), 2.93 (6H, s);
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13

C NMR (100 MHz,

CDCl3) 166.6, 151.3, 135.4, 134.5, 134.2, 132.1, 131.3, 129.0, 128.9, 127.7, 121.3,
119.3, 111.8, 95.6, 70.4, 52.6, 40.1

2-Benzoylamino-3-(4-dimethylamino-phenyl)-acrylic acid methyl ester (15-IIIk)

Yield: 91%, product obtained as red crystalline solid. MP: 216-218°C.
1

H NMR (400 MHz, CDCl3) m), 7.55-7.48(5H, m), 7.21(1H, s), 6.74(2H, d,

J = 8.8 Hz), 3.105(6H, s);

13

C NMR (100 MHz, CDCl3) 168.7, 160.7, 152.4, 135.0,

133.6, 132.4, 128.9, 128.4, 127.9, 127.3, 126.5, 121.9, 111.9, 40.27, 40.24.

Ethoxycarbonylamino-acetic acid (17)

To a stirred solution of glycine (10.0 g, 0.13 mol)) in 2 M NaOH (1.0 equiv.) at 0°C were
added simultaneously ethyl chloroformate (14.45g, 0.13 mol) and 2 M NaOH (1.0 equiv.)
dropwise. The mixture was stirred at 0°C for 3 h then washed with ether (3x 20mL). The
aqueous phase was acidified with 2 M HCl and extracted with ethyl acetate (3 × 50 mL).
The combined organic phase was dried and the solvent evaporated to furnish the product
as colorless solid in 70% yield. M.p. 67-69°C. 1H-NMR (400 MHz, DMSO-d6) 7.34(1H,
t, J =6 Hz), 4.05-3.97( 2H, m), 3.62(2H, d, J =6.4 Hz), 1.15(3H, t, J =6.8 Hz); 13C-NMR
(100 MHz, DMSO-d6)  174.4, 173.7, 157.2, 43.2, 42.6, 62.4, 61.8, 14.6.

3-Hydroxy-2-(3-oxo-decanoylamino)-butyric acid methyl ester (19)

Threonine methyl ester (1g, 6 mmol) and 3-Oxo-decanoic acid were added to 40 mL of
dichloromethane and stirred at room temperature. To this mixture
dicyclohexylcarbodiimide (1.2g, 6 mmol) and sodium bicarbonate (0.5g, 6 mmol) were
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added and stirring is continued. The reaction mixture looked turbid white with
undissolved material. The reaction was stirred overnight at room temperature until the
starting material completely disappeared under TLC. The mixture was then cooled to
0°C and filtered through filter paper and the residue was discarded. The filtrate was
concentrated and filtered through a short silica gel column. The column is washed
thoroughly with a mixture of 3:1 dichloromethane, ethyl acetate solvent system. The
filtrate was left in an uncovered container overnight. Pure product crystallized out as
white longitudinal crystals (1.4g, 80% yield) m.p. 210.3-211.5°C.
1

H-NMR (400 MHz, CDCl3) : 6.29(1H, d, J=16 Hz), 4.63(1H, dd, J=3.2 Hz), 4.35(1H,

dq, J=3.2 Hz), 3.77(3H, s), 2.28(2H, t, J=10 Hz), 1.62-1.68(2H, m), 1.45-1.21(10H, m),
0.86-0.88(3H, m); 13C-NMR (100 MHz, CDCl3)  205.4, 172.7, 171.3, 66.2, 62.2, 51.7,
44.6, 41.9, 32.6, 29.8, 23.2, 23.5, 17.6, 13.9.

3-Acetoxy-2-(3-oxo-decanoylamino)-butyric acid methyl ester (20)

A mixture of 3-Hydroxy-2-(3-oxo-decanoylamino)-butyric acid methyl ester (1.4g, 4.6
mmol) and sodium acetate (0.95g, 11.6 mmol) was dissolved in 10 mL of acetic
anhydride and refluxed overnight. The solvent is removed under vacuum, and then
residue is washed with water and extracted into dichloromethane and concentrated to
yield pure 20 as a colorless oil (1.56g, 98%) yield.
1

H-NMR (400 MHz, CDCl3) : 6.33(1H, d, J=16 Hz), 5.43(1H, dd, J=3.2 Hz), 4.95(1H,

dq, J=3.2 Hz), 3.73(3H, s), 2.28(2H, t, J=10 Hz), 2.07(3H, s),1.61-1.65(2H, m), 1.451.22(10H, m), 0.86-0.87(3H, m); 13C-NMR (100 MHz, CDCl3)  205.4, 172.8, 171.2,
70.5, 62.2, 56.7, 44.6, 41.9, 32.6, 29.8, 23.2, 17.4, 17.8, 13.9.
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2-Diacetylamino-but-2-enoic acid methyl ester (24)

A suspension of L-threonine methyl ester hydrochloride (34g; 0.2 mol), anhydrous
sodium acetate( 100g; 1.2 mol) in acetic anhydride (200 mL) was refluxed with stirring
for four hours. The reaction mixture is continued to stir at room temperature for
additional five hours. Solid material was separated by filtration and filtrate was
concentrated under vacuum and bath temperature of 80°C. After distillation was stopped,
liquid residues was diluted with methanol (150 mL) and again concentrated at 80°C
under vacuum aspirator. This procedure was repeated three more times. The oily residue
was dissolved in methylene chloride (200mL) and washed with saturated NaHCO3
(4x200mL). Organic layer was dried under anhydrous sodium sulfate and solvent was
evaporated to yield pure product (39 g, 97.5%) yield as colorless oil.
1

H-NMR (300 MHz, CDCl3)  7.19(1H, q, J = 7.2 Hz), 3.78(3H, s), 2.32(6H, s), 1.77(3H,

d, J=7.2 Hz);13C-NMR (300 MHz,CDCl3)172.26, 163.97, 140.84, 140.67, 131.08,
52.86, 52.75, 25.90, 25.86, 13.81, 13.73.

Methyl 2-acetylamino-but-2-enoate (25)

A solution of methyl 2(diacetylamino)but-2-enoate (14.45g, 72.54) and triethylamine (1.0
g, 10 mmol) in methanol (200 mL) was heated at reflux overnight. The volatiles were
removed at reduced pressure to afford a yellow liquid (13.43 g) which crystallized over a
course of several hours. The product was titrated with hexane and dried in vacuum to
afford product (11.09 g; 97%) as an off-white solid, m.p. 53-54°C, of adequate purity.
The product was dissolved in ether (20 mL/g) and cooling the resulting solution to -25°C
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to provide the product as snow white needles m.p. 59-60°C. 1H-NMR(300 MHz, CDCl3)
q, J =8 Hzs, 3H2.13(3H, s), 1.77(3H, d, J =8 Hz).

13

C-NMR(300

MHz, CDCl3)

2-Acetylamino-but-2-enoic acid (26)

A solution of methyl 2-acetylamino-but-2-enoate (1.57 g, 10 mmol) in methanol (25 mL)
was added to sodium carbonate (2.8g, 25mmol) in water (25 mL). The mixture was
refluxed for 2 hours and then brought to room temperature. The reaction mixture was
acidified with 2N HCl to a pH 2 and was concentrated in vacuum aspirator and bath
temperature of 80°C. After methanol was completely removed, the product precipitates
out as clear oil. The precipitate was washed with ice cold 2N HCl. The product was
dried first with a filter paper and then co-evaporated with toluene (50 mL x 4). The
product obtained is pure in 97% yield as brownish oil.
1

H-NMR(300 MHz, CDCl3) q, J = 9.6 Hz), 3.40(3H, s), 1.82(3H, d, J=9.6

Hz);

13

C-NMR(100 MHz, DMSO-d6) 

2-p-Tolyl-benzo[de]isoquinoline-1,3-dione (31):

A suspension of 1,3-dioxo-1H,3H-benzo[de]isochromenium (0.76g, 7 mmol) and pamino toluene in 25 mL of pyridine was heated at 70°C for about 20 hours. The excess
solvent was distilled off by increasing the temperature to reflux and setting up a collector
to collect the solvent. The solvent was collected until enough solvent remained for
recrystallization. The compound was obtained as white needles upon bringing the
reaction mixture to room temperature in 80% yield. MP: 311°C.
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1

H-NMR(400 MHz, CDCl3) dd, J=1.2, 1.2 Hz), 8.26(2H, dd, J=1.2, 1.2 Hz),

7.79(2H, dd, J=7.80, 7.80 Hz), 7.36(2H, d, J=8 Hz), 7.20(2H, d, J=8 Hz), 2.44(3H, s);
13

C-NMR(100 MHz, CDCl3) 164.72, 138.85, 134.47, 132.94, 131.96, 131.83, 130.39,

128.76, 128.49, 127.24, 123.09, 55.91, 21.57.

2-(4-Bromomethyl-phenyl)-benzo[de]isoquinoline-1,3-dione (32):

To a solution of 2-p-Tolyl-benzo[de]isoquinoline-1,3-dione (31) (2.7g, 9.4 mmol) in 75
mL of chloroform was added N-bromo-succinimide (3.63, 20.3 mmol) and catalytic
amount of benzoyl peroxide (15 mg) at 0°C. The solution was stirred under a flash light
for the reaction to occur. The reaction was monitored by TLC for completion. After
completion of the reaction the solvent was removed under vacuum and the residue was
subjected to column chromatography with 2:1 dichloromethane and hexane mixture in
85% yield as a white amorphous solid. MP: Starts decomposing before melting at
249.1°C. 1H-NMR(400 MHz, CDCl3) dd, J=1.2, 1.2 Hz), 8.29(2H, dd, J=0.8,
0.8 Hz), 7.81(4H, t, J=7.6 Hz), 7.59(2H, d, J= 8.4 Hz), 3.31(2H, d, J = 8.4 Hz); 13CNMR(100 MHz, CDCl3)  164.49, 138.30, 135.56, 134.61, 131.92, 130.32, 129.27,
127.27, 122.89, 32.84.

Acetic acid 4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-benzyl ester (33)

A suspension of 2-(4-Bromomethyl-phenyl)-benzo[de]isoquinoline-1,3-dione (32) (3.5 g,
10 mmol) and sodium acetate (1g, 12mmol) in 10 mL of dimethylsulfoxide was
sonicated for 4 hours. The reaction mixture was poured on to ice and left for 1 hour.
The product precipitated out as a white solid. The solid was washed with a 100 mL water
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(x 3) to give the crude product. The product was recrystallized from methanol to give
pure product in 95% yield. MP: Does not melt till 400°C.
1

H-NMR(400 MHz, CDCl3) dJ Hzd, J =7.6 Hz), 7.79(4H, t,

J=8 Hz), 7.54(2H, d, J =8 Hz), 7.32(2H, d, 8 Hz), 5.19(2H, s), 2.16(3H, s).

4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-benzyl alcohol (34)

To a solution of acetic acid 4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-benzyl ester
(0.35g, 1mmol) in a 15 mL of 1:1 methanol and dichloromethane was added powdered
NaOH (112 mg, 2.8 mmol) at 0°C and the reaction mixture was stirred for 2 hours and
the methanol was evaporated. The residue was taken into 1N sodium bicarbonate
solution and the product was extracted into dichloromethane, which is dried under
MgSO4. The solvent is evaporated under vacuum to yield a yellowish solid. MP: 282°C.
1

H-NMR(400 MHz, CDCl3)  8.66(2H, dd, J=0.8, 0.8 Hz), 8.29(2H, dd, J=1.2, 1.2 Hz),

7.81(4H, dd, J=7.6, 7.6 Hz), 7.57(2H, d, J=8.4 Hz), 7.33(2H, d, J=8.4 Hz), 4.81(2H, d,
J=6 Hz); 13C-NMR(100 MHz, CDCl3) 163.25, 142.63, 134.49, 131.52, 130.81, 128.76,
127.90, 127.31, 126.90, 122.68, 75.15, 62.65, 55.25, 48.62.
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